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THERAPEUTIC TARGETING OF STROMA DECREASES TUMOR PROGRESSION AND
RESTORES CHEMOSENSITIVITY

by

MALVIKA SHARMA

Under the Direction of Zhi-Ren Liu, PhD

ABSTRACT
Cancer-associated fibroblasts (CAFs) comprise a significant portion of the tumor stroma with
diverse functions, including matrix synthesis and remodeling, production of growth factors and
cytokines, angiogenesis, drug access, and therapy response. CAFs promote tumor growth,
metastases, and chemotherapeutic resistance, thus represent a potential target for optimizing
treatment strategies against cancer. We previously reported a rationally designed protein,
ProAgio that binds to integrin αVβ3 at a novel site and induces integrin-mediated apoptosis. In
this study, we show that CAFs express high levels of integrin αVβ3 and ProAgio effectively
induces apoptosis in CAFs in Triple Negative Breast Cancer (TNBC), the most aggressive breast
cancer subtype, wherein abundance of CAFs is associated with poor overall survival. Depletion

of CAFs by ProAgio decreases intratumoral collagen, reduces growth factors and abolishes CAF
and cancer cell crosstalk, resulting in decreased cancer cell proliferation and apoptotic resistance.
ProAgio also eliminates leaky tumor angiogenic vessels, as these express high levels of integrin
αVβ3, which consequently reduces tumor hypoxia and improves drug delivery. Depletion of
CAFs and reduction in hypoxia decreases Lysyl oxidase (LOX) secretion, resulting in reduced
metastasis. ProAgio stand-alone or in combination with a chemotherapeutic regimen provides a
significant survival benefit in orthotopic and transgenic MMTV-PyMT mouse models of TNBC,
highlighting the therapeutic potential of ProAgio as a treatment therapy. Pancreatic ductal
adenocarcinoma (PDAC) is another deadly cancer abundant in fibrotic stroma. ProAgio
specifically induces apoptosis in cancer-associated pancreatic stellate cells (CAPaSCs) that share
similar characteristics with CAFs. Depletion of CAPaSCs results in resorption of collagen that
opens collapsed vessels and enables drug delivery into the tumor. ProAgio alone or in
combination with gemcitabine prolongs survival when tested in GEM-KPC and orthotopic
mouse models of PDAC. Furthermore, ProAgio decreases intratumoral IGF-1 levels due to
depletion of CAPaSCs and consequently decreases cytidine deaminase, a gemcitabine
metabolism enzyme in cancer cells, thereby reducing resistance to gemcitabine-induced
apoptosis. Our results for the first time demonstrate that ProAgio selectively targets CAFs and
angiogenic vessels, representing a promising strategy for TNBC and PDAC treatment,
particularly in combination with other anti-cancer chemotherapeutics.
INDEX WORDS: Tumor microenvironment, Cancer-associated fibroblasts, Angiogenesis,
Integrin αVβ3, ProAgio, Chemotherapy
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1. INTRODUCTION
1.1. Tumor microenvironment
Cancer comprises of neoplastic cells that are considered a pathological imbalance of
tissue-cell societies. The rapidly growing epithelial cells form the heart of the tumor, and a
variety of mesenchymal cell types and extracellular matrix components comprise the tumor
stroma, often termed as its microenvironment. The normal counterparts of some stromal cells are
thought to limit tumor growth, while tumor-associated stromal cells have been shown to actively
promote tumor progression via dynamic interactions with the nearby carcinoma cells. Therefore,
malignancy emerges from a tumor-host microenvironment, wherein the host participates in the
induction, selection, and expansion of the neoplastic cells. In fact, as the cancer progresses, the
host stromal response evolves with and around the tumor. More recent advances have revealed
that tumor-host interactions extend

well

beyond

the

local

tissue

microenvironment

(i.e. interactions between the neoplastic cells and the nearby stroma) and that tumors not only
respond to, but actively perturb host organs at distant anatomic sites. The tumor
microenvironment (TME), also known as tumor stroma, contains a heterogeneous population of
cells, consisting infiltrating immune cells, the tumor vasculature and lymphatics, as well as
fibroblasts, pericytes, and adipocytes (Figure 1.1). The cancer cells can modify the cells in the
TME to produce abundant extracellular matrix (ECM), several growth factors, chemokines,
cytokines, and matrix-degrading enzymes that enhance the tumor progression. In addition, TME
not only plays a pivotal role during tumor initiation, growth, and metastasis but also profoundly
affects the therapeutic efficacy. The environmental conditions in the tumor, caused by changes in
the stroma, for example changes in vascular flow, and increased interstitial fluid pressure
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contributes to reduced delivery of the anti-cancer drugs (Sahai et al., 2020b). Furthermore, the
attachment of the cancer cells to the stroma triggers several signaling pathways, including
integrin b1-mediated PI3K activation, PI3K/Akt/Bcl-2 activation via integrin a4b1 etc. that
results in decreased sensitivity to anti-cancer therapies. The dominant cell type found in solid
tumors is the fibroblast-cell type, also known as cancer-associated fibroblasts (CAFs), which are
found in the vicinity or direct contact with the neoplastic cells. Among all the cells in the TME,
fibroblasts could be considered the cockroaches of the human body. They survive severe stress
that is usually lethal to all other cells, and they are the only normal cell type that can be live
cultured from the decaying tissue and post-mortem. Their resilient adaptation may reside in their
intrinsic survival programs and cellular plasticity (Kalluri, 2016). Cancer is associated with
fibroblasts at all stages of disease progression, including metastasis, and they are a considerable
component of the general host response to tissue damage caused by cancer cells. Understanding
the nature of this crosstalk will allow for improved therapeutics that simultaneously target
multiple components of the TME, resulting in favorable patient outcomes.

Figure 1.1. The Tumor Microenvironment (TME).
TME comprising of CAFs, tumor vessels, ECM, immune cells etc. is an active and a major
participant throughout the entire process of cancer etiology, progression, and metastasis.
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1.2. Cancer-associated fibroblasts
Fibroblasts have the tendency to survive extreme stress conditions that is usually lethal to
a normal cell. In normal tissues, fibroblasts are defined as non-epithelial, spindle-shaped cells
with a mesenchymal origin, found mostly in the connective tissue. Fibroblasts are usually in a
resting/quiescent phase with negligible metabolic and transcriptomic activity in a normal tissue;
however, they become activated during wound healing or acute and chronic inflammation
(Kalluri, 2016). These activated fibroblasts known as myofibroblasts (MFs) express stress fibers
with α-smooth muscle actin (α-SMA), making it highly contractile, and fibronectin. Activated
fibroblasts undergo programmed cell death, called nemesis upon completion of wound healing
(Bizik et al., 2004).
Fibroblasts surrounding cancer cells are known as CAFs, which are a family or a group of
cells that exhibit mesenchymal-like features. A significant proportion of CAFs likely emerge
from a mesoderm-derived precursor cell, although the precise origin of all CAFs in a given
tumor is not fully comprehended. CAFs share some similarities with MFs like expression of αSMA and extradomain-A (ED-A) splice variant of fibronectin. However, CAFs do not undergo
apoptosis and their activation is irreversible. CAFs are the predominant cell type within the
stroma of many cancers, especially breast, pancreatic, and prostate cancer. Intriguingly, CAFs is
an umbrella term used for the heterogeneous population of cells that includes endothelial cells,
pericytes, epithelial cells, smooth muscle cells, and predominantly fibroblasts. The main
biomarkers of CAFs established so far in all types of cancers are α-SMA, fibroblast activation
protein (FAP), fibroblast specific protein (FSP), and platelet-derived growth factor (PDGF)
receptor-β.
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It is evident that the crosstalk between the neoplastic cells and CAFs is implicated in the
progression of cancer; therefore, comprehending the mutual relationship will enable us to find a
cure for cancer. It has been established that there are two interactive pathways involved in the
cross talk between neoplastic cells and TME: i) Efferent pathway wherein neoplastic cells evoke
a reaction in tumor stroma, and ii) Afferent pathway wherein surrounding tumor stroma
stimulates cancer cells. Tumor growth factor (TGF)-β1 has been recognized as a critical
neoplastic cell derived factor that affects CAF activation (Cirri and Chiarugi, 2011). Several
other inflammatory modulators, including interleukin (IL-1) through nuclear factor-kappa b (NFkb), and IL-6 through activation of signal transducer of activator and transcription (STAT) can
promote CAF activation. Histone acetylation, crosstalk via janus kinase (JAK)-STAT signaling,
and the contractile cytoskeleton can further promote CAF activation. Additionally, physical
modulation in the ECM, physiological stress, such as heat shock factor 1(HSF1) in response to
protein misfolding, and genomic stress, such as double-stranded DNA breaks can also activate
CAFs. These triggers can aid fibroblasts to enter a senescence state, i.e. a non-proliferative state
that contributes to the production of high levels of IL-6 and are also implicated in disease
relapse. The tumor cells are not the only source of CAF activation. Other cells in the TME such
as macrophages release granulin that activate the fibrotic environment in liver metastasis
(Nielsen et al., 2016). Also, cancer therapies, including chemotherapy and radiotherapy can
promote the generation of CAFs and alter their functionality resulting in therapy resistance along
with undesirable adverse effects.
The CAFs have a diverse array of functions (Figure 1.2), which have been extensively
studied in culture experiments, mouse models, and patient cohorts. CAFs are the most effective
cells in TME that are involved in ECM deposition and remodeling. CAFs produce matrix4

crosslinking enzymes that contribute to increased tumor stiffness and enhanced remodeling of
the tumor matrix, resulting in tumor permissive tracks that allow cancer cell dissemination to
distant sites. After the dissemination of cancer cells, the activation of fibroblasts at the secondary
sites favor the colonization of the cancer cells by providing various supporting signals to the
cancer cells. In addition, increased mechanical stress due to tissue stiffness can collapse blood
vessels, leading to hypoxia, resulting in more aggressive cancer. The production of growth
factors, cytokines, and exosomes that promote tumor growth and change the therapy responses
has been well established. The production of TGF-b, fibroblast growth factor (FGF), hepatocyte
growth factor (HGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF)α/β, growth arrest specific protein 6 (GAS6), vascular-endothelial growth factor (VEGF)
promotes invasive and proliferative behavior in cancer cells. In skin tumors, TGF-β1 augments
reactive oxygen species (ROS) in the CAFs, which further downregulates gap junctions between
CAFs, and thereby attribute to their myofibroblast like phenotype. TGF-β1 and stromal cellderived factor (SDF)-1 acquire autocrine signaling loop in human mammary fibroblasts and
therefore initiate and maintain myofibroblast differentiation and tumor progression. It has also
been proposed that in breast adenocarcinoma, induction of oxidative stress because of genetic
inactivation of JunD promotes differentiation of myofibroblasts and tumor metastases (Cirri and
Chiarugi, 2011). Therefore, CAF-directed therapies can mitigate these events. The cytokines
produced by CAFs, including IL-6, CXC-chemokine ligand 9 (CXCL-9), CXCL-12 promote the
immunosuppressive milieu by inhibiting CD8+ T cells. Additionally, cancer cells and CAFs
exchange metabolites and amino acids. In pancreatic ductal adenocarcinoma (PDAC), the
stromal fibroblasts generate alanine by autophagy, which is used by PDAC cells to fuel the
tricarboxylic acid (TCA) cycle. Also, metabolic regulation of CAFs through IL-6 production or
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depletion of immunomodulating amino acids result in altered immunoregulation (Sahai et al.,
2020b). Figure 1.2 below summarizes the functions of CAFs and the mechanisms by which they
are activated.

Figure 1.2. Functions of CAFs.
Matrix remodeling and secretion of soluble factors contribute to increased invasion of cancer
cells. Soluble factors also contribute to changes in tumor progression and the immune cell
milieu, which is also affected by the altered metabolic state of the tumor.

The role of CAFs in triple-negative breast cancer (TNBC) and PDAC is well established,
however, there are no potential therapies yet to target CAFs. An elaborate description about the
role of CAFs in breast cancer and pancreatic cancer is mentioned in sections 1.4.1-1.4.4 and
1.8.1. Below is a detail about TNBC, PDAC, and the role of TME in their progression.
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1.3. Triple-Negative Breast cancer
Breast cancer is the one of the most common cancer types among women resulting in
second leading cancer-mortality after lung cancer across the globe. Classification of breast
tumors into three major types is based on the gene expression profiling, such as basal-like,
luminal, and human epidermal growth factor receptor 2 (HER2). Each of these subtypes has
different disease progression risk, treatment response, risk factors for incidence, and favorable
metastatic organ sites. Luminal tumors express progesterone and estrogen receptors, and the
majority can be effectively controlled by hormonal therapies. HER2 tumors on the other hand
overexpress ERBB2 oncogene and respond well to a wide range of anti-HER2 therapies.
Generally, basal-like tumors lack HER2, estrogen and progesterone receptors; thus, majority of
these tumors, approximately 70% are called triple-negative breast cancer (TNBC). It is
noteworthy that term ‘basal-like’ was chosen for this subgroup of breast cancer as the genes
expressed by tumor cells are characteristic of basal or myoepithelial cells surrounding basement
membrane.
Among 1 to 1.3 million cases of breast cancer diagnosed worldwide, 20% (0.17 million)
cases fall into the triple-negative type. Categorized by the absence of estrogen receptor (ER),
progesterone receptor (PR) and HER2 overexpression, TNBC remains a critical subject of
investigation and focus of increasing interest for both clinicians and basic researchers. First and
foremost, reason is that women in premenopausal phase and women from African-ancestry and
Hispanic descent have a high prevalence of TNBC. Second, the prognosis of TNBC remains a
challenge. Third, there is an overlap of TNBC phenotype with the BRCA-associated breast
cancers. Lastly, no effective targeted therapy is yet available for TNBC (Yao et al., 2017).
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Histologically, 80-90% TNBCs are characterized as the invasive ductal type with a big
tumor size and a high histologic grade. TNBCs demonstrate a remarkable degree of nuclear
pleomorphism, high mitotic index, and lack tubule formation. Majority of the cases exhibit
lymphocytic infiltration, central necrotic areas, and pushing borders. A substantial proportion of
these tumors display medullary characteristics, along with focal metaplastic differentiation areas
with abundant spindle and squamous cells. There is a significant heterogeneous population of
cells within TNBC. As mentioned above, the majority of TNBCs belong to the subtype i.e. basallike, while the remaining comprise of various biologically distinct molecular subtypes. TNBCs
also express basal cytokeratins (CKs) such as CK-5, 14, and 17, EGFR, and HER1, which are
associated with poor prognosis in patients with breast cancer. TNBCs frequently express
myoepithelial markers, such as P-cadherin, c-kit, caveolins (Cav) 1 and 2 and rarely express
epithelial markers, such as E-cadherin in contrary to other tumors. They display increased gene
expression associated with proliferation e.g. Ki67 and TOP2A, elevated cyclin E levels, and low
cyclin D1 levels. Approximately 50% of TNBCs show abnormal expression of p53 or its
homolog p63 as detected by immunohistochemistry (IHC) or mutational analysis (Carey et al.,
2010).
1.3.1. Epidemiology
Patients diagnosed with TNBC are at a multifold risk associated with early metastases to
various distant organs such as lungs, bones, liver, lymph nodes, and brain. Non-TNBCs
metastasize to the bone more frequently, whereas TNBC often metastasizes to the lungs and
CNS, which attributes to its low survival rate. Also, a study has found TNBC affects younger
women of all ethnicities, however, its incidence is three times more in females from African
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ancestry than Caucasian descent. The prognosis of women in TNBC is worse owing to the
aggressiveness of proliferation of cancer cells, metastasis, and recurrence (O'Reilly et al., 2015).
1.3.2. Heterogeneity in breast cancer and its subtype TNBC
Breast tumor is composed of a heterogeneous population of cells and there are various
hypotheses to elucidate the origin of inter patient heterogeneity. HER2-positive and luminal
tumors may arise from progenitors of the luminal lineage, whereas basal-like tumors may
originate from stem cell-like cells that are less differentiated. However, there is experimental
evidence with respect to gene expression patterns in multiple in vivo models, suggesting that
luminal lineage-committed progenitors may also assist in the origination of basal-like tumors by
switching cellular phenotypes due to genetic or epigenetic changes. For instance, loss of PTEN
or BRCA1 gene in the luminal epithelial cells results in the loss of differentiation of lumen
leading to malignant transformation of these cells that ultimately acquire the properties of basallike tumors. Interestingly, breast tumor of a patient also exhibits heterogeneity for various
tumorigenic traits, such as metastasis and angiogenesis. The intratumor/interpatient
heterogeneity could be either attributed to clonal/cellular variability for epigenetic and genetic
modifications or adaptive responses/activity of signaling pathways and fluctuation in protein
levels. The diverse mixture of breast cancer cells producing intratumor heterogeneity may also
trigger intertumor heterogeneity and help understand various subtypes of breast tumor.
It has been revealed in multiple studies that there is an astonishing level of heterogeneity
in TNBC. Lehmann et al. classified TNBC into six different subtypes based on distinctive
expression patterns of the genes that include: a) basal-like 1 (BL1) and basal-like 2 (BL2), b)
mesenchymal (M), c) mesenchymal stem-like (MSL), d) immunomodulatory and, e) luminal
androgen receptor (LAR) sub-type. An increased cell cycle and damage response genes
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expression was observed in BL1 and BL2 subtype and increased EMT genes expression was
observed in M and MSL subtype. Enriched expression of genes associated with androgen
receptor signaling was seen in the LAR subtype (Lehmann et al., 2011). In addition, the
histological analyses have revealed that the major proportion of TNBC is of the invasive ductal
carcinoma. However, other types such as medullary and metaplastic carcinomas, apocrine
carcinoma, and adenoid cystic carcinoma are also negative for ER, PR, and HER2. Despite
sharing the triple-negative phenotype, the clinical outcome of each seems unique. Basal-like and
TNBC display a remarkable similarity with BRCA1 (tumor suppressor gene involved in DNA
repair)-mutated tumors as observed in 50% patients. Other molecular entities such as claudinlow molecular subtype, which lack expression of many claudin genes, for instance, cell-cell
junction proteins also display triple negative phenotype. These tumors show high infiltration of
immune cells, epithelial mesenchymal transition (EMT), and stem cell-like cells. Furthermore,
markers including androgen receptor (AR), EGFR, C-KIT, and immunoglobulin-related genes,
have also been categorized in TNBC by differential gene expression. However, solid conclusions
cannot be drawn from these results owing to the premature study. Copy number anomalies,
including chromosomal deletion and gene amplification have also been reported in TNBC, in
addition to pathway deregulations and different gene expressions, suggesting genomic instability
(Criscitiello et al., 2012).
Comprehending the evolution of breast cancer and its cell-of-origin in humans is almost a
far-fetched task, as it is extremely difficult to detect tumors at their earliest stages and trace their
evolutionary pathways at a molecular level. Three major methods have currently been used to
follow the evolution of human breast cancer. One approach is to study each cell in the tumor at
the cellular level for somatic genetic variations and phenotypic traits because it is assumed that
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some cancer cells could be remnants of the tumor’s past and their occurrence in a tumor may
throw some light on the possible evolution of tumor. Another method involves the analysis of the
tumors collected at a large scale, which comprises of evaluation of molecular changes at
different developmental stages. The possible order of events can be compiled based on the
frequency at which these molecular changes occur at a specific progression step. These
approaches have been used so far to study the pancreatic and colon cancer evolution. It is
noteworthy that describing the cancer cell origin was earlier believed to be important just for
predicting risk and studies involving chemoprevention. Nevertheless, if the tumor cell origin
were implicated in the identity and the frequency of the adopted transforming events, then its
characterization would be relevant in better comprehending breast cancer subtypes.
1.3.3. Approaches for identifying heterogeneous tumors
Whole-genome sequencing is one approach to identify intratumor diversity of distinctive
cells within the tumors. It is a daunting task to study the individual cancer cells comprehensively;
therefore, another very close alternative is to perform deep sequencing or sampling of the tumor
as a whole. Nicholas et al. reported a similar study in which they entirely sequenced 100 tumor
cells of breast {Navin, 2011 #169, and numerous other studies have carried out exome
sequencing or whole-genome sequencing of single tumors or an array of breast tumors. In near
future, deep sequencing of individual cells will most likely be performed in a such a way that the
information of a single cell will remain preserved with the help of advanced DNA sequence
technologies, for instance, location of specific mutations in cancer cells. Nevertheless, it is still a
major challenge to interpret, clinically translate, and analyze these results because filtering the
mutations from “passengers” that lead to tumor formation is not an easy task since the growth
and evolution of tumor may change the functions of passenger and driver mutations. Therefore,
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in addition to whole-genome sequencing, high-throughput functional screens that are well
designed will most probably assist the translation of these technological developments into
clinics in physiologically significant models. The astonishing heterogeneity of tumors seems
frightening and makes the cure for cancer a nearly impossible task. Nonetheless, an in-depth
knowledge regarding constantly evolving nature of tumor will help in the cure and prevention of
this deadly disease (Polyak, 2011).
1.3.4. Current treatment
At present, there is no FDA approved specific molecular targeted treatment against
TNBC; however, they do appear to be responsive to chemotherapy initially. Surgery standalone
or in combination with chemotherapy is an available modality for this disease as they do not
benefit from HER2 directed or hormonal therapy. Atezolizumab/nab-paclitaxel is currently
FDA-approved for PD-L1–positive metastatic TNBC. Recently, olaparib tablets (Lynparza,
AstraZeneca Pharmaceuticals LP), a poly (ADP-ribose) polymerase (PARP) inhibitor, was also
approved by FDA for the treatment of patients with deleterious or suspected deleterious germline
BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with
chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting. In addition, studies have
identified several targeted therapies discussed in later subsections (Wahba and El-Hadaad, 2015).
i) Surgery in TNBC
Simple mastectomy, radical mastectomy and lumpectomy (breast-conserving surgery)
have been the strategies in the early stage TNBC management. Surgical decisions by patients
most likely rest on their preference and several clinicopathological factors despite the aggressive
nature of this disease. New technologies have led to improved breast cancer screening; early
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diagnosis and increased technical skills have made minimal invasive procedures possible, e.g.
conventional axillary dissection is successfully replaced by sentinel lymph node biopsy. In
addition, advances in imaging have led to the increased use of magnetic resonance imaging
(MRI)-targeted tumor biopsy in which MRI-visible lesions are sampled preferentially. This has
led to an increasingly popular less radical surgical approach of breast-conserving surgery (BCS).
Numerous studies have shown that BCS has improved body image perception, self-esteem, and
quality of life in younger females suffering from the disease. Nonetheless, TNBC patients who
decide to go for BCS often require intensive counsel because of increased fear of disease
recurrence (Eiermann and Vallis, 2012).
ii) Radiotherapy in TNBC
Radiation therapy is generally recommended in TNBC following BCS or mastectomy,
but its use still remains controversial. Owing to the aggressive nature of TNBC, radiotherapy
post BCS in early-stage (T1-2 N0) may not be comparable to mastectomy, like other types of
breast cancer. However, it has been reported that tumors of TNBC patients with BRCA1 gene
mutation are deficient in double-stranded DNA repair and are therefore highly radiosensitive
(Abdulkarim et al., 2011) . Radiation therapy post-BCS could remove the tumor foci in breast
and surrounding tissue that is deficient in BRCA1, and thereby decrease locoregional relapse.
iii) Chemotherapy in TNBC
The poor prognosis of TNBC patients and the probability of relapse because of distant
metastasis have fostered a major effort to discover effective systemic therapies for this subtype.
Despite historically poor clinical outcomes in TNBC, chemotherapy has proved to be effective
and therefore, advances in chemotherapy are expected to benefit the patients. Various
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chemotherapeutic strategies used for the TNBC management are: 1) platinum compounds and
taxanes that target DNA repair complex, 2) taxanes that also target tumors with TP53 mutation,
3) anthracycline therapy for inhibiting cell proliferation and other targeted therapies explained in
detail in the subsections below. Currently, the combination of anthracycline and taxane-based
chemotherapy is the standard treatment regime for TNBC patients diagnosed at an early stage as
patients respond well to it. Interestingly, no exclusive guideline for the management of
chemotherapy of TNBC patients is there yet. According to the European Society for Medical
Oncology (ESMO), the standard treatment therapy for TNBC is the cytotoxic one and the
treatment chosen should be based on a) disease-related factors such as tumor burden, prior
treatment regimen and the response, and necessity for the symptom control of the aggressive
disease, b) considerations related to patients such as age, patient preferences, performance status,
menopausal status, comorbidities, and lastly c) psychological and socioeconomic factors. Several
neoadjuvant studies indicate the additional advantage of integrating novel chemotherapy with
standard chemotherapy like antimetabolites, taxanes, platinum agents, anthracyclines, and
microtubule stabilizers etc. For advanced disease, chemotherapeutics of third generation,
wherein metronomic poly-chemotherapy is encouraged indicate the most efficacious tool for
high-risk patients. Preclinical and clinical data suggest that BRCA1 mutations in the tumors are
more sensitive towards DNA damaging compounds such as platinum agents. It is reported that
etoposide and bleomycin have also shown sensitivity to DNA double-strand breaks. Despite the
fact that patients with HER-2-overexpression have derived the most pronounced effect from
anthracycline-based chemotherapy, its efficacy remains controversial in TNBC patients. In the
advanced TNBC disease whereby patients have visceral metastases and a shorter survival of 8-12
months, the response to chemotherapy is also limited. Therefore, selecting the therapies that
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would most likely alleviate this aggressive disease is imperative. Also, in view of cancer
heterogeneity, the identification of molecular biomarkers to assess the effectiveness of
chemotherapy to further improve treatment strategies with targeted therapies is essential. (Wahba
and El-Hadaad, 2015). Below is the detailed information about chemotherapeutic agents
commonly used in TNBC.
a) Microtubule stabilizers
Taxane, the microtubule stabilizer, polymerizes tubulin in breast cancer. It has been
shown that taxanes (docetaxel [Taxotere], paclitaxel [Taxol], cabazitaxel) are effective for
TNBC. Ixabepilone (BMS-247550), analog of epothilone B binds to β-tubulin resulting in
stabilization of the microtubule and mitotic arrest. It shows similar clinical activity and toxicity
as that of taxanes as the dose-limiting adverse events associated with ixabepilone are peripheral
neuropathy and myelosuppression. In addition, it bypasses the resistance mechanism associated
with taxanes and therefore, a prodrug of 5-fluorouracil (FU), capecitabine and ixabepilone
combination is given to patients with anthracycline or taxane-resistant metastatic TNBC as it
improves progression-free survival (PFS) i.e. 4.1 months versus 2.1 months, as compared to just
capecitabine. Patients whose renal functions are compromised or who do not tolerate cisplatin
can benefit from the combination strategy of ixabepilone and capecitabine (Yao et al., 2017).
b) Anthracyclines
Anthracyclines such as epirubicin and doxorubicin are one of the utmost effective drugs
for the treatment of breast cancer. Numerous studies have elucidated the advantage of
anthracycline-based therapies for treatment of TNBC; however, there are controversial reports on
its efficacy. In a study, Liedtke et al. demonstrated that epirubicin in TNBC exhibited a 22%
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pathological complete remission (PCR) rate when compared to non-TNBCs, which is barely
11% (Liedtke et al., 2008). However, both groups showed a disease-free survival (DFS) of 3
years. On the contrary, a study by Carey et al. showed that doxorubicin and cyclophosphamide
elicit a much better clinical response in TNBC patients than non-TNBCs (Carey et al., 2007). In
summary, the significance of anthracyclines alone in TNBC is yet dubious; however,
combination strategy with taxane has shown benefit in node-positive TNBC patients (Yao et al.,
2017).
c) Platinum compounds
Molecular similarities and phenotypic characteristics between basal-like and BRCAassociated breast cancer have focused the interest on platinum compounds such as carboplatin
and cisplatin in TNBC. Platinum agents produce intra strand and inter strand ds DNA crosslinks,
thereby inhibit replication fork formation, resulting in ds DNA breaks. Platinum compounds
induce cell death in tumors associated with BRCA mutation due to dysfunctional DNA repair
cascade. Staudacher et al. demonstrated in a retrospective investigation that platinum-based
chemotherapy improved median overall survival (OS) (27 months over 8 months) and PFS (10
months over 4 months) in TNBC patients (Staudacher et al., 2011). It is noteworthy that platinum
agents combined with other chemotherapeutic agents such as epirubicin and 5-FU can increase
response and survival.
Other cytotoxic drug being studied in TNBC patients is trabectedin, which is a natural
product, obtained from sea sponges. Binding to the minor groove of DNA makes trabectedin
cytotoxic. However, it failed to show efficacy as a single agent in clinics (Yao et al., 2017).
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d) Targeted therapies
i) PARP (Poly (ADP ribose) polymerase) inhibitors
PARP inhibitors, including olaparib (AZD 2811), iniparib and BSI-201 appear to be
promising treatments for TNBC. PARP is a family of nuclear enzymes that repair ss DNA breaks
through base excision repair. Because the frequency of BRCA1 mutation is higher in TNBC,
PARP inhibitors can exert a cytotoxic effect owing to the inability of the cell to repair damaged
DNA. A combination of PARP inhibitors with platinums, topoisomerase inhibitors, ionizing
radiations elicit additive benefit. The results from clinical trials suggest the beneficial effect of
olaparib in women with metastatic breast cancer having BRCA1 mutations; olaparib was
therefore was approved by FDA. TNBC women without BRCA1 mutations still question
olaparib’s effect. Olaparib along with different cytotoxic agents is being evaluated in ongoing
clinical trials in the hope of developing treatment regimens that are more effective than olaparib
alone (Yao et al., 2017).
ii) Epidermal growth factor receptor (EGFR) inhibitors
EGFR/HER1 is overexpressed in approximately 72% of TNBC tumors. Therefore, EGFR
inhibitors (monoclonal antibodies and small molecules) were studied in clinical trials, however,
they failed miserably. In randomized clinical studies, TNBC patients with metastasis were
administered anti-EGFR antibody, cetuximab, in combination with other therapeutic agents such
as carboplatin, cisplatin or ixabepilone. These findings suggested that EGFR inhibitors when
used alone have low efficacy in TNBC patients as compared to the combination therapy, as the
combination of cetuximab and carboplatin was well tolerated, but OS was less (Mirzania, 2016).
Taxane and cetuximab combination was given to a small group of 12 patients with metastatic
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TNBC, wherein 9 of them responded well and other 3 developed brain metastases during the
treatment (Carey et al., 2010).
iii) Angiogenesis inhibitors
Several studies demonstrate the increased expression of VEGF in TNBC patients over
non-TNBC patients. Anti-VEGF monoclonal antibody, bevacizumab (Avastin), has shown
positive results in various clinical trials in breast cancer. Interestingly, TNBC patients with
metastases showed significant improvement when administered with the combination of
bevacizumab and chemotherapy in three independent trials. Those three trials are a) Avastin &
Docetaxel (AVADO) study, b) the E2100 trial (Avastin and Paclitaxel) and, c) the Regimens in
Bevacizumab for Breast Oncology (RiBBOn) study. TNBC progression was reduced by 47% in
AVADO trial, 51% in E2100 and RiBBOn-2 trial. Two other neo-adjuvant studies, National
Surgical Adjuvant Breast and Bowel Project 40 (NSABP)-B40 and GeparQuinto, highlighted the
contrary effects of bevacizumab when given with neoadjuvant taxane-anthracycline therapy.
(NSABP)-B40 showed no improvement in PCR whereas GeparQuinto reported a significant
improvement. Variations in reports from these two studies might probably throw some light on
disparities in how absence of HER2 was described in the patients treated in the clinical trials.
FDA questioned the efficacy of bevacizumab later in 2010 for the treatment of breast cancer
because

of

the

related

adverse

effects,

including

wound

healing

complications,

thromboembolism, perforations in gastrointestine, congestive heart failure, hemorrhage,
nephrotic syndrome, and hypertensive crisis. Bevacizumab was gradually removed for breast
cancer treatment; however, it was revoked and granted approval in 2011. Management of
metastatic breast cancer patients with bevacizumab is risky, as it has life-threatening side effects
and there is no evidence as such that bevacizumab will be beneficial in delaying tumor growth.
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In addition, there is no proof that bevacizumab will improve the quality of life of patients or help
them survive longer (O'Reilly et al., 2015).
iv) Androgen receptor inhibitors
It has been reported that 10-35% TNBC tumors express androgen receptors and that
androgen can stimulate these receptors resulting in breast cancer cells proliferation and hence
tumorigenesis. Androgen was shown to induce growth and proliferation of MDA-MB-453 cell
line, which is ER-negative, AR-negative and much similar to TNBC due to the same phenotype
of biomarkers. Therefore, the androgen blockade may benefit a subset of TNBC population.
Bicalutamide, a competitive androgen inhibitor is used for advanced prostate cancer owing to its
efficacy, but it was not tested in women until recently. NCT00468715 was a clinical trial
wherein 65 metastatic breast cancer women with AR-positive and ER/PR negative phenotype
were treated with bicalutamide and it was reported that bicalutamide was well tolerated in these
patients (O'Reilly et al., 2015).
v) Src inhibitors
Some of the src inhibitors such as dasatinib, neratinib, and sunitinib have been studied in
TNBC. Dasatinib has been shown to be effective in hematology malignancies and prostate
cancer. It has been reported that dasatinib is effective in inhibiting TNBC cell lines growth in
vitro, however, the benefit rate was merely 9.3% in Phase II trials of women with metastatic
TNBC. Also, a combined therapy of sunitinib with docetaxel showed no beneficiary effect in
metastatic breast cancer patients. Another src inhibitor, neratinib when given in combination
with mammalian target of rapamycin (mTOR) inhibitior, temsirolimus displayed no effect both
in the metastatic TNBC and metastatic HER2 amplified patients in Phase I/II trial. The tyrosine
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kinase phosphatase, PTPN12 that is found mutated in 5% TNBCs inhibits many oncogenic
tyrosine kinases such as EGFR and HER2. Breast cancer cells lacking PTPN12 displays tumor
suppressor effect on being reintroduced into the cells in vitro. Therefore, HER2 and EGFR dual
tyrosine kinase inhibitor, sunitinib and lapatinib might be beneficial against these tumors
(O'Reilly et al., 2015).
vi) Inhibition of PI3K/Akt/mTOR pathway
The aberrant activation of phosphatidylinositol-3-kinase (PI3K)/Akt and the mTOR
pathway is crucial in various types of cancer as it leads to uncontrolled growth and prolonged
survival of cells resulting in a pathological condition. A serine/threonine kinase, mTOR is
expressed ubiquitously in mammalian cells and is known to initiate signaling on being stimulated
by growth factors, intake of nutrients, and other initiating factors that regulate protein synthesis
and downstream signaling. The p70 S6 kinase (S6K) and 4EBP1 are the effectors downstream of
the mTOR pathway, which initiate mRNA translation into proteins required for cell growth,
metabolism, and progression of cell cycle. Similarly, PI3K/Akt pathway activation prolongs
survival of cells during cellular stress that is characterized by inadequate oxygen supply,
nutrients, and low pH. Interestingly, these two pathways are so interconnected that these are
almost considered as a single pathway. Mechanisms for activation of this pathway include loss of
PTEN (tumor suppressor) function, mutation/amplification of PI3K, Akt, growth factor receptors
activation, and exposure to carcinogens. Around 10% of TNBC patients exhibit inappropriate
activation of this pathway (Mirzania, 2016).
vii) Glembatumumab vedotin (GV)
GV is a glycoprotein Non-metastatic Melanoma B (gpNMB)- specific monoclonal
antibody conjugated to the potent cytotoxic monomethyl auristatin E. gpNMB is an
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internalizable transmembrane protein and a poor prognostic marker that is overexpressed in 40%
of TNBCs. gpNMB is implicated in migration, invasion, angiogenesis, and metastasis. In one
phase II study, GV was well tolerated and demonstrated promising activity, however there were
adverse effects like neuropathy, neutropenia, and rashes (Mirzania, 2016).
viii) Luteinizing hormone-releasing hormone (LHRH) conjugated to cytotoxic agent
Specific LHRH receptors are expressed in the pituitary gland and also in the healthy
tissues of male and female reproductive organs. They are not found in other tissues or in benign
tumors, but strikingly these receptors have been detected in various tumors such as breast,
ovarian, prostatic, and endometrial tumors. LHRH expression quantified by IHC staining was
found to be approximately 49% of pathological human tissue specimens. AEZS-108 is an analog
of LHRH conjugated to doxorubicin. In a retrospective study, AEZS-108 demonstrated toxicity
on the LHRH-R positive TNBC cell line. These in vitro findings suggest that LHRH conjugated
to cytotoxic agents, such as doxorubicin can be successfully used in TNBC (Mirzania, 2016).
1.4. TME in breast cancer progression
TME has been recognized as a key participant in breast cancer growth and metastasis.
Tumor-host crosstalk facilitates selection, induction, and expansion of breast cancer cells. Tumor
cells interact with the supporting cells that surround them, including endothelial cells,
leukocytes, fibroblasts, immune cells, adipocytes, and pericytes by secreting various cytokines
and growth factors. It results in the activation of the microenvironment, which in turn alters the
proliferative and invasive behavior of breast cancer cells (Balkwill et al., 2012).
The normal breast duct is formed of an inner luminal epithelium, surrounded by an outer
myoepithelial cell layer, which assists in attachment to the basement membrane. The
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microenvironment of the breast mainly comprises of ECM, fibroblasts, endothelial cells, and
immune cells. Tumor in breast evolves sequentially through defined stages, first being
hyperproliferation of epithelial cells, leading to invasive and metastatic cancer. The non-invasive
breast cancer, ductal carcinoma in situ (DCIS), is characterized by the confinement of the
proliferating cancer cells to the ducts whereas the invasive ductal carcinoma (IDC) is
characterized by the invasion of cancer cells to distant sites due to the damage in myoepithelial
cell layer and basement membrane. It has been reported in innumerable studies that DCIS
precedes IDC (Place et al., 2011). Detailed description of the cells forming TME is discussed in
the subsections below.
1.4.1. CAFs in breast cancer progression
CAFs are the most abundant cell type in breast tumor stroma and they actively engage in
a crosstalk with other cells in breast tumor promoting cancer progression and drug resistance.
One such crosstalk is production of plethora of chemokines, ECM proteins like elastin and
mainly collagen, adhesive proteins like laminin and fibronectin, and proteases that degrade ECM
like matrix metalloproteinases (MMPs). This interaction regulates ECM turnover and
subsequently maintains its homeostasis. In a study by Orimo et al., CAFs have been shown to
enhance tumor angiogenesis and growth by secreting stromal derived factor (SDF)-1, also known
as C-X-C chemokine ligand 12 (CXCL12), which acts via CXCR4 stimulation (Orimo et al.,
2005). CAFs have been shown to enhance TNBC progression through TGF-β activation. Coculture experiments have demonstrated that fibroblasts and basal-like cancer cells interaction
induced expression of various chemokines and interleukins, including IL-8, IL-6, CXCL-1/3, and
TGF-β. Also, myeloid cells expressing CXCL16 activated CAFs, resulting in myeloid cells and
fibroblasts recruitment in TNBC. In addition, CAFs have been shown to express higher levels of
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galectin-1, which regulates MMP-9 production further promoting tumorigenesis by ECM
degradation and remodeling. It has also been reported that syndecan-1 expression by stromal
fibroblasts promoted MDA-MB-231 cell growth and angiogenesis. Higher glucose uptake,
glucose oxidation, and glycogen synthesis is exhibited by co-cultured CAFs and basal-like breast
cancer cells. In other study, Tchou et al. have demonstrated that CAFs derived from HER2positive breast cancer enhanced tumor cell migration. Takai et al. have reported that targeting
CAFs could be a potential treatment for TNBC patients (Takai et al., 2016; Tchou et al., 2012).
1.4.2. CAFs in metastasis
An increasing number of experimental evidences have highlighted the role of CAFs as
primary mediators of cancer cell dissemination to metastatic sites. CAFs enriched in the primary
tumor release abundant growth factors and chemokines into the blood circulation that can
stimulate invasiveness and cancer cells growth at a metastatic site. It has been reported that
CAFs enhance stiffening of ECM at a primary site and form ECM tracks to assist cancer cell
metastases to distant sites. Activated mammary fibroblasts express tenascin C and VEGF-A to
mediate breast cancer metastases to lungs. Metastasis to liver in melanoma is due to activation of
hepatic stellate cells that contribute to angiogenesis. In colorectal cancer, TGFβ1 and PDGF
stimulate CAFs to secrete IL-11 and stanniocalcin 1 (STC1) respectively, leading to colorectal
cancer cells intravasation and metastases. Fsp-1 knockout mice exhibit reduced metastasis owing
to the reduced fibroblast motility. CAFs may be recruited from the primary tumor or bone
marrow to the metastatic site or they may be activated at the secondary tumor site (tissueresident fibroblasts) due to metastatic cell seeding or inflammatory mediators. Lysyl oxidase
(LOX), mainly produced by CAFs is one such mediator that is involved in metastatic cell
seeding at the secondary tumor site (Kalluri, 2016).
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1.4.3. CAFs in tumor immunity
In addition to CAFs role in the ECM protein synthesis and secretion of various ECM
remodeling enzymes, growth factors, cytokines and chemokines, they have pleiotropic
immunomodulatory functions as they regulate immune cell recruitment and activation. CAFs
secretome contributes to its activated state during tumor development potentially regulating
tumor immunity at different stages of the tumor. CAFs have also been reported to promote
immunosuppressive tumor microenvironment in numerous studies, however it can be context
dependent. For instance, in hypoxic conditions, immune cells dynamically interact with plethora
of cancer cells and other cells in TME, such as endothelial cells, which could potentially enhance
paracrine-signaling responses. The in vitro and in vivo studies conducted so far that link CAF
secretomes and immune responses involve CAFs expansion in vitro and injection with neoplastic
cells in mouse models. The secreted chemokines, cytokines and angiogenic mediators of CAFs
in tumors, for example, IL- (4, 6, 8, 10), TGF-β, tumor necrosis factor (TNF), CXCL-9, 10, Cmotif chemokine ligand 2 (CCL2), CCL5 (also known as RANTES), nitric oxide (NO), SDF1,
HGF, and prostaglandin E2 (PGE2) may influence tumor immunity directly or indirectly.
IL-6 has been shown to restrict maturation of dendritic cells, disable activation of T cells
and induce T cell anergy. Also, IL-6 produced by fibroblasts redirects monocyte differentiation
to macrophage rather than differentiation to dendritic cells. It also recruits mast cells. It is yet to
be elucidated whether IL-6 produced by CAFs is rate limiting in immunological responses or the
combined effect of IL-6 derived from other sources in TME and growth factors such as TGF-β
exhibit a synergistic response. CAF-derived IL-4, 6, 8 may stimulate myeloid cell differentiation
and therefore, form an immunosuppressive TME.
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CXCL14 production by CAFs affects recruitment of macrophages to the tumor site.
CCL2 has been implicated in breast cancer progression in vitro, however there is no compelling
evidence in vivo. Fibroblasts derived from disease free colons of humans have been found to
express negative co-regulatory immune mediators such as programmed cell death ligand (PDL1,
PDL2), which impacts T cell activation. Similarly, in lung cancer patients, it has been shown that
CAFs express PDL1 and PDL2 thereby exert immunosuppressive effect on T cells activation. It
is not clear so far if CAFs in solid tumors express negative co-regulatory signals that suppress
immune response. CAFs may also affect tumor immunity by regulating tumor angiogenesis i.e.
by modulating trans-endothelial immune cell migration. CAFs express adhesion molecules e.g.
ICAM1, which leads to the activation, polarization, or regression of immune cells by specific
reactions. Immune cells via paracrine signaling also influence CAFs, although dynamic network
of responses needs to be further studied. ECM proteins secreted by CAFs are hypothesized to
create a physical barrier around the tumor, restricting infiltration of immune cells in tumor
vicinity. Nevertheless, it has also been proposed that ECM remodeling by CAFs may enable Tcell and the tumor contact, as it unveils hidden attachment sites, thereby aid the adhesion of the
immune cells to the cancer cells. Pre-clinical studies in genetically engineered mouse models
(GEMM) and orthotopic tumor grafts revealed that therapeutically targeting FAP expressed by
CAFs enhanced intratumor cytotoxic T-cells recruitment, however it showed no efficacy in the
clinical trials (Kalluri, 2016).
1.4.4. CAFs in drug resistance
Despite endless therapeutic efforts, a major clinical challenge today in treating cancer is
the acquired resistance during the treatment or in response to the cancer therapy later. Stroma
rich in CAFs has been an instrumental player in drug resistance against chemotherapies such as
25

epirubicin, 5-fluorouracil and cyclophosphamide in breast cancer. Poor response to
chemotherapy due to CAFs has not been completely established. Various theories have been
proposed and studied to show the association of stroma in drug resistance, which involves CAFECM adhesion, neoplastic cell-ECM interactions, and chemokine or cytokine mediated signaling
pathways. CAFs may exhibit increased intratumoral interstitial fluid pressure that affects
anticancer drugs uptake. CAFs effect on immune cell modulation, metabolic reprogramming of
TME and, pro-angiogenesis may also promote drug resistance. Most of the data is based on in
vitro analysis; therefore extensive in vivo analysis using GEMMs and xenograft mouse models is
required to study drug resistance mediated by CAFs for therapeutic interventions.
Cancer cells adherence to ECM may enhance pro-survival responses through integrin β1mediated cell cycle arrest. For instance, in BRAF mutant melanomas, CAFs generate ECM rich
in fibronectin that enhances activation of FAK-Src-ERK through integrin β1, compensating for
BRAF inhibition in neoplastic cells. It is noteworthy that this could be an indirect effect of CAFs
in mediating resistance, as CAFs could just be involved in promoting cancer development by a
new mechanism such as facilitating resistance clones outgrowth. Nevertheless, there could be a
direct relation between drug resistance and CAFs, perhaps via AKT pro-survival signaling or Ncadherin binding in cancer cells. EMT is another parameter that could confer drug resistance as
CAF-remodeled ECM induces EMT in cancer cells. EMT is proposed to induce cell cycle arrest
and alter expression of cellular transporters facilitating chemotherapeutic drug uptake.
Soluble factors such as TGF-β, HGF, and IL-6 produced by CAFs could be another
reason for therapeutic resistance. TGF-β may facilitate increased cancer cells-ECM adhesion by
inducing mesenchymal signaling in cancer cells. CAFs resistance to RTK inhibitors could be
attributed to HGF. It is reported that HGF derived from CAFs promoted resistance to EGRF
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inhibitors in pre-clinical models. Also, there is a mounting evidence that IL-6 produced by CAFs
are implicated in pro-survival signaling cascade. CAF-mediated autocrine and paracrine
signaling within TME has shown enhanced cancer cells survival. Therefore, co-targeting CAFs
and cancer cells would be a good therapeutic approach in abrogating stromal induced lethal
pathways. Intriguingly, targeting Hedgehog signaling in CAFs in PDAC did not show any effect
in phase II trial. However, later studies in preclinical models and specific genetic studies in
PDAC corroborated the antitumorigenic effect of CAFs and hedgehog signaling. Several
approaches to overcome CAF-mediated drug resistance are being evaluated in clinic, for
example, enzymatic breakdown of ECM deposited by CAFs. Clinical trials for therapies
targeting hyaluronic acid degradation or angiogenesis to normalize tumor vessels and facilitate
chemotherapeutic sensitivity in solid tumors were performed, however the clinical results were
not satisfactory and the studies were terminated (Kalluri, 2016).
1.4.5. Extracellular matrix
ECM is necessary for the structural support of the tissues as it forms a basement
membrane. It regulates tissue homeostasis by providing tight junctions and firm contacts
between cells. ECM comprises of several macromolecules, including laminin, collagen,
basement membrane, fibronectin, and heparan sulphate proteoglycans, which are linked in a 3-D
matrix (Kalluri, 2003). ECM surrounds normal cells and remodeling of ECM in tumors can
override the protective constraints and lead to invasion of cancer cells into blood, lymphatic
system, and surrounding normal tissues. The remodeling is mediated by matrix degrading
enzymes, including MMPs, cysteine and serine proteases, and endoglycosidases such as
heparanase. The ECM is abundant in heparin binding pro-growth and angiogenic factors owing
to the increase in secretion of enzymes that degrade matrix. Infiltration of innate immune cells
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provides matrix-degrading enzymes (heparanase and cysteine cathepsins) in many tumors, and
inhibition of these enzymes blocks multiple pathways in TME. However, ECM degradation
needs a critical balance and therefore, matrix degrading enzymes inhibitors of broad spectrum
should be used with caution in clinics. Nevertheless, matrix-degrading enzymes, for instance
MMPs can inhibit tumorigenesis by secreting antiangiogenic proteins, such as tumstatin,
endostatin, and angiostatin (Hamano et al., 2003; Kalluri, 2003), which could be a potential
reason for the failure of MMP-I (matrix metalloproteinase inhibitors) in clinical setting. Other
therapeutic agents in the extracellular environment include the heterodimeric receptors, integrins
that connect cells to ECM and relay intracellular signals. In cancer cells and endothelial cells,
some of the integrins such as αVβ3, α5β1, αVβ5, and α6β4 are upregulated. Therefore, integrin
blocking impacts tumor growth owing to their participation in cell survival, angiogenesis, cell
motility, and adhesion. Integrin targeting using small molecule inhibitors or antibodies has
produced fascinating results in the preclinical studies, and a few of them are in clinical trials. αV
integrins have shown contrary results as αV knockout animals displayed increased angiogenesis.
Integrins have been implicated in cell-adhesion mediated drug resistance (CAM-DR) in several
cancer types, such as myeloma, small cell lung cancer, and glioma and in fact, integrin β1
blocking antibodies have demonstrated decreased CAM-DR. Extensive ECM remodeling in
cancer can promote cell-adhesion mediated drug resistance by altering integrins repertoire and
ECM composition and therefore, β1 integrins appear to be potential therapeutic targets (Joyce,
2005). Additionally, increased collagen production by CAFs also correlates with metastases. In
human breast tumors, increased collagen deposition increases stromal tension/stiffness, further
influencing breast cancer metastases through integrin dependent mechano-transduction signaling.
Breast tumor cells migrate along linear collagen fibrils and therefore, collagen fibrils are
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implicated in increased relapse and decreased survival. Longmore and colleagues showed that
activation of DDR2, a collagen 1 receptor stimulates ERK2 activity in Src-dependent manner,
thereby regulate Snail1 protein stability. ERK2 activation phosphorylates Snail1, resulting in its
accumulation in the nucleus, following decrease in ubiquitination and ultimately enhancing its
half-life. Stabilization of Snail1 protein results in enhanced migration, invasion, and metastasis
of breast cancer cells (Zhang et al., 2013). It has also been demonstrated that collagen type 1
promotes human breast cancer cells survival by overexpressing potassium (Kv10.1) and calcium
(Orai1) channels (Badaoui et al., 2018)
1.4.6. Endothelial cells
Hanahan and Folkman in 1996 reported that a tumor grows beyond a certain size only if
there is adequate supply of oxygen and nutrients. Basically, the tumor size depends on the
diffusion capacity of oxygen from the closest blood vessel, ranging from 100-200 μm (Folkman
et al., 2000). New blood vessel grows in the tumor from the pre-existing vessels, a process
known as angiogenesis, and by circulating endothelial progenitor cells recruitment, a process
known as vasculogenesis (Carmeliet, 2003; Rafii et al., 2002). Judah Folkman initially proposed
angiogenesis concept in 1971. It was criticized for a long period of time, however it is widely
accepted now and used in cancer therapeutics as multiple antiangiogenic agents. Endothelial
cells are surrounded by pericytes, which provide them structural support and survival signals.
Interactions between endothelial cells and pericytes, involving various growth factor signaling
pathways and PDGF-B/PDGFRβ, TGF-β1, VEGF-A/VEGFR2 result in functional and mature
vessels formation. It has been demonstrated that loss of VEGF production due to absence of
pericytes or decreased pericytes coverage in mouse models may make the endothelium
vulnerable to VEGF blockage. Blocking the signals that recruit pericytes to endothelial cells is
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one of the ways to reduce pericytes coverage. PDGFR inhibitors implicated in blocking the
signaling pathways have displayed limited efficacy as single agents. However, PDGFR
antagonist and VEGFR2 inhibitor in combination have exhibited decreased pericytes-endothelial
cell interactions and reduced tumor in a mouse model and of note, pericytes-endothelial
interactions in normal tissues have remained unaffected. It clearly suggests that there is a striking
difference between pericytes in normal tissues and tumor, which could be harnessed
therapeutically. Modifications of this therapy with the combination of chemotherapeutic regimen
and RTK inhibitors have shown even more efficacy in regressing tumors and enhancing survival.
In addition, preventing homing of endothelial progenitor cells to the tumor site can block blood
supply to the tumor. There are contrasting reports regarding endothelial cell contribution to the
tumor endothelium, ranging from 0-90% in mouse models and less than 5% in humans.
Concurrent VEGFR1/R2 inhibition displayed reduction in tumor growth in mouse models due to
reduced recruitment of endothelial progenitor cells. However, the failure of antiangiogenic drugs
in clinics has been disheartening, given the efficacy these drugs have shown in mouse models.
The discrepancy in the results could be attributed to the use of subcutaneous xenografts models
in this study. The major limitation with these models is that TME in a xenograft mouse model is
dramatically dissimilar from TME of endogenous tumors, which may lead to significant changes
at the molecular level, including changes in vascular-specific proteins profile. Therefore,
genetically engineered and orthotopic mouse models may recapitulate the TME of a specific
cancer. Clinical trials of VEGF specific antibody, bevacizumab in combination with
chemotherapy prolonged survival of metastatic colorectal cancer patients, resulting in FDA
approval of bevacizumab (Avastin) (Ferrara, 2004; Hurwitz et al., 2004). Bevacizumab exhibited
similar efficacy in Phase III trials of patients with non-small cell lung cancer when combined
30

with chemotherapy, implying that combined approach of targeting tumor cells along with
surrounding stromal cells may be more beneficial in treating human cancers (Joyce, 2005).
1.5. Metastases
Metastases or the treatment consequences are the biggest contributors of cancer-related
deaths. Once the cancer cells at the primary site evade the host immune defense system, they
enter circulation resulting in metastatic dissemination. The pattern of blood flow away from the
primary tumor site is one of the major factors that determine the location of metastases. Tumor
cells travel to the heart after entering the bloodstream and then to the lung capillary beds. Some
cancer cells may reside there while others come back into the circulation to access other sites.
However, a circulatory pattern is not the only deciding factor for tumor dissemination. Certain
tissues provide a favorable microenvironment replete with growth factors and nutrients for the
circulating tumor cells (CTCs) to thrive. Additionally, the tumor at the primary site may form
pre-metastatic niche for the incoming cancer cells i.e. a hospitable microenvironment in the
secondary organs before the arrival of tumor cells. Cancel cells travel throughout the body but
they thrive and grow at a place best suitable for them in terms of nutrition. Lungs, liver, brain
and bones provide the best soil to the breast cancer cells.
It has been proposed in multiple studies that EMT is one of the initial steps of primary
tumor invasion, wherein tumor cells lose epithelial traits and gain mesenchymal features, leading
to a migratory phenotype. However, secondary lesions at later stages of metastasis exhibit
epithelial phenotype, implying that the metastatic outgrowth often relies on mesenchymalepithelial transition (MET). This highlights the significance of phenotypic switching for
metastasis and indicates that tumor cells in response to diverse stimuli may oscillate along an
epithelial-mesenchymal gamut.
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Furthermore, the tumor margin in the TME is a critical site where recruited stromal cells
and immune cells interact with the tumor and support metastases. Immature myeloid cells
accumulated in the tumor margin prevent differentiation of antigen-presenting dendritic cells and
therefore aid tumor immune evasion. Macrophages present at the tumor margin, recruited by
cancer cell-derived chemo attractants promote metastases by secreting migratory factors e.g.
EGF, regulating production of fibrillar collagen to enhance tumor motility, and proteolytically
remodeling ECM. Similarly, CAFs at the tumor edge secrete various pro-invasive factors for
rapid dissemination of cancer cells.
The process of metastasis is extremely inefficient as only 0.01% of cancer cells that enter
circulation are capable of secondary growth at a distant site. Platelets play a vital role during
dissemination as they interact with tumor cells in the hostile microenvironment of the
bloodstream and enhance their survival. Platelets in circulation enhance fibrin deposition on
cancer cells; thereby evade cytotoxicity by NK (natural killer) cells. In response to a vascular
injury, platelets get activated by thrombin, adhere to endothelium, and aggregate. They reminisce
their normal physiological role in a pathological condition wherein they adhere to the
endothelium on arrival of cancer cells at secondary organs, and the collagen exposed on the
stripped region of endothelium interacts with integrins expressed on platelets causing their
activation.
Metastatic TME has not been studied at a molecular and cellular level so far. However,
several functional studies highlight the interactions between epithelial cells and stroma in the
tumor. Tumor cells survive in different microenvironments during metastatic progression, such
as blood, distant organs, and lymph nodes. Metastatic cells colonization may be mediated by
chemo attractants produced by the local organ or secretion of products by the primary tumor that
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creates a favorable niche at the distant site. It has been shown that secretion of osteopontin in
MDA-MB 231 xenograft tumors recruited bone marrow derived cells to the metastatic sites to
support the secondary growth of metastatic cells (Place et al., 2011). Similarly, LOX secretion by
CAFs and breast cancer cells facilitate pre-metastatic niches and metastases in organs such as
lungs, bones, brain etc. Seed and soil hypothesis was first proposed by Stephen Paget in 1889,
clearly stating that metastatic cells dissemination is not random, but organ-specific. It was
hypothesized that tumor cells at primary site release factors that create a favorable environment,
abundant with fibroblasts, bone-marrow derived precursors, and cytokines resulting in premetastatic niche formation. In a study, LOX expression by breast cancer cells was reported to
promote recruitment of myeloid cells and colonization of metastatic cells in the lung.
Furthermore, LOX inhibition in breast cancer cells prevented myeloid cells recruitment to
premetastatic niches, and thereby reduced lung metastasis. Hypoxia in primary tumor has also
been a crucial factor in facilitating pre-metastatic niche formation. It was shown that injection of
breast cancer cells conditioned media cultured under hypoxia in mice induced bone marrow
derived cells infiltration in the lungs even in the absence of cancer cells. It implies that during the
initial phase of the disease, a therapeutic intervention that disrupts the metastatic niche before the
arrival of cancer cells may be beneficial (Quail and Joyce, 2013).
1.5.1. Metastatic sites
TNBC is a rapidly dividing cancer with a high mitotic index, a high histologic grade, and
higher rates of recurrence in soft tissues and visceral organs. The metastatic sites for patients
with TNBC are mainly lungs, lymphatics, and brain. Out of 180 women diagnosed with TNBC,
40% had positive lymph nodes (Dent et al., 2009). Patients with basal-like tumor had lower rates
of bone relapse when compared to the patients with luminal tumor; however, lungs and brain
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relapse was more frequently observed in patients with basal-like subtype. Additionally, studies
also suggest an increase in incidence and aggressive trait of brain metastasis in TNBC patients
(Anders and Carey, 2009).
1.6. Lysyl oxidase
LOX (protein lysine 6 oxidase) is a copper dependent enzyme that oxidizes primary
amine into reactive aldehydes. It plays a crucial role in remodeling ECM in mammals by
crosslinking proteins such as collagen and elastin, necessary for maintaining the structural
integrity and tensile strength of tissues. LOX family consists of five different enzymes, namely
LOX and LOX-like (1-4), comprising of a highly conserved catalytic carboxy domain. LOX is
synthesized as a preproprotein, secreted as N-glycosylated proenzyme (50 kDa) and then
proteolytically cleaved to the catalytically active, mature enzyme (32 kDa) (Pinnell and Martin,
1968). LOX expression is controlled during normal development; however, abnormal levels have
been reported in many diseases, including cancer that involve ECM regulation.
Interaction between the cancer cells and the microenvironment is a critical factor in
tumor initiation and progression. Benign tumors arising due to genetic mutations in the
epithelium become malignant because of the alterations in the microenvironment, for example
ECM remodeling. A stiffer microenvironment by enhanced deposition of ECM and remodeling
destabilizes cell polarity and cell-cell adhesion, increases growth factor signaling, and promotes
tumor progression. CAFs being a prominent cell type of the TME facilitate remodeling and
increase ECM, growth factor secretion, cytokine, and chemokine production. The expression of
LOX family has been shown to be upregulated in stroma and tumor cells in certain types of
cancers. It has been demonstrated that in various types of cancers, including head and neck
squamous, renal, colorectal, prostate, and breast cancer, there is an increase in LOX mRNA and
34

protein expression. Increased LOX expression has also been shown in stromal cells in DCIS.
High LOXL2 levels correlates with desmoplasia and high expression of other LOX members
may correlate with desmoplastic stroma of aggressive tumors. LOXL2 is implicated in
supporting survival of tumor cells, providing chemotherapeutic resistance, remodeling of TME,
and metastasis. It is noteworthy that LOXL2 is associated with high tumor grade, poor prognosis,
and low overall patient survival and can also be used as a prognostic biomarker in head and neck
cell carcinoma. LOXL2 is also implicated in patients with ER-negative breast cancer resulting in
an aggressive phenotype and increased metastasis, suggesting that remodeling the TME
promotes cancer progression.
1.6.1. Targeting LOX family in cancer
It is often suggested that metastasis results from the overexpression of genes that promote
metastasis or inactivation of genes that suppress metastasis. Therefore, therapeutically targeting
metastasis-associated genes could prevent tumor cells colonization. LOX family members have
been shown to possess opposing roles both as tumor promoters and suppressors. Hence, targeting
LOX may be beneficial in alleviating the metastatic disease. Multiple studies have shown that
LOX family members promote metastasis and their inhibitors, including LOX and LOXL2 have
demonstrated a remarkable decrease in dissemination of metastatic cells. As discussed above,
LOX family causes increase in fibrosis that is often observed in fast growing cancers. Therefore,
targeting LOX enzymes activity may decrease fibrosis development and further improve patient
prognosis.
It has been demonstrated that LOX inhibition by treatment with the LOX, LOXL2 and
LOXL4 inhibitor, such as β aminopropionitrile (βAPN), LOX specific RNA interference, and
function-blocking antibodies inhibit metastases to liver and lungs in transgenic and xenograft
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mouse models. However, βAPN did not show decrease in primary tumor burden. βAPN was
earlier applied topically in humans for the treatment of keloidal and hypertrophic fibrotic scars
and keloidal scars, however the clinical trials were terminated due to its toxicity. Also,
teratogenic effects of βAPN were observed in developing zebrafish on systemic treatment.
The efficacy of inhibiting LOXL2 antibodies has been tested in mouse models of cancer
by using D-pencillamine (DPEN), the nonspecific LOXL2 inhibitor that prevents the formation
of crosslinks by binding to the intermediary reaction products. An allosteric inhibitory
monoclonal antibody and several other antibodies have also been tested in the same regard. It has
been reported that the treatment of LOXL2 antibodies in orthotopic breast cancer and gastric
cancer reduced primary tumor growth, however it had various side effects. Perhaps, more
selective small-molecule LOXL2 inhibitors are likely to have fewer adverse effects because of
the low levels of LOXL2 expression in normal tissues (Hutchinson et al., 2017). In fact, LOXL2
antibody, AB0023 had no abnormal effects in the normal tissue of mice and a humanized version
of LOXL2 antibody, AB0024 was in the clinical trials (NCT01323933), however the study was
terminated later.
LOX family has been targeted indirectly by tetrathiomolybdate (TM), a copper-chelating
agent that inhibits copper uptake by cells. Patients with metastatic breast cancer treated with TM
exhibited stabilization and also disease regression for months. HER2 transgenic mice treated
with TM showed decreased breast tumor growth by preventing formation of new blood vessels
and reducing activation of NF-κB signaling. In this study, the catalytic activity of LOX family
may have decreased due to low copper availability, albeit the activity of the LOX inhibitors was
not assessed. It is noteworthy that depleting systemic copper for a long-term may adversely
affect hematological function, such as leukopenia, and neuropathy; therefore, this strategy has to
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be used cautiously. Abrogating hypoxia response is another approach to prevent tumor
progression and metastasis. HIF1α targeting inhibited LOX expression under hypoxia in vitro,
and reduced tumor growth and invasion in colorectal and breast cancer mouse models. Indeed,
one of the strategies for cancer therapy is targeting hypoxia, as hypoxia regulates the expression
of LOX family members. Even the solid tumors of a smaller size harbor hypoxic areas,
suggesting the crucial role of LOX family members in cancer cells survival. Intriguingly, there
are several other mechanisms, for example TGF-b that regulate the expression of LOX family
members; therefore, in this scenario, it is unclear if HIF1α inhibition can be effective. Also, LOX
L1, LOXL3 and LOXL4 inhibitors as anticancer drugs have not been studied in detail so far
because of the inadequate evidence of their tumor promoting activity. One of the studies
demonstrated that high expression of LOXL4 correlates with metastasis to lymph nodes in
patients with head and neck squamous cancer. Also, LOXL4 expressing engineered dendritic
cells could stimulate T-cells to secrete interferon (IFNγ), an antitumor cytokine, suggesting the
importance of dendritic cells as a vaccination therapy in head and neck squamous cell cancer
patients (Kim et al., 2008).
LOX and LOXL1 are activated by bone morphogenetic protein 1 (BMP1), and it has
been shown that inhibition or knockdown of BMP1 results in the reduction of LOX levels in
vitro. However, inhibiting BMP1 can lead to serious side effects because of its crucial role in the
development of cartilage and bone.
One of the main roles of the LOX family is the crosslinking of ECM, which results in
alterations in biomechanical properties. So, targeting the capability of a cell to track all the
changes and respond to them could be another approach. Integrin targeting is one method that
could preclude this ‘outside-in’ signal transduction; however, studies have not been performed
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yet to evaluate the effects of integrin inhibition on LOX family mediated modulations of ECM
(Barker et al., 2012).
1.7. Pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is the fourth highest cause of cancer-related
mortality in the US and other developed countries. If the outcomes do not improve, PDAC is
predicted to be the second leading cause of cancer deaths within the next decade as it has the
worst outcome among all cancers. The fundamental biology of PDAC makes it uniformly and
rapidly lethal. The overall 5-year survival for the disease is less than 5%, with a median survival
of 4-6 months. The normal pancreas is comprised of acinar cells that secrete digestive enzymes,
ductal cells that secrete bicarbonate, centro-acinar cells that are the geographical transition
between ductal cells and acinar cells, endocrine islets that secrete hormones and quiescent
stellate cells. The most common malignant neoplasms of the pancreas are adenocarcinomas;
other neoplasms include neuroendocrine tumors, which secrete hormones such as glucagon,
insulin; and acinar tumors, which secrete digestive enzymes into the circulation; the latter tumors
are rare. Ductal carcinoma is commonly referred to as pancreatic tumor as it is the most common
carcinoma of the pancreas. It represents a significant health problem affecting hundreds of
thousands of people worldwide, with an estimated diagnosis of 367,000 new cases and 359,000
deaths worldwide in the year 2015. PDAC is associated with an extremely poor prognosis for
various reasons. It is often diagnosed at advanced stages, which is due to non-specific and nonsensitive tumor markers and limitations in imaging early stage tumors. Also, in some cases, it is
difficult to figure out, as there are no warning signs or symptoms. PDAC is very aggressive, with
perineural and vascular local growth, and early metastases to distant organs that impede surgical
resection in most of the patients. In addition, resistance or tolerance to most conventional
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treatments, such as chemotherapy, radiotherapy, or molecular targeted therapy makes it even
more difficult to manage. PDAC also harbors multiple genetic and epigenetic variations and has
highly dense TME. All these factors result in a low 5-year survival, with almost all survivors
(10-20%) being the patients who undergo surgical resection. Although some areas of research
and patient care have made incremental progress, such as more-efficacious combined
chemotherapeutic strategies, new preoperative treatment options, better perioperative care and
safer surgery, the overall effect on the prognosis of PDAC patients has been marginal. The
strategies to manage or cure pancreatic cancer include individualized therapies for a subgroup of
patients, therapies targeting molecular pathways, immunotherapies, and therapies that target
TME. Additional areas of intense investigation are early detection, validation of tumor marker,
and standardization of patient care (Kleeff et al., 2016).
1.7.1. Patient population and diagnoses
PDAC largely affects older population, 71 years being an average age of diagnosis. The
symptoms are non-specific, e.g. abdominal pain and weight loss. The patients and doctors are
usually accustomed to aches and pains; therefore, the earliest signs of malignancy go unobserved
in majority of the cases. In contrast to breast, melanoma, and prostate cancers, no simple
examination can lead to detection of pancreatic cancer as pancreas are too deep to palpate and
lack of specific blood test. Other symptoms include new onset of diabetes, inexplicable painless
jaundice and unprovoked thrombosis. Hence, by the time that patient approaches a doctor, often
many months pass, and patients’ condition further worsens. PDAC affects patients’ overall
health and can be life threatening. It shows symptoms related to pain and depression that
deteriorates with progression of the disease. Patients not only suffer from biliary obstruction,
jaundice, infection, ascites, pancreatic insufficiency, but also experience hypercatabolic state of
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cachexia and muscle wasting. Risk factors such as type II diabetes mellitus, tobacco smoking,
and chronic pancreatitis account for approximately one-quarter to one-third of pancreatic cancer.
Cases and efforts to change the long-term outcome of patients through modifications of risk
factors have been disappointing so far. Although cigarette smoking should be highly
discouraged, other factors such as dietary habits are less definitive, as there is limited evidence to
prove that dietary changes reduce the risk of pancreatic cancer. Low-dose aspirin is the only
promising chemopreventive agent that reduces the risk of pancreatic cancer in a dose dependent
manner. Also, it is believed that the first-degree relatives of patients are at increased risk,
however, these comprise of a minority of patients (5-10%). This knowledge is not of much use
because of lack of validated screening tests for PDAC diagnoses at an early stage. Pancreas is
located in retroperitoneum; therefore, it is difficult to access and sample it with a traditional
endoscope. Endoscopic ultrasound techniques have higher yields, however, deaths associated
with it make it unsuitable as a screening tool in an unselected population. Even with the targeted
population of patients, it seems to be at a higher risk as per the ongoing studies. Cross-sectional
imaging can identify small and asymptomatic pancreatic lesions at an early stage when it is
possible to surgically resect. But unfortunately, due to poor innate contrast between pancreatic
tumor and its surroundings, it is difficult to image pancreatic tumor. Specialized imaging
protocols are needed to optimize imaging by computerized tomography (CT) and magnetic
resonance imaging (MRI). Serum sampling has also not been identified as a suitable screening
test for early detection of PDAC. Although pancreatic lesions secrete carbohydrate antigen (CA)19-9, it is not an ideal screening marker as it gives high rates of false positivity in nonmalignant
hepatobilliary disease patients. No validated molecular makers have been identified so far
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despite extensive efforts, as a result of which diagnoses gets delayed (Oberstein and Olive,
2013).
1.7.2. Risk factors
Age is the main determinant of PDAC as most patients are often diagnosed at an age
above 50 years, with a peak incidence at 70s or 80 years. Tobacco smoking is another major risk
factor as smokers have two-fold or three-fold chances of developing this lethal disease than nonsmokers. Sedentary lifestyles that lead to obesity are also associated with pancreatic cancer.
Some dietary products such as red and processed meats, saturated fats and low intake of fruits
and vegetables also lead to higher risk. Studies have shown an association of heavy drinking with
PDAC, but no such reports highlight the association with moderate drinking. Diabetes mellitus is
also considered as a risk factor and a consequence of early-stage pancreatic cancer. Long-term
diabetes mellitus doubles the risk of pancreatic cancer.
Diabetes mellitus is both a risk factor for disease and a consequence of early-stage
pancreatic cancer; long-term diabetes mellitus approximately doubles the risk of pancreatic
cancer. Diabetes mellitus can also be caused by pancreatic cancer (type 3c diabetes mellitus) and,
accordingly, new-onset diabetes mellitus can be the first clue to the diagnosis of pancreatic
cancer in elderly patients. Gastrointestinal ulcer and gastrectomy are also associated with a
modest increase in risk of PDAC but has limited influence on overall disease burden in the
modern era.
10% of patients have a family history of pancreatic cancer. Indeed, some hereditary
conditions carry an increased risk of pancreatic cancer, such as Peutz–Jeghers syndrome.
Mutations in BRCA1/2, P53, KRAS, CDKN2A, ATM, STK11, PRSS1, MLH1 and PALB2 are
associated with pancreatic cancer with variable penetrance, and common variants that confer
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modest risk, such as those at the ABO blood group locus have also been identified (Kleeff et al.,
2016).
1.8. TME in pancreatic cancer progression
PDAC has an abundant and dense collagenous stroma (desmoplasia), resulting in a
considerable hypoxic environment for cancer cells. This stroma is composed of ECM proteins,
including collagen, laminin, and fibronectin, as well as non-collagenous proteins, including
glycoproteins, proteoglycans, and glycosaminoglycans. Other factors in the stroma that mediate
the interactions of neoplastic cells with the ECM include growth factors, periostin, osteopontin,
and serine protein acidic and rich in cysteine (SPARC). Cellular elements of the stroma include
pancreatic stellate cells (PaSCs), which produce the collagenous matrix, endothelial cells, and
infiltrating immune cells. The immune cell complement in PDAC includes T-cells, a majority
being CD4+ regulatory T-cells, myeloid-derived suppressor cells (MDSCs), macrophages, and
mast cells. The immune cell infiltration suggests an immunosuppressive phenotype, even at the
earliest stages of pancreatic cancer (PanINs and IPMNs). Extensive evidence suggests that
stromal CD4+ regulatory T-cells play a crucial part in immunosuppression. It is clinically
relevant because factors that ward off the active antitumor immunity, such as the ligand for
programmed cell death protein 1 (PD-1) - PD-L1 i.e. expressed on cancer cells form the basis of
an immunotherapeutic approach that is currently being investigated with different combinations
in pancreatic cancer.
However, targeting stroma in PDAC remains debatable due to different clinical
outcomes. The largest study to date, reported an association between the activated PaSCs number
and poor clinical outcome (n=233). But this finding was contrary to two subsequent smaller
studies. The contrary results could be due to differences in the calculation or assessment of
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stromal activity and the patient cohort selected. Another study with 145 patients reported that
early stage PDAC (T1-T2) with moderate to strong α-SMA (a marker of activated PaSCs)
expression was associated with poor overall survival and progression free survival than the
tumors with low α-SMA expression. It is noteworthy that the interaction between PDAC cells
and PaSCs is bidirectional, wherein both cells types stimulate proliferation and migration of each
other. PaSCs have also been shown to increase survival of PDAC cells by inhibiting their
apoptosis. Further, PaSCs facilitate cancer stem cell niche formation and provide
chemoresistance and relapse (Kleeff et al., 2016)
1.8.1. Pancreatic stellate cells
In 1998, the rare stromal cells were classified in normal healthy pancreas as PaSCs. They
were identified as cells with periacinar star-shaped morphology, expressed a characteristic
marker protein, and stored vitamin A rich fat droplets like hepatic stellate cells (HSCs). In
normal physiological conditions, PaSCs are quiescent; however, in acute and chronic
inflammatory conditions, PaSCs get activated. Activation of PaSCs involves changes in
morphology, α-smooth muscle actin (α-SMA) expression, ECM deposition, and loss of retinol.
The embryonic origin of PaSCs has not been addressed yet, however, bone marrow
mesenchymal cells are the most likely source of PaSCs in mice after injury. PaSCs have a short
life span in culture; therefore, immortalized PaSC lines from mouse, human, and rat pancreata
have been generated. Co-culturing PaSCs with PDAC has enabled identification of several
crosstalk pathways between the cells. PaSCs are implicated in PDAC progression as they
enhance proliferation and migration of PDAC cells by releasing growth factors and cytokines.
These findings are corroborated in in vivo studies wherein co-injection of PaSCs with PDAC
cells in orthotopic models of PDAC increases size of the tumor and metastasis. PaSCs have also
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been reported to increase the proliferation of endothelial cells and promote angiogenesis, the
effects mediated by VEGF and/or HGF secreted by PaSCs. Subsequently, Xu and colleagues
investigated that PaSCs orchestrate metastasis by co-migrating with cancer cells to potentially
establish the appropriate metastatic niche (Xu et al., 2010). Further in vitro experiments reveal
that PaSCs increase the stem cell phenotype of PDAC cells, suggesting the additional benefits of
targeting PaSCs. The signaling pathways activated in PaSCs due to cross talk with neoplastic
cells can be important therapeutic targets. For example, mitogen activated protein kinase
(MAPK) pathway activation in cancer cells upon PDGF stimulation plays a vital role. Others
include FGF, TGF-b and its downstream effectors, CTGF (connective tissue growth factor), and
EGF. Targeting PaSCs have been shown to modulate other aspects of TME, including immune
and vascular system. It has been reported that PaSCs suppress immune system by sequestering
tumor-suppressive CD8+ T cells, inducing T cells apoptosis via galectin-1 (β-galactoside-binding
protein) secretion, and stimulating MDSCs migration into the stroma. Thereafter, this cascade
induces mast cells degranulation, resulting in the release of IL-13 and tryptase, which stimulates
the proliferation of PaSCs and PDAC cells. Mast cells degranulation induces cytokine release by
macrophages leading to further activation of PaSCs.
Extensive evidence suggests a role of PaSCs in PDAC growth and metastasis; however,
recent studies have controversial findings suggesting the protective role of PaSCs in PDAC.
These contrary studies reveal that stromal cell influence may be dependent on context or timings.
For instance, upregulation of PaSCs during early carcinogenesis could highlight host’s attempt to
isolate PDAC cells, but in later stages, PDAC cells may be able to subvert PaSCs into cancerpermissive cells.
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1.8.2. Extracellular matrix as an obstacle to therapy
PDAC is histologically characterized by the abundance of ECM, commonly referred to as
desmoplasia. ECM accumulation distorts the architecture of the pancreas leading to abnormal
blood and lymphatic vessels. One important factor that could contribute to therapy resistance in
PDAC is the rigid ECM, mainly collagen fibrils that compress blood vessels, resulting in
hypoperfusion, ultimately blocking drug delivery into the tumor. In fact, the active metabolite of
gemcitabine, 2-difluorodeoxycytidine triphosphate (dFdCTP) was detectable in stroma-poor
subcutaneous or orthotopic xenografts but hardly detectable in stroma-rich tumors in genetically
modified KPC animal model (GEMM KPC) (Feig et al., 2012).
1.9. Current approaches to target PDAC
1.9.1. Conventional therapies
FDA has approved several drugs and drug combinations for PDAC, including 5flourouracil, albumin-bound paclitaxel, gemcitabine, and FOLFIRINOX. Gemcitabine is
administered in higher and repeated doses owing to its short half-life and rapid body clearance
resulting in adverse effects. It also induces resistance in tumor through various mechanisms.
Gemcitabine and erlotinib (EGFR inhibitor) are the only two drugs approved in advanced PDAC
despite their moderate benefits. Approx. 5-10% of PDAC patients respond to gemcitabine
therapy, despite the survival benefits observed in clinical studies. Gemcitabine and erlotinib
combination prolongs one-year survival by just 23%. Gemcitabine (2’, 2’-difluoro-2’deoxycytidine; dFdC) is a deoxycytidine analog with multiple modes of action inside the cell. As
a prodrug, dFdC must be metabolized to the active triphosphate form of gemcitabine (2’, 2’difluoro-2’-deoxycytidinetriphosphate; dFdCTP). Cellular uptake of gemcitabine is mediated by
a family of integral membrane proteins termed human nucleoside transporters (hNTs), which
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overcome the inherent barrier to diffusion imposed by the hydrophilic nature of nucleosides and
nucleoside analogs. Once inside the cell, gemcitabine is phosphorylated in the cytoplasm by
deoxycytidine kinase (Dck) to the monophosphate (dFdCMP) and then phosphorylated again by
pyrimidine nucleoside monophosphate kinase (UMP-CMP kinase) into gemcitabine diphosphate
(dFdCDP). The enzyme responsible for the final phosphorylation step (dFdCDP into the active
metabolite dFdCTP) is unclear, although nucleoside diphosphate kinase may play this role. The
first phosphorylation by Dck is considered the rate-limiting step for dFdCDP and dFdCTP
production. Gemcitabine may become inactivated through deamination by cytidine deaminase
(Cda) and deoxycytidylate deaminase (dCTD). The product of gemcitabine deamination by Cda
is 2’,2’-difluoro-2’-deoxyuridine (dFdU), which is the inactive metabolite of gemcitabine. dFdU
monophosphate (dFdUMP) could inhibit the activity of thymidylate synthase, directly effecting
the deoxynucleotide triphosphate (dNTP) pool. The most important mechanism of action of
gemcitabine is inhibition of DNA synthesis. When dFdCTP is incorporated into DNA, a single
deoxynucleotide is incorporated afterwards, preventing chain elongation. This non-terminal
position of gemcitabine makes DNA polymerases unable to proceed, in a process known as
‘masked chain termination, which also inhibits removal of gemcitabine by DNA repair enzymes.
In addition, FOLFIRINOX significantly improves overall survival in patients with
metastatic PDAC by 4 months, whereas gemcitabine shows the overall survival of 6.8 months. It
is difficult to treat PDAC with conventional therapies for the reasons mentioned below. Genomic
instability limits the effectiveness of therapy as it contributes to secondary or acquired resistance.
For instance, mutations in p53 can result in loss of their suppressor functions, decrease apoptosis
and reduce response to therapeutics. The frequency and number of gene mutations is associated
with overall survival of patients. Additionally, an extreme complex network of signaling, genetic
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alternations, and cross talk between PDAC cells and TME is another hurdle in PDAC treatment.
Around 63 genetic alternations in 12 different signaling pathways are usually abnormally
activated in the majority of PDAC cases. Lastly, decompressed vessels because of high
desmoplasia act as an important drug delivery barrier resulting in reduced exposure of PDAC
cells (Aslan et al., 2018).
1.9.2. Sonic hedgehog pathway inhibitor
Sonic Hedgehog (SHH) ligands overexpression in PDAC results in a significant
desmoplastic reaction. SHH binds to the PTCH1 receptor that acts in the regulation of
Smoothened protein (SMO), wherein overexpression of SMO results in aberrant activation of the
SHH pathway in PDAC. SMO receptor inhibitor, saridegib in combination with gemcitabine
provided promising results as it increased overall survival in PDAC mouse model. It
significantly decreased desmoplasia, deposition of collagen and increased gemcitabine
concentration in the tumor. However, clinical trials showed no promising results. Additionally,
SMO antagonist, vismodegib showed disappointing results in patients with metastatic PDAC in
phase II clinical trial (NCT01064622) (Aslan et al., 2018).
1.9.3. Secreted protein acidic and rich in cysteine
Secreted protein acidic and rich in cysteine (SPARC) is a target to facilitate depletion of
the tumor stroma in pancreatic cancer. SPARC is overexpressed by fibroblasts and reported to
inversely correlate with overall survival. It has been reported that a drug formulation, nabpaclitaxel (Abraxane) consisting of paclitaxel associated with albumin accumulates and depletes
PDAC tumor stroma via binding of albumin to SPARC-positive fibroblasts. This represents a
mechanism for targeting a specific cell type within the PDAC microenvironment. Gemcitabine
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and nab-paclitaxel combination showed a survival benefit of 12.2 months in the first clinical
trial. However, on the contrary, a separate report showed poor prognosis when the combination
of gemcitabine and nab-paclitaxel was given in SPARC-enriched tumors. The mean overall
survival in patients with high SPARC was 17.8 months compared to low SPARC i.e. 8.1 months
(Feig et al., 2012).
1.9.4. Hyaluronidase, PEGPH20
It was previously believed that one promising strategy to decompress vessels and aid
drug delivery is to break down the ECM enzymatically. PDAC is one such cancer, which is rich
in hyaluronan (HA), a glycosaminoglycan that has high affinity for water due to its high colloid
osmotic pressure. In healthy organs, it provides elasticity, however, the excessive accumulation
of HA in solid tumors compresses vessels and increases interstitial fluid pressure. A
hyaluronidase, PEGPH20 decreased interstitial fluid pressure, enhanced drug delivery, and
prolonged survival in murine PDAC tumors (Hingorani et al., 2005). It showed promising results
in the pre-clinical and early clinical trials; however, the study was terminated in phase 3 clinical
trial. The drug showed no improvement in progression free survival and overall survival. The
drug was given an orphan status by US FDA for pancreatic cancer treatment in 2014.
1.9.5. FAK inhibitor
Jiang et al. reported the effects of FAK (focal adhesion kinase) inhibition in GEM models
of PDAC. FAK inhibitor in combination with the immune checkpoint blockade modulated the
immune microenvironment in PDAC GEM models. They demonstrated that FAK signaling in
cancer cells regulates the TME composition. FAK inhibitor decreased FAP+ fibroblasts, myeloid
derived suppressor cells (MDSCs), CD206+ macrophages, and T-regs, however it increased
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CD8+ T-cell infiltration into FAK-depleted PDAC tumors. In addition, FAK inhibition reduced
deposition of collagen within the tumor, consequentially overcoming a physical barrier to T-cell
infiltration. These alterations reprogramed the pancreatic TME, shifting the balance in favor of
anti-tumor immunity. The authors identified that FAK regulates the secretion of a number of
chemokines in PDAC cells. In particular CXCL12 results in stromal expansion within the tumor
through increased proliferation of fibroblasts. In short, FAK regulates chemokine expression
through which cancer cells modulate TME to escape an anti-tumor response. Jiang et al. explored
the therapeutic effect of FAK inhibitor in KPC and KPPC GEM models of PDAC. The
combination of anti-CTLA4 and anti PD-1 had no effect on these tumors, which reflects the
clinical trials outcome. However, a combination of VS-4718, one of the FAK inhibitors, and
gemcitabine, a significant anti-tumor response was observed in GEM mice. Unfortunately, VS4718 did not show promising results in the clinical trials and therefore, the trial was terminated
(Jiang et al., 2016).
1.9.6. PARP inhibitor
The US FDA recently approved a drug, Lynparza (olaparib) for PDAC patients. The
study showed that Lynparza nearly doubled the time PDAC patients lived without disease
progression or death. Olaparib is a PARP inhibitor administered to adults with metastatic disease
that has not progressed after first-line therapy with platinum chemotherapeutic. Also, it is given
to biomarker-selected patients, who have certain germline mutations in the BRCA1 or BRCA2
gene.
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1.10. Integrins
Integrins are heterodimeric transmembrane receptors (∼280 Å long) found on the cell
surface. There are 18 α- and 8 β-subunits of integrins forming 24 different pairs, each pair having
its own functional and tissue specificity. The NH2-terminal halves of the two subunits (α and β)
together form a globular head region and the remaining portion forms two rod-shaped tails,
spanning the plasma membrane. Integrins have 12 domains, which make an oval-shaped “head”
and two protruding “tails”. These receptors regulate tight interactions with ligands through
divalent cation-dependent cell-cell and cell-extracellular matrix adhesion and are found in a wide
range of organisms, from sponges to mammals. Unlike many cell surface receptors, integrins are
bi-directional signaling molecules, as they transduce information from the extracellular
environment and modulate intracellular responses, including adhesion, migration, survival, and
proliferation (“outside-in”). Similarly, the integrins can achieve their active state upon receiving
signals from cytosolic kinases, which are downstream of growth factor receptors as well as
cytokine and chemokine receptors (“inside-out”). Integrins regulate cytoskeleton organization,
cell cycle, gene expression, and activate various kinase-signaling cascades. Integrins like αVβ3,
αVβ5, αVβ6, αVβ8, αllbβ3, and α5β1 generally bind to their extracellular ligands by recognizing a
short sequence of the peptide such as arginine-glycine-aspartic acid (RGD). Other integrins use
different peptide sequences (Harburger and Calderwood, 2009).
These heterodimeric receptors cause initiation and/or progression of numerous diseases
like neoplasia, tumor metastasis, ischemia-reperfusion injury, viral infections, immune
dysfunction, osteoporosis, and coagulopathies. Integrins, such as αIIbβ3, lymphocyte functionassociated antigen-1 (LFA-1), and α4β1 are effective therapeutic targets. Search for many other
integrins are underway. However, integrin αVβ3, which was first to be crystalized can still not be
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successfully targeted (Xiong et al., 2001; Xiong et al., 2002). Integrins have been targeted in the
field of immunology using monoclonal antibodies, however, targeting integrins such as αVβ3,
αVβ5, α5β1, and αVβ1 differs from integrins on immune cells. It is because the primary function of
integrins, including αVβ3, αVβ5, α5β1 and αVβ1 is attachment of the activated cells whereas
attachment is conditional in case of integrins on immune cells. This may explain integrinmediated death via integrins αVβ3 and α5β1 observed in endothelial cells, CAFs and
myofibroblasts derived from stellate cells.
1.10.1. Integrin αVβ3
Integrin αVβ3 “vitronectin receptor” communicates with the environment outside and
responds through its signaling network, leading to various biological outcomes. A wide spectrum
of human pathologies, such as thrombotic diseases, inflammation, cancer, fibrosis, and infectious
diseases involve integrin adhesion. This makes integrin αVβ3 an exciting pharmacological target
as it is exposed on the surface of the cell and is sensitive to the pharmacological block. However,
the current efforts involving therapeutics related to integrins are surprising. αV-null mice have a
lethal phenotype although these mice show normal development until embryonic day 9.5. Nearly
80% mice die before birth and 100% die on the day they are born. Since αVβ3 is a heterodimer
and β3-knock out mice are viable, fertile, and develop a vascular network without any observable
defects, studies were carried out on αVβ3 knockout mice. Antagonists of β3 integrin were
developed and a few exhibited high efficacies as antiangiogenic agents either in in vitro or in
vivo preclinical angiogenesis assays.
Integrin αVβ3 plays a very prominent role by regulating the cell behavior. It has been a
focus of research because it plays a major role in several distinct process, including osteoclast
mediated bone resorption, tumor metastasis, angiogenesis, and pathological neovascularization.
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In fact, its antiangiogenic function has been implicated by its ability to bind to the proteolytic
cleaved fragments of ECM that inhibit angiogenesis. Stupack et al. showed unligated integrin
αVβ3 as a negative regulator of cell survival, which initiates apoptosis by a process known as
integrin-mediated death (IMD). In IMD, caspase-8 recruits to the plasma membrane of unligated
integrins and induces apoptosis (Stupack et al., 2001).
Integrin αVβ3 is expressed at low levels in most normal tissues. However, it is expressed
in high levels in several cell types, including myofibroblasts, stellate cells, CAFs, mature bone
resorbing osteoclasts, angiogenic endothelial cells, and activated macrophages. These cell types
clearly reflect the involvement of this receptor in a pathological condition and represent a
rationale therapeutic for diseases, including invasive tumors, fibrosis, and rheumatoid arthritis.
Notably, quiescent fibroblasts and resting endothelial cells express little to no αVβ3. It has been
reported that integrin αVβ3 regulates stress fiber formation in myofibroblasts and therefore, aids
the mechanical properties, such as contraction, migration etc. In addition, integrin αVβ3 has been
detected in tumor tissues of patients with melanoma, breast cancer, pancreatic cancer, and
particularly in metastatic tissues. Tumors with high expression of integrin αVβ3 metastasize
aggressively, as integrin plays a key role during the metastatic cascade in cancer progression.
Metastasis mediated through αVβ3 depends on the integrin activation, suggesting that integrin
function is regulated on the transcriptional and post-translational level. The role of integrin αVβ3
has also been demonstrated in drug resistance and stemness. Additionally, integrin αVβ3 is
implicated in osteoporosis owing to its importance in osteoclast function and therefore,
polymorphism of this receptor is associated with increased rate of fracture (Cox et al., 2010;
Wilder, 2002).
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Therapeutic targeting of integrin αVβ3 has been challenging. Several integrin αVβ3
targeting antibodies (Etaracizumab; Abegrin; Vitaxin) and small peptides (cilengitide) were well
tolerated when tested in clinic, however these exhibited very less therapeutic efficacy. Increased
expression of integrin αVβ3 has been observed in melanoma and glioblastoma cancer cells, which
correlates with poor survival. Nevertheless, therapeutic targeting of this integrin demonstrated no
effect in the clinic. Approaches to target integrin αVβ3 have been discussed in the subsections
below.
1.10.2. Therapeutic approaches for targeting integrin αVβ3
The most common approach of targeting this receptor includes ligand mimetics and
monoclonal antibodies discussed in the subsections below. Many are still under investigation.
i) RGD binding drugs
Most of the small molecule ligand site targeting drugs affect both αVβ3 and αVβ5 integrins
as they have similar RGD site. The most studied small molecule RGD peptidomimetic is
Cilengitide (EMD 121974), a cyclic RGD pentapeptide. The efficacy of cilengitide was
disappointing when used a monotherapy and even a combination treatment was not successful.
Amid several ongoing trials, it attained orphan drug status for glioblastoma. Several trials are
underway for the treatment of head and neck carcinoma, non-small cell lung cancer, high-grade
glioma and squamous cell carcinoma.
Various other targeting approaches including, cyclic peptides, other small proteins and
peptides that incorporated RGD via grafting were not successful in the clinic. The reason behind
the failure was not the efficacy but the mechanistic approach of drugs binding to the integrin
αVβ3.
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The activity of conventional kinase inhibitors targeting integrin αVβ3 decreases when
these fall below the effective concentration. In this scenario, they mimic the natural ligand,
vitronectin, and activate the downstream signaling. Additionally, Legler et al. reported that the
low doses of an RGD-peptide could enhance the adhesive function of integrin αVβ3 to
vitronectin. In another report, Reynolds et al. demonstrated that integrin αVβ3/αVβ5 inhibitors are
less effective in repressing tumor growth and angiogenesis than originally predicted because
when the plasma concentrations of such inhibitors are allowed to drop to very low levels, they
act to enhance VEGFR-2 levels and hence increase angiogenesis and tumor growth. Taken
together, these inhibitors could have counteractive effects on the treatment of cancer (Legler et
al., 2001; Reynolds et al., 2009).
ii) Small molecule inhibitors
The orally administered MK-0429 completed a Phase II study in solid tumors with no
reported safety issues. However, no further development has been made.
iii) αVβ3 Monoclonal antibody
Integrin αVβ3, specifically targeted by the monoclonal antibody, Etaracizumab
(humanized engineered mAb LM609; Vitaxin, Abegrin) was investigated in Phase II trials in
metastatic castration-resistant prostate cancer (CRPC) and in metastatic melanoma, however, the
study was terminated later. Further, it was investigated in other cancers, including irinotecanrefractory colorectal cancer, breast cancer, and leiomyosarcoma. Overall, the safety profile after
systemic long-term αVβ3 blockade appeared favorable. The randomized trial in metastatic
melanoma showed that etaracizumab in combination with dacarbazine (chemotherapy) did not
provide a relevant survival benefit as compared to dacarbazine alone.
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iv) Endogenous inhibitors
A series of fragments derived from naturally occurring ECM and basement membrane
exhibit strong anti-angiogenic activity through integrin αVβ3 binding. The basement membranederived endogenous fragments including, endostatin, angiostatin, and tumstatin have an affinity
for multiple integrins because of their surface charge. Due to this reason, the exact and complete
mechanism of each of these endogenous inhibitors could not be elucidated. The other important
hurdle was that the PK/PD properties of these endogenous inhibitors were below desired levels
(O'Reilly et al., 1997).
v) ProAgio: a rationally designed protein
Our laboratory used an in silico and in situ approach to search for proteins that potentially
bind to integrin αVβ3 at a site other than the ligand binding site. Domain 1 of both human and rat
CD2 (D1-CD2), which has a structural resemblance with several endogenous angiogenic
inhibitors with inverse beta sheets was well studied in our lab (Yang, Wilkins et al. 2005, Yang
et al. 2008). D1-CD2 was found to have a very weak affinity for integrin αVβ3. Therefore, a short
fragment of peptide mimicking the active sites of the endogenous angiogenic inhibitor was
grafted. To incorporate grafted peptides, several mutations were made on D1-CD2 residues to
form important interactions with the βA domain of b3 and counter structure disturbances. In
retrospect, the βA domain on integrin b3 was chosen because of its functional importance in
ligand binding and integrin signaling. The rationally designed D1-CD2 variants were expressed
in E.coli, and one variant with mutations including, D99N, I102V, Q103I, E104I, E8T, T9V,
W10Q, G11M, A12K was chosen based on solubility, stability, and other parameters. Further,
ProAgio was PEGylated (30 kDa branched PEG-chain) to decrease antigen presentation and
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increase circulation time. PEGylated ProAgio had a strong affinity (Kd 2 nM) with integrin αVβ3.
Notably, the interaction of ProAgio and integrin was metal ion (Ca2+, Mn2+, Mg2+) dependent.
ProAgio can bind with integrin αVβ3 either in the open conformation (bound to Mn2+ or Mg2+) or
in the closed conformation (bound to Ca2+). However, in the presence of EDTA or any other
metal ion chelator, interaction of ProAgio with integrin αVβ3 is disrupted (Turaga et al., 2016).
ECM ligands, including vitronectin and fibronectin bind to the RGD site on integrin αVβ3
and regulate different signaling events, such as cell adhesion, migration, proliferation,
differentiation etc. ProAgio does not compete with the RGD binding site; it binds at the βA
grove away from the ligand-binding site and induces apoptosis in integrin αVβ3 expressing cells
by recruiting caspase 8 to the b3 tail (Figure 1.3). Importantly, this approach provides a novel
concept to develop integrin αVβ3 targeted therapies that would be able to effectively target and
remove integrin αVβ3-expressing cells regardless of ligated or unligated integrin.

Figure 1.3. Schematic illustration of the pathway upon binding of the ECM ligand (left)
and ProAgio (right) to integrin αVβ3. Integrin αVβ3 binds to the ECM ligand and its derived
fragments. ProAgio binds to integrin αVβ3 at a novel site and induces apoptosis in cell by
recruiting caspase 8 to the b3 tail.
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The βA-groove in the βA domain is very close to the RGD-binding site. It is an open
question as to how the interaction of ProAgio and integrin at the groove triggers effects that are
so different from those of RGD binding drugs. One speculation is that ProAgio binding to the
bA-groove induces conformation changes that are different from RGD ligand binding, which
consequently triggers different signaling that allows caspase 8 recruitment to the cytoplasmic
domain of b3. An answer to this question may require a comprehensive crystallographic study to
understand the differences in structure/conformation changes on ProAgio binding and RGD
ligand binding.
ProAgio induces apoptosis in HUVEC as they express high levels of integrin αVβ3. The
treatment with ProAgio significantly decreased tumor growth in the PC3 xenograft model by
decreasing tumor angiogenesis. The developed protein was found to be non-toxic to noncancerous blood vessels and other tissues/organs, providing an excellent candidate for future
clinical development (Turaga et al., 2016). We have extensively explored and discussed the
effect of ProAgio in highly aggressive cancer models, including TNBC and PDAC in chapter 2
and 3 respectively.
In the next chapter, we present a treatment strategy for TNBC by simultaneously
depleting CAFs and angiogenic vessels using ProAgio. We report that CAFs both at the primary
and metastatic site (lungs) in TNBC express high levels of integrin αVβ3, and ProAgio effectively
induces apoptosis in integrin αVβ3-expressing CAFs and angiogenic endothelial cells
simultaneously. By using three murine breast cancer models, including orthotopic 4T1,
orthotopic MDA-MB-231, and transgenic MMTV-PyMT, we demonstrate that depletion of
CAFs by ProAgio decreases collagen, intratumoral growth factors, including PDGF, EGF, and
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IGF-1, resulting in decreased breast tumor growth. In addition, depletion of CAFs by ProAgio
reduces LOX enzyme in the tumor and blood circulation, leading to reduced metastasis. Further,
ProAgio eliminates angiogenic vessels, thereby enhances blood perfusion, decreases hypoxia,
and facilitates drug delivery in the tumor. Furthermore, depletion of CAFs at the metastatic site
decreases collagen and LOX at the secondary metastatic site, resulting in reduced cancer cells
colonization and inhibition of metastatic tumor growth. Additionally, ProAgio in combination
with chemotherapeutic agents, demonstrates higher tumor growth inhibition and prolonged
overall survival, suggesting a unique treatment strategy for TNBC, especially in patients with
dense tumor stroma.
In chapter 3, we present a strategy for PDAC treatment by specifically targeting cancerassociated pancreatic stellate cells (CAPaSCs). CAPaSCs in PDAC tumor express high levels of
integrin αVβ3. By using three murine PDAC models, including Panc1/Panc1+PaSCs s.c.
xenograft, orthotopic KP, and GEMM KPC, we report that ProAgio induces apoptosis in
CAPaSCs, consequentially resorbs collagen in the tumor, which results in opening of the
collapsed tumor vessels. Opening of the vessels increases tumor permeability and facilitates drug
delivery. Further, ProAgio decreases insulin-like growth factor 1 (IGF1), which leads to
reduction in cytidine deaminase (Cda) in the PDAC tumor, resulting in much enhanced
gemcitabine efficacy in addition to an increase in the drug delivery. Our study reports that
ProAgio specifically targets CAPaSCs, leaving the normal or quiescent PaSCs, which may
provide important treatment advantage in PDAC.
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2. SIMULTANEOUSLY TARGETING CANCER ASSOCIATED FIBROBLASTS AND
ANGIOGENIC VESSELS AS A TREATMENT FOR TRIPLE-NEGATIVE BREAST
CANCER

2.1. Abstract
Fibrotic tumor stroma plays an important role in facilitating triple-negative breast cancer
(TNBC) progression and chemotherapeutic resistance. We previously reported a rationally
designed protein (ProAgio) that targets integrin αvβ3 at a novel site. ProAgio induces apoptosis
via the integrin. Cancer associated fibroblasts (CAFs) and angiogenic endothelial cells in TNBC
tumor express high levels of integrin αvβ3. ProAgio effectively induces apoptosis in CAFs and
angiogenic endothelial cells. Depletion of CAFs by ProAgio reduces intratumoral collagen and
decreases growth factors released from CAFs in the tumor, resulting in decreased cancer cell
proliferation and apoptotic resistance. ProAgio also eliminates leaky tumor angiogenic vessels,
which consequently reduces tumor hypoxia and improves drug delivery. Depletion of CAFs and
reduction in hypoxia by ProAgio decreases Lysyl oxidase (LOX) secretion and thereby reduces
metastasis. ProAgio, stand-alone or in combination with chemotherapeutic agents, provides
survival benefit in TNBC murine models, highlighting the therapeutic potential of ProAgio as a
treatment strategy.
2.2. Significance
We present a treatment strategy by simultaneously depleting breast cancer CAFs and
tumor angiogenic vessels using a rationally designed protein that induces integrin avb3 target
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specific cell apoptosis. Combination of stroma targeting with chemotherapeutics offers a unique
opportunity for TNBC treatment, especially for patients with dense tumor stroma.
2.3. Introduction
Triple negative breast cancer (TNBC), the most aggressive form of breast cancer is
characterized by the absence of estrogen (ER), and progesterone (PR) hormone receptor and lack
of human epidermal growth factor 2 (HER2) expression. TNBC patients are at high risk of
locoregional or distant recurrence, poor prognosis, and low overall survival (Haffty et al., 2006;
O'Shaughnessy et al., 2011). In fact, TNBC patients with metastatic disease have a poorer
prognosis, with a median survival of approximately 1 year (O'Shaughnessy et al., 2011). There
are very limited targeted therapies available for TNBC, and the treatment option is broadly
cytotoxic chemotherapy drugs, despite their low efficacy and strong unwanted side effects
(Cleator et al., 2007). Previous studies have highlighted the significance of tumor
microenvironment (TME) in mediating TNBC progression and affecting treatment efficacy (Dias
et al., 2019; Sahai et al., 2020a). It is noteworthy that the presence of abundant stroma in the
patient tumor has a poorer outcome than with low stroma in the breast tumor in TNBC (de Kruijf
et al., 2011; Moorman et al., 2012). CAFs are the most prominent cell types in the TME of
TNBC, which actively engage in a crosstalk with the surrounding cells promoting cancer cell
proliferation and survival. The interaction between CAFs and cancer cells is through excessive
production of growth factors (GFs), chemokines, and cytokines. Additionally, CAFs secrete
excessive extracellular matrix (ECM) proteins particularly collagen, and fibronectin, both of
which initiate angiogenesis in the tumor (LeBleu and Kalluri, 2018; Neve et al., 2014; Zhou et
al., 2008). Dense collagen secretion by CAFs impedes drug delivery and decreases drug uptake
in solid tumors, which contributes to drug resistance (Baumgartner et al., 1998).
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Microvasculature in tumor of TNBC and basal-like breast cancer is denser than in non-TNBC
and non-basal-like breast cancer (Mohammed et al., 2011; Ribatti et al., 2016), indicating high
angiogenic activity in TNBC and basal-like breast cancer. Furthermore, dense tumor
microvasculature closely correlates with shorter recurrence-free survival and overall survival.
Dense tumor vasculature is associated with a shorter time from diagnosis to relapse and from
relapse to death (Linderholm et al., 2009). The dysregulated vessel structure in the tumor of
TNBC patients often results in resistance to blood flow into tumor, which is another important
barrier for drug delivery. Interestingly, activation of fibroblasts and intratumoral angiogenesis
are tightly coupled in tumor. CAFs secrete a number of molecular factors that promote
angiogenic endothelial cells growth and migration (LeBleu and Kalluri, 2018; Mayrand et al.,
2012; Wang et al., 2019), thus, facilitating tumoral angiogenesis, while angiogenic endothelial
cells also play a role in maintaining CAFs activation (Lopes-Bastos et al., 2016; Relf et al.,
1997). In addition, ECM that is released by CAFs also plays a role in promoting intratumoral
angiogenesis (Sewell-Loftin et al., 2017; Vong and Kalluri, 2011).
Both CAFs and tumor angiogenesis have been implicated as the primary mediators of
cancer cell dissemination to distant sites. Intratumoral hypoxia induces CAFs and cancer cells to
secrete an enzyme, Lysyl oxidase (LOX), which crosslinks and stabilizes ECM components,
particularly collagen, present in abundance in the TME of breast tumor. The stiffer
microenvironment at the primary tumor site forms ECM tracks to assist cancer cell migration and
therefore metastases (Emon et al., 2018). In addition, secretion of LOX promotes collagen
remodeling at the metastatic site that facilitates bone marrow derived cells (BMDCs)
accumulation, subsequently promoting cancer cells colonization at a secondary site. Overall,
CAFs and angiogenesis cooperatively play an important role in TNBC growth, survival,
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metastasis, and drug resistance. Therefore, simultaneously targeting CAFs and angiogenic
vessels in TNBC could be a promising therapeutic strategy.
Both angiogenic endothelial cells and CAFs in breast cancer express high levels of
integrin αvβ3 (Attieh et al., 2017; Brooks et al., 1994). We previously reported a rationally
designed protein, ProAgio that targets integrin αvβ3 at a novel site and induces apoptosis in the
integrin expressing cells by recruiting caspase 8 at the cytoplasmic domain of b3 (Turaga et al.,
2016). We report here that ProAgio induces apoptosis in integrin αvβ3-expressing CAFs and
angiogenic endothelial cells in TNBC. Depletion of CAFs by ProAgio decreases intratumoral
collagen. In addition, depletion of CAFs by ProAgio reduces growth factors, platelet-derived
growth factor (PDGF), epidermal growth factor (EGF), and insulin growth factor-1 (IGF-1)
levels in the tumor, abrogating the CAFs and cancer cells crosstalk, which consequentially
decreases tumor growth and cancer cells apoptosis resistance. Depletion of CAFs by ProAgio
also reduces LOX levels in tumor and blood circulation and therefore reduces cancer metastasis.
Further, anti-angiogenic effect of ProAgio eliminates angiogenic leaky tumor vessels, which
consequently facilitates drug delivery and decreases hypoxia in murine models of TNBC.
Depletion of CAFs by ProAgio at metastatic site decreases collagen and LOX at metastatic site,
which reduces cancer cell colonization by preventing formation of pre-metastatic niche.
Furthermore, depletion of CAFs at metastatic site by ProAgio may also inhibit metastatic tumor
growth. ProAgio, stand-alone or in combination with other chemotherapeutic agents,
demonstrates high anti-tumor efficacy and prolonged survival of tumor bearing mice, suggesting
an excellent treatment strategy for TNBC, especially for the poor prognosis patients with high
tumor stroma.
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2.4. Results
2.4.1. Abundant stroma rich in integrin αVβ3-expressing CAFs and collagen is associated
with poor TNBC patient survival.
TNBC patients with stroma rich tumors have a higher risk of relapse, treatment
resistance, and a low overall survival compared to the patients with low stroma tumors (de Kruijf
et al., 2011; Moorman et al., 2012). We first analyzed the tumor sections of TNBC patients for
the abundance of stroma. H&E staining demonstrated both high and low amount of stroma in
TNBC patient tumor sections (Fig. 2.1A). We next performed Sirius red staining for collagen
and immunostaining for α-smooth muscle actin (a-SMA) and fibroblast activation protein (FAP)
and observed both high and low expression of collagen, a-SMA, and FAP positive cells in the
tumor of TNBC patients (Fig. 2.1A). We then analyzed survival of TNBC patients with high and
low gene expression of collagen (COL1A1, COL1A2) and FAP (CAF) from a publicly available
data set. Consistent with the previous studies, high amount of collagen and FAP correlates with
the poor survival in TNBC patients (Fig. 2.1 B & C; Fig. 2.2 A, B, D, E). Previous studies have
reported the expression of integrin αvβ3 in CAFs (Attieh et al., 2017). We evaluated integrin avβ3
expression in breast cancer CAFs in the tumor of TNBC patients. IHC staining of integrin b3
demonstrated that the integrin was highly upregulated in the histologically evident stromal
component of the tumors (Fig. 2.1D). To verify expression of the integrin in breast cancer CAFs,
we first assessed whether the integrin is expressed in human mammary fibroblasts (hMF) upon
TGF-b activation. Immunoblot revealed that integrin αvβ3 was highly expressed in activated hMF
but not in inactivated hMF (Fig. 2.1E). Immunofluorescence (IF) co-staining of integrin b3 with
a-SMA in the activated hMF also demonstrated the expression of the integrin in the activated
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fibroblasts. Murine CAFs were isolated from orthotopic 4T1 tumors. Co-IF staining revealed that
integrin b3 was highly expressed in the α-SMA positive murine CAFs (Fig. 2.1F). Expression of
the integrin in breast cancer CAFs was further verified by co-IF staining of integrin b3 and aSMA in 4T1 tumor sections (Fig. 2.2G). Patient survival data showed that high and low integrin
b3 (ITGB3) expression correlates with patient survival in TNBC (Fig. 2.2 C & F). Altogether,
our data suggests that high levels of αvβ3-expressing CAFs and collagen are associated with poor
prognosis of TNBC patients.
2.4.2. Depletion of CAFs by ProAgio decreases tumor growth, metastasis, and prolongs
tumor bearing mice survival.
We previously reported that a rationally designed protein ProAgio induces apoptosis in
integrin αvβ3-expressing cells (Turaga et al., 2016). We reasoned that ProAgio would be effective
in inducing apoptosis in breast cancer CAFs. Apoptosis assay showed that ProAgio effectively
induced apoptosis in hMF activated by TGF-b by recruiting caspase 8 to the intracellular domain
of β3, while it had no effect on the inactivated hMF (Fig. 2.1 G & H). Similarly, ProAgio also
effectively induced apoptosis in CAFs isolated from 4T1 tumor (Fig. 2.1H). Furthermore, IF costaining of vinculin and actin in the activated hMF showed that actin filament stress fibers and
focal adhesion complex diminished upon ProAgio treatment (Fig. 2.2H), indicating the loss of
integrin αvβ3-mediated focal points. Integrin αvβ3 is expressed in highly metastatic breast cancer
cells, especially bone metastatic cancer cells (Havaki et al., 2007; Liapis et al., 1996). To test
whether ProAgio also affects breast cancer cells via integrin αvβ3, we examined integrin αvβ3
expression in several TNBC cell lines. Immunoblot analyses showed different integrin
expression patterns in different TNBC cell lines (Fig. 2.4A). ProAgio did not affect the cell
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viability of these TNBC cells although the integrin αvβ3 is expressed in MDA-MB-468 (Fig.
2.4B). We do not fully understand why ProAgio does not induce apoptosis in integrin αvβ3expressing cancer cells. Resistance to caspase 8 mediated apoptosis may be one of the reasons.
To test whether ProAgio indeed acts on CAFs in tumor, we employed three breast cancer
mouse models. 4T1 murine breast cancer cells were orthotopically implanted into the mammary
gland of syngeneic Balb/c mice. MDA-MB-231 cells were orthotopically implanted in the
mammary gland of nude mice. Cancer cells in these models do not express ER, and PR, and have
low HER2 expression (Foulkes et al., 2010). In addition, we also employed a genetically
engineered mouse (GEM) MMTV-PyMT model. Tumors in this GEM model are ER and PR
negative and gradually lose HER2 expression at late stage (Christenson et al., 2017). Tumors in
all three models contain dense fibrotic stroma with abundant collagen fibers. Hence, these
murine models are suitable to analyze the effects of ProAgio on CAFs, and the effects of
modulation of fibroblasts on the progression of the tumor (Calvo et al., 2013; Zhang et al., 2013).
In 4T1 model, ProAgio treatment was started after the tumor volume reached around 250 mm3,
while in MDA-MB-231 model, the treatment was started after the tumor volume reached around
150 mm3. In MMTV-PyMT model, the treatment was initiated at 75 days of age. The mice
bearing 4T1 and MDA-MB-231 tumors were administered with 12 intraperitoneally (i.p.) doses
of ProAgio (10 mg/kg) (Fig. 2.3 A & B). Due to rapid tumor progression and increased overall
tumor burden, dosage and doses of ProAgio were increased (15 daily doses i.p. 20 mg/kg) in the
MMTV-PyMT mice (Fig. 2.3K). ProAgio significantly prolonged survival (p<0.0001) of 4T1
mice than the vehicle treated mice (Fig. 2.3C). Consistently, ProAgio treatment inhibited tumor
growth and reduced tumor weight (p<0.001) as compared to the vehicle treated group (Fig. 2.3
D-F). Similarly, significant increase in survival and reduction in tumor volume/burden and tumor
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weight were observed in MDA-MB-231 mice (Fig. 2.3 G-J) and MMTV-PyMT mice upon
ProAgio treatment (Fig. 2.3 L-O). Concomitant reduction in the tumor proliferation marker, Ki67
(Fig. 2.4 C-F, 2.17C) was observed in tumors of all ProAgio treated mice. Co-IF staining of Ki67
and pancytokeratin, an epithelial cell marker, revealed that cancer cell proliferation was
significantly reduced in ProAgio treated 4T1 tumors (Fig. 2.4 G & H).
We next analyzed the effects of ProAgio on tumor stroma and CAFs. Sections from
tumors of the treated mice were stained with α-SMA for CAFs and Sirius red for collagen.
ProAgio treated tumors exhibited markedly reduced α-SMA positive cells and intratumoral
collagen compared to the vehicle treated mice (Fig. 2.5 A-H; 2.17 A & B). The mRNA levels of
α-SMA and FAP in the 4T1 tumor were analyzed by qRT-PCR. Consistently, decreased α-SMA
and FAP mRNA levels were observed in the mice bearing 4T1 tumor treated with ProAgio when
compared to the vehicle group (Fig. 2.4I). To verify that ProAgio indeed induces apoptosis in
CAFs, we performed co-IF staining of α-SMA and cleaved caspase-3 (CC3) with the sections
from 4T1 tumors. Clearly, a significantly higher co-stain in ProAgio treated tumors was
observed than the vehicle treated group (Fig. 2.5 I-K). In addition, to determine whether ProAgio
mediated apoptosis in cancer cells, we co-stained CC3 with pancytokeratin. A smaller increase in
co-stain compared to the a-SMA and CC3 co-staining indicated that, although cancer cell
apoptosis was higher in the ProAgio treated 4T1 tumors as compared to the vehicle group,
ProAgio induced more CAF apoptosis (Fig. 2.4 J & K, and compare Fig. 2.5K to Fig. 2.4K).
Thus, our experiments reveal that ProAgio inhibits tumor growth and prolongs survival of tumor
bearing mice by inducing apoptosis in breast cancer CAFs. Apoptosis in CAFs induced by
ProAgio also increased apoptosis in cancer cells.
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An important cancer-promoting role of CAFs is that CAFs engage in a symbiotic “crosstalk” with cancer cells that supports cancer cell growth, metastasis, and resistance to apoptosis.
CAFs secrete GFs, such as PDGF, EGF, and IGF1, in tumor, which promote cancer progression
(LeBleu and Kalluri, 2018). Because ProAgio depletes CAFs, we reasoned whether ProAgio
would reduce the intratumoral GFs, and consequently decrease activation of GF receptors in
cancer cells. We first analyzed the levels of PDGF, EGF, and IGF1 in the primary 4T1 and
MMTV-PyMT tumors by immunostaining and ELISA. Clearly, ProAgio decreased intratumoral
PDGF, EGF, and IGF1 in both 4T1 and MMTV-PyMT tumors (Fig. 2.6 A-C, 2.7 A & B). We
then examined phosphorylation of PDGFRb, EGFR, IGF1R, and the downstream targets,
including Akt and ERK, in the sections of treated tumors by immunostaining. The ProAgio
treated 4T1 and MMTV-PyMT tumors had reduced activation of the aforementioned growth
factor receptors and their downstream target molecules (Fig. 2.6 D & E, 2.7 C & D). Secretion of
GFs by CAF activates GF receptors that mediate apoptotic resistance in cancer cells (Antonyak
et al., 2004; Fingas et al., 2011). We cultured TNBC cells, MDA-MB-231, 4T1, BT549, and
HCC1806 with the GFs cocktail (PDGF, EGF, IGF1, and HGF) and subsequently treated them
with different concentrations of chemotherapeutics, paclitaxel (PTX) and doxorubicin (DOX).
Clearly, addition of GFs increased viability of all the TNBC cells (Fig. 2.8 A-F). Furthermore,
we cultured MDA-MB-231 and 4T1 cells with the conditioned medium (CM) from mammary
CAFs. Consistently, an increase in cell viability was observed upon treatment with DOX (Fig.
2.8 G & H). The results suggest that CM from CAF or GFs conferred chemoresistance in TNBC
cells. To verify whether decrease in GFs due to depletion of CAF by ProAgio sensitizes cancer
cells to apoptosis induction, we co-cultured mammary fibroblasts with MDA-MB-231 cells and
thereafter treated with DOX in the presence or absence of ProAgio. Immunoblot analysis
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demonstrated that ProAgio treatment decreased pERK and pAkt in MDA-MB-231 cells (Fig.
2.8I). DOX induced higher levels of apoptosis in MDA-MB-231 cells in the presence of ProAgio
(Fig. 2.8J), suggesting that depletion of CAFs by ProAgio sensitizes cancer cells to apoptosis
induction.
2.4.3. ProAgio reduces TNBC metastasis by modulating fibrotic stroma at both primary and
metastatic sites.
Lung is one of the major metastatic organ sites in breast cancer patients, especially in
TNBC as the incidence of lung metastasis is 40% in TNBC as compared to 20% in non-TNBC
(Foulkes et al., 2010). Lung is also the major metastatic site in orthotopic 4T1, orthotopic MDAMB-231, and MMTV-PyMT mouse models (Jonkers and Derksen, 2007). It is well known that
CAFs play an important role in promoting cancer cell metastasis (Quail and Joyce, 2013). Since
ProAgio depletes CAFs in the breast tumor, we reasoned whether ProAgio would have effects on
metastasis. We analyzed the effects of ProAgio on lung metastasis in three models. ProAgio
treatment reduced the number (Fig. 2.9 A & B, Fig. 2.10 A & B) and the size of lung metastatic
nodules in 4T1 and MDA-MB-231 mice (Fig. 2.10 C & D), and MMTV-PyMT mice (Fig. 2.9 C
& D, Fig. 2.10E), suggesting that depletion of breast cancer CAFs reduces breast cancer
metastasis.
ProAgio induced CAF apoptosis and reduced collagen content in the primary tumors of
three tested breast cancer models. We asked whether ProAgio also exerted its effects on CAFs
and collagen at the lung metastatic site. We analyzed CAFs and collagen in the lung metastatic
tumors in both 4T1 and MMTV-PyMT models. The metastatic tumors in the lung in ProAgio
treated animals displayed reduced α-SMA positive cells (Fig. 2.9 E & F) and intratumoral
collagen (Fig. 2.9 E & G) compared to the vehicle treated mice in both models. ProAgio
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treatment also led to over 2.5-fold increase in co-staining of α-SMA with CC3 in sections of 4T1
lung metastatic tumors (Fig. 2.9 H & I), suggesting that ProAgio induces lung CAFs apoptosis in
TNBC. To verify the effects of ProAgio on lung CAFs, we examined expression of integrin αvβ3
and a-SMA in human lung fibroblasts (hLF) upon activation with TGF-b. Evidently, TGF-b
activated hLF express high levels of integrin αvβ3, a-SMA (Fig. 2.9J, 2.10F), and vimentin (Fig.
2.10F) however, inactivated hLF did not express high levels of integrin αvβ3 (Fig. 2.9J).
Consistently, ProAgio effectively induced apoptosis in the activated hLF by recruiting caspase 8
to the intracellular domain of β3, while it had no effect on the inactivated hLF (Fig. 2.10 G & H).
To confirm the effects of ProAgio at lung metastatic site, 4T1 cells were i.v. injected into balb/c
mice via tail vein (spontaneous model). The mice were treated with ProAgio next day after
cancer cell injection for 12 daily doses (Fig. 2.9K). Animals were sacrificed 3 days post ProAgio
treatment. Tumor nodules in the lung were analyzed. Clearly, ProAgio reduced both lung tumor
nodule number (Fig. 2.9 L-M) and size (Fig. 2.10I). Sirius red and a-SMA staining in the
metastatic tumor sections demonstrated that ProAgio reduced a-SMA positive CAFs and
collagen in the tumors (Fig. 2.10 J-M). The results suggest that ProAgio decreases metastatic
tumor colonization at metastatic site due to the action on CAFs and fibrotic stroma.
2.4.4. Eliminating angiogenic vessels by ProAgio increases blood perfusion into the tumor,
enhances chemotherapeutic delivery and efficacy.
Studies have shown that tumor angiogenesis leads to leaky tumor vessels, which impairs
blood flow into and from the tumor leading to hypoxia. The leaky vessels form a major barrier to
the drug delivery (Polydorou et al., 2017). We have previously demonstrated anti-angiogenesis
activity of ProAgio due to induction of apoptosis in integrin αvβ3 expressing angiogenic
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endothelial cells (Turaga et al., 2016). A decrease in CD31 staining in 4T1 and MMTV-PyMT
tumors in the ProAgio treated mice corroborated our previous findings (Fig. 2.11 A & B, Fig.
2.12 A & B). In addition, ProAgio treated 4T1 mice displayed a decrease in number of branch
points and vessel length in the breast tumor (Fig. 2.11 C & D). We reasoned that removal of
leaky angiogenic tumor vessels would improve blood perfusion into tumor. To test this
speculation, lectin perfusion assay was carried out using fluorescent conjugated lectin in 4T1
mice at the end of ProAgio treatment. Clearly, lectin perfusion in the tumor was more than
doubled in the ProAgio treated mice when compared to the vehicle treated mice (Fig. 2.11 E-G).
Vascular leakage was analyzed by dextran leakage assay (Park et al., 2016). Evidently, the
intratumoral vessels leakage was decreased in the 4T1 tumor treated with ProAgio compared to
the vehicle treated group (Fig. 2.12 C & D). The results suggest that ProAgio decreases leaky
vessels in tumors and increases tumor blood perfusion.
Removal of the leaky blood vessels in the breast tumor would facilitate drug molecule
delivery into the tumor, thus enhancing the efficacy of the chemotherapy (Jain, 2005). ProAgio
effectively depletes CAFs, reduces intratumoral collagen, and eliminates leaky tumor angiogenic
vessels. It is therefore expected that ProAgio would facilitate drug delivery. To evaluate the
effects of ProAgio on drug delivery, 4T1 mice were treated with 12 daily doses of ProAgio,
followed by one i.v. dose of PTX. Tumor lysates were subsequently analyzed by HPLC.
Intriguingly, ProAgio treatment resulted in an increase in intratumoral PTX in 4T1 mice (Fig.
2.11H). The observation was further verified by analyzing delivery of the fluorescence probe
conjugated PTX to the tumors of 4T1 mice treated with vehicle or ProAgio (Fig. 2.11 I & J).
Removal of disorganized leaky tumor angiogenic vessels improves tumor blood flow and
oxygenation, which would consequently decrease tumor hypoxia (Jain, 2005). Therefore, we
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assessed whether ProAgio treatment altered tumor hypoxia in the 4T1 and MMTV-PyMT
tumors. Pimonidazole was intravenously administered in 4T1 mice. A significant decrease in
hypoxyprobe-1 signal in ProAgio treated mice was observed (Fig. 2.11 K & L). In addition,
immunostaining analyses demonstrated that HIF-1a was decreased in ProAgio treated 4T1
(p<0.01) and MMTV-PyMT (p<0.001) mice compared to the vehicle treated group (Fig. 2.12 EH).
2.4.5. Depletion of CAFs and decreased hypoxia in the tumor by ProAgio reduces LOXmediated cancer metastasis.
LOX is an enzyme mediating lysine oxidation in ECM, which helps ECM, mostly
collagen crosslinking to enable metastasis progression. It is documented that hypoxia in tumor
upregulates LOX expression and secretion in the cancer cells (Erler et al., 2006). We examined
the LOX expression in 4T1 and MDA-MB-231 cells under hypoxia and normoxia conditions.
Consistent with observations made by the other laboratories, hypoxia strongly increased LOX
expression and secretion in cancer cells (Fig. 2.13 A & B). Myofibroblasts are the main source
cells for LOX release during tissue repair and wound healing (Fushida-Takemura et al., 1996).
CAFs share most of the characteristics with myofibroblasts (Kalluri, 2016). We therefore
examined LOX expression in activated/inactivated hMF. Clearly, hMF expressed high levels of
LOX upon TGF-b activation (Fig. 2.13C). Our results suggest that CAFs are another major
source of LOX in breast tumor. ProAgio depletes breast cancer CAFs and reduces tumor hypoxia
due to abrogation of tumor angiogenesis. We reasoned that ProAgio would decrease LOX
expression and secretion in tumor and, consequentially reduce TNBC metastasis. To test this
speculation, we first analyzed LOX in the sections of primary 4T1 and MMTV-PyMT tumors by
immunostaining. A significant reduction in LOX staining in ProAgio treated tumors was
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observed (Fig. 2.13 D & E; 2.14 A & B). We further analyzed mRNA levels of other LOXfamily members, including LOXL2 and LOXL4 in 4T1 tumor by qRT-PCR. ProAgio treatment
led to reduced LOX, LOXL2, and LOXL4 mRNA levels in 4T1 tumors (Fig. 2.13F, 2.14C). Our
data clearly indicates that, in addition to decrease in LOX, ProAgio also reduced other LOXfamily members, LOXL2 and LOXL4 that are associated with a high invasive potential. Next,
we measured LOX activity in 4T1 and MMTV-PyMT tumor lysates. ProAgio decreased LOX
activity in both 4T1 and MMTV-PyMT tumor lysates (Fig. 2.13G, 2.14D). As LOX facilitates
collagen crosslinking, we analyzed collagen crosslinks in tumor sections by polarized light
microscopy on Sirius red staining. Clearly, ProAgio led to a reduction in cross-linked collagen
compared to the vehicle treated 4T1 and MMTV-PyMT tumors (Fig. 2.14 E-G).
LOX creates a favorable milieu at the metastatic site for cancer cells to colonize.
Consistently, it is shown that LOX is important for the pre-metastatic niche formation in
orthotopic 4T1 and MMTV-PyMT mouse models (Cox et al., 2013; Pickup et al., 2013). LOX in
the metastatic cancer site would first likely come from the release of the enzymes by primary
tumors into blood circulation. Colonization and growth of the metastatic tumors would create
second source for more LOX accumulation at the metastatic site. CAFs in the metastatic tumor
site may be one of the major sources of LOX secretion at the metastatic site (Pickup et al., 2013).
Therefore, we asked whether ProAgio affects LOX levels in blood circulation and in the
metastatic tumor. We analyzed LOX levels in the serum of 4T1 and MMTV-PyMT mice by
LOX activity assay. ProAgio treatment led to a significant decrease in serum levels of LOX in
both 4T1 and MMTV-PyMT mice (Fig. 2.13G, 2.14H). IHC analyses of sections of metastatic
lung tumors also demonstrated a ~ 3-fold and ~ 5-fold decrease in LOX in 4T1 and MMTVPyMT mice respectively upon ProAgio treatment (Fig. 2.13 H & I; 2.14 I & J). These
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observations are consistent with the results of the primary tumor sections. Concomitantly, we
found a significant decrease in cross-linked collagen in the lung metastatic tumors of ProAgio
treated 4T1 and MMTV-PyMT mice (Fig. 2.13 J & K; 2.14 K-M).
LOX at the metastatic cancer site recruits CD11b positive myeloid cells, which facilitates
colonization of metastatic cancer cells (Erler et al., 2009). Because we observed a decrease in the
LOX levels in the lungs of 4T1 and MMTV-PyMT mice, we analyzed CD11b positive myeloid
cell population gated on CD45+ tumor infiltrating leukocytes in the metastatic lungs by flow
cytometry. Evidently, ProAgio decreased CD11b positive myeloid cells in the lungs of both 4T1
and MMTV-PyMT mice (Fig. 2.13 L & M; 2.14 N & O). Reduction in CD11b cells by ProAgio
at metastatic tumor site also supports the notion that depletion of CAFs at metastatic site
abolishes cancer cell colonization at metastatic site (Erler et al., 2009). Altogether, our data
demonstrate that ProAgio modulates breast cancer TME by inducing apoptosis in CAFs,
consequentially reduces levels of LOX both at primary and metastatic tumors, thereby reducing
the cancer cells colonization in the lungs. Further, we carried out a retrospective study to
examine the clinical relevance of LOX in women with TNBC using publicly available data set.
High expression of LOX was closely associated with poor overall survival (Fig. 2.14 P & Q),
suggesting a critical role of LOX in TNBC patients.
2.4.6. Simultaneous depletion of CAFs and tumor angiogenic vessels by ProAgio enhances
efficacy of chemotherapeutics
Increase in chemotherapy drug delivery, in addition to decrease in cancer cell
proliferation and apoptosis resistance due to reduction in intratumoral GFs would corroborate
synergistic effects of ProAgio in combination with chemotherapeutics. To test the hypothesis,
4T1 and MMTV-PyMT mice were treated with ProAgio and PTX either alone or in combination.
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PTX alone did not have a significant effect in the overall survival and tumor growth, while
ProAgio alone provided survival benefit and inhibited tumor growth in 4T1 mouse model.
Interestingly, a low dose of PTX and ProAgio combination provided a significant survival
benefit, inhibited tumor growth and decreased end-point tumor weight (Fig. 2.15 A-E).
Consistently, treatment of 4T1 mice with a combination regimen of ProAgio and a low dose of
DOX significantly prolonged survival, decreased tumor growth, and tumor weight (Fig. 2.16 AE). Additionally, MMTV-PyMT mice also showed similar results upon treatment with ProAgio
and PTX combination. The combination therapy significantly increased overall survival,
decreased total tumor volume and tumor volume of every nodule along with decrease in total
tumor weight (Fig. 2.15 F-I; 2.16 F & G). Immunostaining of tumor sections with a-SMA and
Sirius red staining for collagen revealed that ProAgio treatment alone decreased a-SMA and
collagen; however, the combination of ProAgio+PTX further reduced a-SMA levels and
collagen content when compared to ProAgio. PTX alone had no significant effect on the a-SMA
levels and collagen content (Fig. 2.17 A & B). Also, the tumor proliferation marker, Ki67 was
dramatically reduced in the combination group (Fig. 2.17C). Next, analyses of the tumor tissues
revealed an increase in apoptosis in the ProAgio+PTX group than ProAgio or PTX alone group
in both 4T1 and MMTV-PyMT mice (Fig. 2.16 H & I; 2.17D). Consistently, increase in
apoptosis in the tumor of ProAgio+DOX combination therapy was observed in 4T1 mice (Fig.
2.16 H & I). Our data suggests that ProAgio increased the delivery of PTX/DOX, which led to
overall increase in the apoptosis in breast tumor. Examination of lung metastasis demonstrated
that ProAgio+PTX combination further reduced metastatic nodule number (Fig. 2.16 J & K; 2.17
E-G). Altogether, our results indicate that ProAgio treatment conferred improved
chemotherapeutic efficacy in the murine models by modulating breast cancer TME.
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2.5. Discussion
CAFs are one of the main components of the TME. CAFs facilitate tumor progression
through close crosstalk with cancer cells (LeBleu and Kalluri, 2018). Because of cancer
promoting properties of CAFs, therapeutic strategies targeting tumor fibrotic stroma have been
actively explored, particularly in treatment of pancreatic ductal adenocarcinoma (PDAC) due to
unique properties of desmoplasia of PDAC. However, there is very limited success (Barnett and
Vilar, 2018; Chen and Song, 2019). Although evidences have demonstrated that dense fibrotic
stroma closely correlates with poor prognosis of TNBC patients (de Kruijf et al., 2011; Moorman
et al., 2012), targeting CAFs as a potential treatment for TNBC is not extensively explored
(Takai et al., 2016). Angiogenic vessel is another important component of breast cancer TME.
Tumor angiogenesis plays a critical role in promoting cancer progression (Carmeliet and Jain,
2000; Fox et al., 2007). Active angiogenesis in tumor closely correlates with poor prognosis of
patients in TNBC (Linderholm et al., 2009). It is well established that angiogenic endothelial
cells express high levels of the integrin αvβ3 (Brooks et al., 1994). We demonstrate here that the
fibril producing breast CAFs also express high levels of the integrin. We previously reported a
rationally designed protein, ProAgio that targets integrin αvβ3 at a novel site specifically induces
apoptosis in the αvβ3-expressing cells (Turaga et al., 2016). The unique targeting specificity of
ProAgio provides an effective approach to simultaneously deplete breast cancer CAFs and
angiogenic tumor vessels (Fig. 2.15J, Fig. 2.18). Depletion of CAFs in TNBC tumor by ProAgio
leads to decrease in intratumoral collagen. Depletion of CAFs by ProAgio also reduces
intratumoral GFs that are likely released by CAFs, which breaks-down the cancer promoting
CAF-cancer cell crosstalk. LOX plays an important role in cancer metastasis. Both cancer cells
and CAFs secrete high levels of LOX. In the tumor with dense fibrotic stroma, CAFs may be the
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main source cells that secrete LOX (Pickup et al., 2013). Our data demonstrate that depletion of
CAFs by ProAgio decreases LOX in the primary tumor, blood circulation, and the metastatic site
(Fig. 2.15J). Clearly, decrease in LOX both in the primary tumor and metastatic site reduces
TNBC metastasis as shown in both 4T1 and MMTV-PyMT models.
ProAgio also induces apoptosis in angiogenic endothelial cells in TNBC tumors and
therefore diminishes the leaky tumor vasculature. Removal of dysregulated tumor angiogenic
vessels increases blood perfusion into tumor, which consequentially overcomes a drug delivery
barrier. Interestingly, increase in blood perfusion into tumor due to abrogation of angiogenic
tumor vessels by ProAgio not only facilitates drug molecule delivery but also reduces tumor
hypoxia. Hypoxia is a critical regulatory factor in controlling expression and secretion of LOX.
Hypoxia is also one main driving force for cancer metastasis (Rankin and Giaccia, 2016).
Simultaneous depletion of CAFs and angiogenic vessels in TNBC tumor by ProAgio leads to
decrease in secretion of LOX by CAFs and reduction in hypoxia, which also decreases hypoxiadriven LOX expression and secretion. Thus, it is clear that the dual action of ProAgio in LOX
expression/secretion and reduction in tumor hypoxia due to anti-angiogenesis activity of ProAgio
orchestrate special tumor microenvironment both at primary and metastatic tumor to reduce
metastasis. Altogether, multiple drug effects of ProAgio due to depletion of CAFs and antiangiogenesis (Fig. 2.15J, Fig. 2.18) enable the protein to be a promising treatment drug for
TNBC, especially for patients with tumor rich in dense fibrotic stroma.
Dense intratumoral collagen fibrils and leaky tumor vessels constitute barriers for drug
delivery (Jain, 2005; Miao et al., 2015). Therefore, removal of dense collagen fibrils and
reduction in leaky tumor angiogenic vasculature would enhance the delivery of
chemotherapeutic agents. On the other hand, depletion of CAFs by ProAgio also decreases
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intratumoral levels of GFs that are mostly secreted by CAFs, which cuts-off the crosstalk
between cancer cells and CAFs. One important consequence is the reduction in cancer cell
apoptosis resistance, which is stimulated by intratumoral GFs. The dual action of ProAgio results
in high efficacy of the combination therapies, e.g. ProAgio + chemotherapy agents in the TNBC
murine models. Importantly, the dual action of ProAgio allows achievement of high efficacy
using very low dose of chemotherapeutic agents (2 – 6 fold less dosage of PTX and DOX).
Significant lower dosage of cytotoxic anti-cancer drugs would greatly reduce toxic side effects of
the chemotherapeutic agents and improve the treatment efficacy. Our study apparently introduces
a strategy for TNBC treatment by simultaneously targeting stromal fibroblasts and angiogenic
vessels by ProAgio, particularly in combination with other anti-cancer chemotherapeutics.
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Figure 2.1. Abundant stroma rich in integrin αVβ3-expressing CAFs and collagen is
associated with poor TNBC patient survival.
(A) Representative images of H&E staining, Sirius red staining, a-SMA, and FAP IHC staining
of low (upper panel) and high stroma (lower panel) in the breast tumor of TNBC patients (n=80).
(B, C) Kaplan-Meier overall survival (B), and disease-free survival (DFS) (C) analysis of low
and high COL1A1 expression (COL1A1 low (n=44); COL1A1 high (n=38) in the breast tumor
of TNBC patients. (D) Representative images of IHC staining of integrin b3 in the breast tumor
of TNBC patients (lower panel, n=80; scale bar, 100µm) compared with the breast cancer
adjacent breast tissue (upper panel, n=3; scale bar, 500µm). (E) Levels of integrin aV (IB:
Integrin aV), integrin b3 (IB: Integrin b3), and a-SMA (IB: a-SMA) in the inactivated (-TGF-b)
and activated (+TGF-b) human mammary fibroblasts were analyzed by immunoblot. Mammary
fibroblasts were activated by culturing for 48 h in the presence of 5ng/mL TGF- b. Inactivated
mammary fibroblasts are the cells that are cultured for one day without TGF- b. b-actin is the
loading control. (F) Representative co-IF images of integrin β3 (green), and a-SMA (red) in
activated human mammary fibroblasts (upper panel) and murine CAF (lower panel). Nuclei were
counterstained with Hoechst (blue). (G) Co-immunoprecipitation of caspase 8 with integrin b3
(IP: Integrin b3) was analyzed by immunoblot (IB: caspase 8). Activated mammary fibroblasts
were treated with 5 µM ProAgio for 3 h before the preparation of extract. Immunoblot of integrin
b3 (IB: Integrin b3) indicates the amount of b3 that was precipitated down in co-IP. Input
represents 10% of the total protein used for IP and b-actin is the loading control. (H) Apoptosis
of murine CAF (left panel) and activated human mammary fibroblasts (right panel) that were
treated with 5 µM ProAgio (red bar) compared to the vehicle (PBS, grey bar) was analyzed by
apoptosis kit. The experiments were performed in triplicate. Error bars represent mean ± S.E.M.
Scale bars, 100 µm. *P<0.05, ****P<0.0001, by log-rank test (B, C) or unpaired Student’s t-test
(H).
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Figure 2.2. Stroma rich in integrin αVβ3-expressing CAFs and collagen is associated with
poor TNBC patient overall survival and disease-free survival.
(A-C) Kaplan-Meier survival analysis of low and high COL1A2 (low (n=34); high (n=48)) (A),
FAP (low (n=39); FAP (n=43)) (B), and ITGB3 (integrin β3) (low (n=50); high (n=32)) (C) gene
expression in the breast tumor of TNBC patients. (D-F) Kaplan-Meier disease free survival
(DFS) analysis of low and high COL1A2 (low (n=40); high (n=35)) (D), FAP (low (n=46); high
(n=29)) (E), and ITGB3 (integrin β3) (low (n=45); high (n=30)) (F) gene expression in the breast
tumor of TNBC patients. TCGA data set of TNBC patients was obtained from cbioportal
(htttp://cbioportal.org). (G) Representative IF images of co-staining of α-SMA (red) and integrin
b3 (green) in the breast tumor sections of 4T1 orthotopic mice. (I) Representative images of coIF staining of vinculin (green), and rhodamine phalloidin (actin, red) of activated mammary
fibroblasts treated with vehicle or ProAgio. Nuclei were counterstained with DAPI (blue). Scale
bars, 100 µm. *P<0.05, **P<0.01 by log-rank test.
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Figure 2.3. ProAgio effectively reduces breast tumor growth and prolongs survival in
tumor bearing mice.
(A, B) Therapy regimen of 10 mg/kg ProAgio (i.p.) in 4T1 orthotopic Balb/C (A), and MDAMB-231 orthotopic nude (B) female mice. (C-F) Kaplan-Meier survival analysis (n=18; median
survival (low=22 days, high=26 days)) (C), mean tumor volume (D), mean tumor weight (E),
and representative gross images of breast tumor (F) of orthotopic 4T1 bearing mice treated with
vehicle or ProAgio (Vehicle (n=15); ProAgio (n=30)). (G-J) Kaplan-Meier survival analysis
(n=8; (n=18; median survival (low=29 days, high=41 days)) (G), mean tumor volume (n=10)
(H), mean tumor weight (n=6) (I), gross images of breast tumor (J) of orthotopic MDA-MB-231
female nude mice treated with vehicle or ProAgio. (K) Therapy regimen of 20 mg/kg ProAgio
(i.p.) in MMTV-PyMT FVB/N mice. (L-O) Kaplan-Meier survival analysis (n=12; median
survival (low=27 days, high=42.5 days)) (L), mean tumor burden (n=12) (M), average tumor
weight (n=6) (N), and representative images showing gross appearance of tumors where dotted
lines demarcate tumor masses (O) of MMTV-PyMT mice treated with vehicle or ProAgio. Error
bars represent mean ± S.E.M. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, by log-rank test
(C, G, & L) or unpaired Student’s t-test.
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Figure 2.4. ProAgio decreases cancer cell proliferation in the breast tumor of 4T1
orthotopic and MDA-MB-231 mouse models.
(A) Levels of integrin aV (IB: Integrin aV) and integrin b3 (IB: Integrin b3) in the indicated
TNBC cell lines was analyzed by immunoblot. b-actin is the loading control. (B) Cell viability of
indicated cells upon treatment with indicated concentrations of ProAgio was analyzed by MTT
assay. The indicated cells were treated with different concentrations of ProAgio for 24 h. (C-F)
Representative images of IF staining of Ki67 (green) (C, E), and quantification of percentage of
Ki67+ve cells (D, F) in the breast tumor sections of 4T1 orthotopic (C, D) and MDA-MB-231
(E, F) mice upon treatment with vehicle or ProAgio. (G, H) Representative IF images of costaining

of

pancytokeratin

(red)

and

Ki67

(green)

(G),

and

quantification

of

Ki67+pancytokeratin+ staining (H) in 4T1 orthotopic mice treated with vehicle or ProAgio. (I)
mRNA analysis of a-SMA (left panel) and FAP (right panel) measured by qRT-PCR in the
breast tumor of 4T1 orthotopic mice treated with vehicle (grey bar) or ProAgio (red bar). (J, K)
Representative IF images of co-staining of pancytokeratin (red) and cleaved caspase 3 (CC3,
green) (J), and quantification of CC3+pancytokeratin+ staining (K) in 4T1 orthotopic mice treated
with vehicle or ProAgio. Nuclei were counterstained with DAPI (blue). Scale bars, 100 µm;
(n=4-5). *P<0.05, **P<0.01, ***P < 0.001, ns denotes non-significant by unpaired Student’s t
test.
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Figure 2.5. ProAgio decreases CAFs and collagen in the breast tumor of TNBC mouse
models by inducing apoptosis in breast CAFs.
(A, B) Representative IF images of α-SMA staining (A), and quantification of αSMA+ area (B)
in the breast tumor of vehicle or ProAgio treated 4T1 orthotopic mice. (C, D) Representative
IHC images of α-SMA staining (C), and quantification of α-SMA+ area (D) in the breast tumor
of vehicle or ProAgio treated MDA-MB-231 orthotopic nude mice. (E, F) Representative images
of Sirius red staining of collagen (E), and quantification of collagen area (F) in the breast tumor
of vehicle or ProAgio treated 4T1 orthotopic mice. (G, H) Representative images of Sirius red
staining of collagen (G), and quantification of collagen area (H) in the breast tumor of vehicle or
ProAgio treated MDA-MB-231 orthotopic nude mice. (I-K) Representative IF images of costaining of α-SMA (red) and cleaved-caspase 3 (C-Caspase 3, green) (I), and quantification of
apoptotic cells (CC3+) (J) and apoptotic breast CAF (a-SMA+ CC3+) (K) in vehicle or ProAgio
treated 4T1-bearing mice. Nuclei were counterstained with DAPI (blue). Scale bars, 100 µm
(inset in E, 20 µm); (n = 6-8). **P < 0.01, ***P < 0.001, ****P<0.0001 by unpaired Student’s t
test.
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Figure 2.6. ProAgio decreases growth factors and downstream targets in 4T1 orthotopic
mouse model.
(A, B) Representative images of IHC staining of PDGF-BB (left panel), EGF (middle panel), and
IGF1 (right panel) (A), and quantitative analysis of PDGF-BB, EGF, and IGF-1 +ve area (B) in
the breast tumor sections of 4T1 mice treated with vehicle or ProAgio. (C) Intratumoral levels of
PDGF-BB, EGF, and IGF-1 were determined by ELISA assay in the breast tumors of 4T1 mice.
(D, E) Representative images of IF staining of pPDGFRb, pEGFR, IHC staining of pIGF1R,
pAKT, and pERK (D), and quantitative analysis of pPDGFRb, pEGFR, pIGF1R, pAKT, and
pERK +ve cells (E) in the breast tumor sections of 4T1 mice treated with vehicle or ProAgio.
Scale bars, 100

m (n=4-6). *P<0.01, **P<0.01, ***P<0.001 by unpaired Student’s t test.
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Figure 2.7. ProAgio decreases growth factors and downstream targets in MMTV-PyMT
mouse model.
(A, B) Representative images of IHC staining of PDGF-BB (left panel), EGF (middle panel), and
IGF1 (right panel) (A), and quantitative analysis of PDGF-BB, EGF, and IGF-1 +ve area (B) in
the breast tumor sections of MMTV-PyMT mice treated with vehicle or ProAgio. (C, D)
Representative images of IHC staining of pPDGFRb, pEGFR, pIGF1R, pAKT, and pERK (C),
and quantitative analysis of pPDGFRb, pEGFR, pIGF1R, pAKT, and pERK +ve cells (D) in the
breast tumor sections of MMTV-PyMT mice treated with vehicle or ProAgio. Scale bars, 100
m (n=4-6). *P<0.01, **P<0.01, ***P<0.001 by unpaired Student’s t test.
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Figure 2.8. ProAgio confers chemosensitivity to breast cancer cells.
(A-F) Cell viability of TNBC cells, including MDA-MB-231 (A, B), 4T1 (C, D), BT549 (E), and
HCC1806 (F) upon treatment with indicated concentrations of indicated drugs for 48 h in the
culture media containing the vehicle i.e. ProAgio formulation buffer (black line) or indicated
growth factors (red line). (G, H) Cell viability of MDA-MB-231 (G) and 4T1 (H) cells upon
treatment with indicated concentrations of doxorubicin for 48 h in the culture media containing
the conditioned medium from activated breast fibroblasts (blue line) or the indicated growth
factors (red line) compared with the vehicle (black line). (I) Levels of pERK and pAKT in
MDA-MB-231 cells co-cultured with activated mammary fibroblasts (CAFs) treated with vehicle
or ProAgio were analyzed by immunoblot. b-actin is the loading control. (J) Cell viability of
MDA-MB-231 cells upon treatment with indicated concentrations of doxorubicin for 48 h in the
co-culture of activated breast fibroblasts (CAFs) and MDA-MB-231 cells (red line) or the pretreated activated breast fibroblasts and MDA-MB-231 cells with ProAgio (blue line) compared
with the vehicle (black line). ProAgio (5µm) was added to the activated breast fibroblasts
(CAFs) for 6 h followed by doxorubicin treatment for 48 h. Cell viability was analyzed by MTT
assay. Experiments were performed in triplicate. Error bars represent mean ± S.E.M. *P<0.05,
**P<0.01, ***P<0.001 ****P<0.0001 by unpaired Student’s t test.
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Figure 2.9. ProAgio reduces metastasis to the lungs by modulating fibrotic stroma at the
lung metastatic site.
(A, B) Representative images of H&E staining of the lungs (A), and quantification of number of
metastatic lung nodules (B) of vehicle or ProAgio treated 4T1 orthotopic mice (Vehicle (n=13);
ProAgio (n=22)). (C, D) Representative images of H&E staining of the lungs (C), and
quantification of number of metastatic lung nodules (D) of vehicle or ProAgio treated MMTVPyMT mice (n=6-8). (E-G) Representative IHC images of a-SMA staining (E, upper panel),
Sirius red staining of collagen (E, lower panel), and quantification of a-SMA area (F) and
collagen area (G) in metastatic lungs of 4T1 mice treated with vehicle (grey bar) or ProAgio (red
bar) compared to the normal mice (white bar) (n=6-8). (H, I) Representative IF images of costaining of α-SMA (red) and cleaved-caspase 3 (C-Caspase 3, green) (H), and quantification of
apoptotic α-SMA+ CAF (a-SMA+ CC3+) (I) in the metastatic lungs of vehicle or ProAgio treated
4T1-bearing mice. Nuclei were counterstained with DAPI (blue). (J) Levels of integrin aV (IB:
Integrin aV), integrin b3 (IB: Integrin b3), and a-SMA (IB: a-SMA) in the inactivated (-TGF-b)
and activated (+TGF-b) human lung fibroblasts were analyzed by immunoblot. Lung fibroblasts
were activated by culturing for 48 h in the presence of 5 ng/mL TGF- b. Inactivated lung
fibroblasts are the cells that are cultured for one day without TGF- b. b-actin is the loading
control. (K) Therapy regimen of 10 mg/kg ProAgio (i.p.) in 4T1 spontaneous model. 4T1 cells (1
x 104) were injected into the tail vein of Balb/C mice and ProAgio (10mg/kg; 12 doses, i.p.) was
administered. On day 15, the mice were sacrificed, and the lungs were collected. (L, M)
Representative images of H&E staining (L), and quantification of tumor nodules (M) in lung
sections of vehicle or ProAgio treated 4T1 spontaneous mouse model. Scale bars in L (top panel:
1000 µm, lower panel: 100 µm); scale bars in A, E, and H, 100 µm; (n = 6-8). **P < 0.01, ***P
< 0.001, ****P<0.0001 by unpaired Student’s t test.
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Figure 2.10. ProAgio effectively induces apoptosis in lung CAFs and reduces the number
and size of lung metastatic nodules.
(A-C) Representative images of H&E staining of lungs (A), and quantification of metastatic lung
nodule number (B), and lung metastatic nodule diameter (C) of MDA-MB-231 mice treated with
vehicle or ProAgio. (D, E) Quantification of the lung metastatic nodule diameter of 4T1
orthotopic (D) and MMTV-PyMT (E) mice treated with vehicle or ProAgio. (F) Representative
images of IF staining of integrin αVβ3 (green), a-SMA (red), and vimentin (green) in the activated
human lung fibroblasts. Nuclei were counterstained with DAPI (blue). (G) Apoptosis of activated
lung fibroblasts that were treated with 5 µm ProAgio was analyzed by Annexin V kit. (H) Co-IP
of caspase 8 with integrin b3 (IP: Integrin b3) was analyzed by immunoblot. Human lung
fibroblasts were activated with 5ng/mL TGF-b for 48 h and subsequently treated with 5 µm
ProAgio for 4 h before the preparation of extract. Immunoblot of integrin b3 (IB: Integrin b3)
indicates the amount of integrin b3 that was precipitated down in Co-IP. IgG is the loading
control. Input represents 5% of the total protein used for IP and b-actin is the loading control. (I)
Quantification of the lung metastatic nodule diameter from the lung sections of 4T1 spontaneous
mouse model. (J-M) Representative images of IHC staining of α-SMA (J), Sirius red staining of
collagen (M), and quantification of α-SMA +ve area (K) and collagen +ve area (L) in the lung
sections of vehicle or ProAgio treated 4T1 spontaneous mice (tail vein model) compared with the
normal mice. Error bars represent mean ± S.E.M. (n= 6-8); Scale bars, 100 µm; Scale bars in M,
1000 µm (left panel). **P<0.01, ***P<0.001, ****P<0.0001 by unpaired Student’s t test.
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Figure 2.11. ProAgio eliminates angiogenic vessels, enhances blood perfusion into the
tumor and consequentially reduces hypoxia.
(A-D) Representative IF images of CD31 staining (A), quantification of vessel number per field
(B), number of branch points (C), and vessel length (D) in 4T1 mice treated with vehicle or
ProAgio. Nuclei were counterstained with DAPI (blue). (E-G) Representative IF images of lectin
perfusion in tumor vessels (E), and quantification of CD31+ area (F) and lectin per CD31+ area or
total sectional area of co-staining of CD31 (green), and lectin (red) (G) in 4T1 orthotopic mice
treated with vehicle or ProAgio. (H) Intratumoral levels of paclitaxel in the extracts of breast
tumor of 4T1 orthotopic mice treated with vehicle or ProAgio measured by HPLC. Paclitaxel
levels were presented as ng of paclitaxel per mg breast tumor. (I, J) Representative IF images of
FITC-conjugated paclitaxel (~1 KDa) (I), and quantification of fluorescence signals (J) in the
breast tumor sections of 4T1 orthotopic mice treated with vehicle or ProAgio harvested at the
end of the experiment. (K, L) Representative IHC images of hypoxyprobe-1 (K), and
quantification of hypoxia (L) in the breast tumor of 4T1 mice treated with vehicle or ProAgio.
Scale bars, 100 µm; scale bars in K, 500 µm (left panel); (n=4-6) *P < 0.05, **P < 0.01, ***P <
0.001, ****P<0.0001 by unpaired Student’s t test.
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Figure 2.12. ProAgio eliminates angiogenic leaky vessels and reduces hypoxia in breast
tumor mouse models.
(A, B) Representative IHC images of CD31 staining (A), and quantification of CD31+ area (B) in
the breast tumor of MMTV-PyMT mice treated with vehicle or ProAgio. (C, D) Representative
IF images of dextran leakage of tumor vessels (C), and quantification of dextran+ area (D) in the
breast tumor sections of 4T1 orthotopic mice. Dextran+ area is presented as a percentage per
total section or CD31+ area. (E, F) Representative images of IF staining of HIF-1a (E), and
quantitative analysis of HIF-1a (F) in the breast tumor of 4T1 orthotopic mice treated with
vehicle or ProAgio. Nuclei were counterstained with DAPI (blue). (G, H) Representative images
of IHC staining of HIF-1a (G), and quantitative analysis of HIF-1a (H) in the breast tumor of
MMTV-PyMT mice treated with vehicle or ProAgio. Scale bars, 100 µm; (n = 4-6). **P < 0.01,
***P < 0.001 by unpaired Student’s t test.
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Figure 2.13. ProAgio decreases hypoxia induced LOX-mediated metastasis to the lungs in
4T1 orthotopic model.
(A-C) mRNA analysis of LOX measured by qRT-PCR in 4T1 cells (A), MDA-MB-231 cells (B)
in normoxia (grey bar) or hypoxia (red bar) condition and inactivated (-TGF-b, grey bar) or
activated (+TGF-b, red bar) human mammary fibroblasts (C). (D-F) Representative IF images of
LOX staining (D), quantification of LOX staining (E), and mRNA analysis of LOX measured by
qRT-PCR (F) in the breast tumor of 4T1 orthotopic mice treated with vehicle or ProAgio. Nuclei
were counterstained with DAPI (blue). (G) Quantification of LOX activity in the breast tumor
(left panel) and serum (right panel) of vehicle or ProAgio treated 4T1 mice. (H, I)
Representative IHC images of LOX staining (H), and quantification of LOX (I) in the metastatic
lungs of 4T1 tumor bearing mice treated with vehicle or ProAgio (n=4-6). (J, K) Representative
images of Sirius red staining (upper panel) and the corresponding cross-linked collagen images
by polarized light microscopy on Sirius red staining (lower panel) (J), and quantitative analysis
of cross-linked collagen (K) in the metastatic lungs of 4T1 orthotopic mice treated with vehicle
or ProAgio. (L, M) Representative flow cytometric plots (L), and population of CD11b positive
myeloid cells (M) gated on CD45+ tumor infiltrating leukocytes in the metastatic lungs of vehicle
or ProAgio treated orthotopic 4T1 mice. Scale bars, 100 µm. Experiments were performed in
triplicate. Error bars in A, B, and C represent mean ± S.E.M. (n=4-6); *P < 0.05, **P < 0.01,
***P < 0.001, ****P<0.0001 by unpaired Student’s t test.
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Figure 2.14. ProAgio decreases hypoxia induced LOX-mediated metastasis to the lungs in
MMTV-PyMT mouse model.
(A, B) Representative images of IHC staining of LOX (A), and quantification of LOX staining
(B) in the breast tumor of MMTV-PyMT mice treated with vehicle or ProAgio. (C) mRNA
analysis of LOXL2 (left panel), and LOXL4 (right panel) measured by qRT-PCR in the breast
tumor of 4T1 orthotopic mice treated with vehicle (grey bar) or ProAgio (red bar). (D)
Quantification of LOX activity in the breast tumor of MMTV-PyMT mice treated with vehicle or
ProAgio. (E-G) Representative images of Sirius red staining (left panel) and the corresponding
cross-linked collagen images by polarized microscopy on Sirius red staining (right panel) (E) and
quantitative analysis of cross-linked collagen (F, G) in the breast tumor of 4T1 orthotopic (upper
panel) and MMTV-PyMT (lower panel) mice treated with vehicle or ProAgio. (H)
Quantification of LOX activity in the serum of MMTV-PyMT mice treated with vehicle or
ProAgio. (I, J) Representative images of IHC staining of LOX (I), and quantification of LOX
staining (J) in the metastatic lungs of MMTV-PyMT mice treated with vehicle or ProAgio. (KM) Representative images of Sirius red staining for collagen (left panel) and its corresponding
cross-linked images by polarized microscopy on Sirius red staining (right panel) (K), and
quantification of collagen (L), and cross-linked collagen (M) in the metastatic lungs of MMTVPyMT mice treated with vehicle or ProAgio. (N, O) Representative flow cytometric plots of
CD11b (N), and population of CD11b positive cells gated on CD45+ infiltrating leukocytes (O)
in the metastatic lungs of MMTV-PyMT mice treated with vehicle or ProAgio (n=5-8). (P)
Representative IHC images of low and high LOX staining in the breast tumor of TNBC patients.
(Q) Kaplan-Meier survival analysis of low and high LOX [low (n=34), high (n=48)] gene
expression in the breast tumor of TNBC patients. TCGA data set of TNBC patients was obtained
from cbioportal (htttp://cbioportal.org). Scale bars, 100 µm. *P < 0.05, **P < 0.01, ***P <
0.001, ****P<0.0001 by unpaired Student’s t test and log-rank test (Q).
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Figure 2.15. ProAgio enhances chemotherapeutic efficacy in 4T1 orthotopic and MMTVPyMT mouse model.
(A) Therapy regimen of 10 mg/kg ProAgio (i.p.) and 3 mg/kg Paclitaxel (PTX, i.p.) in 4T1
orthotopic Balb/C mice. (B) Representative gross images of breast tumor of orthotopic 4T1 mice
treated with indicated agents. (C-E) Kaplan-Meier survival analysis (n=8-11; median survival
(days) vehicle=17, ProAgio=21, PTX=20, ProAgio+PTX=26.5) (C), mean tumor volume (n=812) (D), and mean tumor weight (E) of orthotopic 4T1 mice treated with indicated agents (n = 58). (F) Therapy regimen of 20 mg/kg ProAgio (i.p.) and 5 mg/kg Paclitaxel (PTX, i.p.) in
MMTV-PyMT mice. (G) Representative images showing gross appearance of tumors where
dotted lines demarcate tumor masses of MMTV-PyMT mice treated with indicated agents. (H-I)
Kaplan-Meier survival analysis (n=18-21; median survival (days) vehicle=32, ProAgio=43,
PTX=33, ProAgio+PTX=48) (H), mean tumor burden (I) of MMTV-PyMT mice treated with
indicated agents (n = 6-8). (J) Schematic illustration of action of ProAgio in TNBC. Error bars
represent mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001, ****P<0.0001, ns - nonsignificant by unpaired Student’s t test.
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Figure 2.16. ProAgio enhances chemotherapeutic efficacy and cancer cell apoptosis in
breast cancer mouse models.
(A) Therapy regimen of 10 mg/kg ProAgio (i.p.) and 3 mg/kg Doxorubicin (DOX, i.p.) in 4T1
orthotopic mice. (B) Representative gross images of breast tumor of orthotopic 4T1 mice treated
with indicated agents. (C-E) Kaplan-Meier survival analysis [n=11-12; (Median survival (days),
vehicle=21, ProAgio=31, DOX=23, ProAgio+DOX=36)] (C), mean tumor volume (D), and
mean tumor weight (E) of orthotopic 4T1 mice treated with indicated agents. (F, G) Mean tumor
volume of each nodule (F), and average tumor weight (G) of MMTV-PyMT mice treated with
indicated agents (n = 6-8). (H, I) Representative IHC images of cleaved caspase 3 (CC3) staining
(H), and quantification of CC3 +ve cells (I) in 4T1 mice treated with indicated agents. (J, K)
Representative H&E staining of lungs (J), and quantification of lung nodules number (K) in 4T1
mice upon treatment with indicated agents. Scale bars, 100 µm; Scale bars in J, 1000 µm (n = 58). Error bars represent mean ± S.E.M. *P<0.05, **P<0.01 and ***P<0.001, ****P<0.001, ns
denotes non-significant by Student’s unpaired t-test or log-rank test (C).
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Figure 2.17. Combined therapy of ProAgio and chemotherapy decreases stroma and cell
proliferation in MMTV-PyMT mouse model.
(A-D) Representative images of IHC staining and quantitative analyses of a-SMA (A), Sirius
red staining and quantitative analyses of collagen (B), IHC staining and quantitative analyses of
Ki67 (C) and cleaved caspase 3 (CC3) (D) in the breast tumor of MMTV-PyMT mice treated
with indicated agents. (E-G) Representative H&E images of lung sections (E), number of
metastatic lung nodules by histology (F), and number of metastatic lung nodules on the lung
surface (G) of MMTV-PyMT mice treated with indicated agents. Scale bars, 100 µm; scale bars
in E, 100 µm; (n = 6-8). *P<0.05, **P<0.01 and ***P<0.001, ****P<0.001, ns denotes nonsignificant by Students unpaired t-test.
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Figure 2.18. Graphical abstract illustrating the sequence of events in the tumor resulting in
tumor growth and metastasis; and the action of ProAgio in TNBC.
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2.6. Materials and Methods:
2.6.1. Cells
MDA-MB-231 cell lines were purchased from ATCC and the cells were cultured as per
vendor’s instructions. MDA-MB-468, BT549, HCC1806, and 4T1 cell lines were a kind gift from
Dr. Aneja’s lab at GSU. Human mammary fibroblasts and human lung fibroblasts were purchased
from Cell Biologics (H-6071) and Lonza (C57-6013) respectively and cultured in complete
fibroblast medium (Cell Biologics, M2267). The primary cells were activated by culturing in TGFb (5ng/ml) for 48 hours. For cell hypoxia, MDA-MB-231 and 4T1 cells were cultured in a modular
incubator chamber that was infused with a mixture of 1% O2, 5% CO2 and 94% N2 at 37°C. Cells
were incubated in normoxic or hypoxic condition for 48 hours.
2.6.2. Mouse fibroblasts isolation from 4T1 tumor
Breast tumor from 4T1 mouse (generally when the tumor volume reached around 500-700
mm3) was cut into small pieces and collagenase digested. After filtering the undigested tissue, the
solution was serial centrifuged, and the final pellet re-suspended in DMEM with 10% FBS and 1%
ITS (insulin–transferrin–selenium; #41400-045; Thermo Scientific) and seeded on a culture dish.
After 30 min, the fibroblasts had already adhered to the dish whereas other cellular types remained
in suspension. Fibroblasts were subsequently grown on a culture dish and the population was
expanded (Calvo et al., 2013).
2.6.3. 4T1 orthotopic, MDA-MB-231 orthotopic, and GEM MMTV-PyMT mouse models
Female Balb/C and nude mice 5-7 weeks old were obtained from Jackson Laboratory for
experiments with 4T1 and MDA-MB-231 cells respectively. MMTV-PyMT male mice
heterozygous for the oncogene were bred with a non-carrier female. Hemizygous breeding pair of
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FVB/N background was obtained from The Jackson Laboratory [Stock no. 002374, Strain name:
Tg(MMTV-PyVT)634Mul]. The offsprings were genotyped as per the protocol provided by the
vendor (Table 2.3). Female mice positive for MMTV-PyMT were used in the study. Survival
studies were scored based on the humane end points of mice. Survival studies involving large
groups of transgenic MMTV-PyMT mice were performed by enrollment of mice at 75 days of age.
The transgenic mice were randomized in groups by excluding obvious outliers such as unusually
large mammary tumors. All animal experiments were carried out in accordance with the guidelines
of Institutional Animal Care and Use Committee (IACUC) of Georgia State University.
2.6.4. Patient samples
Patient tissue analyses were carried out in accordance with the guidelines of NIH. All tissue
samples were de-identified. It falls under IRB exemption 4. Tissue samples were sectioned and
analyzed by IHC and H&E staining. Samples were obtained either from US Biomax or Harbin
Medical University Cancer Hospital, China (n=80).
2.6.5. Tumor implantation in orthotopic tumor mouse model
4T1 cells (0.5 X 106) and MDA-MB-231 (5 X 106) were implanted orthotopically in the
mammary fat pad of 6-8-week-old female syngeneic Balb/C and nude mice respectively. Tumor
volumes were assessed twice a week. Tumor volumes were measured by the formula: 0.5 x
(length) x (width)2. The tumor-bearing mice were subjected to intraperitoneal injections of
appropriate agents at indicated frequencies (detailed description in figures and legends). The
treatments for 4T1 and MDA-MB-231 were initiated when the tumor reached the average size of
220-250 mm3 and 150 mm3 respectively. The tumors were collected and weighed at the end of the
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experiments. Tissue sections were prepared from collected tumors and lungs. Lung metastases
were defined as gross lesions of at least 25 cells.
2.6.6. In vivo tail-vein tumor mouse model
4T1 cells (1 X 104) were injected intravenously into the tail vein of female Balb/C mice.
Vehicle or ProAgio treatment started next day after 4T1 cells injection. Mice were sacrificed on
day 15th after 12 daily doses of ProAgio (10mg/kg, i.p.). Microscopic quantification of lung foci
was performed on representative cross-sections of formalin fixed, paraffin-embedded lungs stained
with hematoxylin and eosin (H&E).
2.6.7. Drugs preparation
Paclitaxel (PTX) and Doxorubicin (DOX) were purchased from Sigma-Aldrich and
suspended in sterile DMSO and water at 50 mg/ml respectively. GMP grade ProAgio-30 kDA
PEG provided by Amoytop Biotech was prepared in PBS at a stock concentration of 7 mg/ml.
Drugs were filter sterilized through a 0.22 μM Millex GV syringe filter before usage. The working
solution was stored at 4ºC for up to a maximum of one week.
2.6.8. Drug study treatment groups
Mice were treated with either 5mg/kg PTX or 3mg/kg DOX or 10 mg/kg ProAgio in case
of 4T1 and MDA-MB-231 and 20mg/kg ProAgio in case of MMTV-PyMT mice. 10 mg/kg
ProAgio was administered based on the dose dependent efficacy in a xenograft model (Turaga et
al., 2016). A higher dose, 20 mg/kg ProAgio was used in MMTV-PyMT mouse model because of
the significantly higher tumor burden. The toxicity studies of ProAgio were performed in mice,
rats, dogs, and multiple non-human primates and dose upto 80 mg/kg was found safe. Vehicle is
the control group, which received only PBS. Survival study structure enrollment of 4T1, MDA113

MB-231, and MMTV-PyMT mice was completely random. Endpoint criteria for survival
experiments included the development of abnormal/ulcerative tumors, cachexia, and physical
activity. Significant weight loss exceeding 20% of initial weight was an additional criterion in case
of 4T1 and MDA-MB-231 mice. Mice were enrolled into treatment groups randomly by an
investigator blinded to their current tumor burden.
2.6.9. Histology
5-μm-thick sections of paraffin embedded tissues were analyzed for H&E studies (Thermo
Scientific), Picro Sirius Red (IHC world) according to vendor’s instructions. Lungs were perfused
with formalin prior to paraffin embedding.
2.6.10. Immunofluorescence
Tumor tissues were embedded in OCT and lungs were perfused with a 1:1 ratio of
PBS/OCT post-excision before embedding in OCT (Tissue-Tek). 10-μm-thick sections were
washed with PBS, fixed in acetone and incubated with primary antibodies. Antibodies used for IF
staining are listed in Table 2.1. Alexa Fluor 488 and 555 secondary antibodies were used to
visualize IF staining. Nuclei were counterstained with DAPI or Hoechst. Images were taken using
a Keyence microscope camera and analyzed using Adobe Photoshop CS6. For cell
immunofluorescence staining, 3,000 mammary and lung fibroblasts were seeded on glass
coverslips coated with poly-L-lysine in a 6-well chamber plate and cultured overnight. To activate
fibroblasts, TGF-b (5ng/mL) was added to the culture media for 72 hours, followed by fixation in
4% paraformaldehyde. Slides were then processed as described previously for tissue
immunofluorescence staining. Whole tissue slides scans at 4x, 10x, 20x, and 40x magnification
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were taken on the Keyence microscope. Image analysis was performed by thresholding for positive
staining and normalizing to total tissue area using ImageJ.
2.6.11. Immunohistochemistry
Tissues were fixed in 10% formalin, embedded in paraffin, and incubated with antibodies
as previously described (Ref). Lungs were perfused with formalin prior to formalin fixation
followed by paraffin embedding. 5-μm-thick sections were deparaffinized in xylene, rehydrated in
graded ethanol and subjected to antigen retrieval in a pressure cooker (120°C) for 15-20 minutes in
0.01M Citrate buffer pH 6.0 (Sigma-Aldrich). After blocking, slides were incubated with primary
antibodies listed in Table 2.1. Immunostaining was detected using DAB and image acquisition and
analysis was similar to that of IF imaging. Quantifications of Picro-Sirius red, IHC, and IF staining
were carried out using ImageJ software. Quantifications are presented as percent (%) of positive
stain area in each view field, unless otherwise specified in the figures and legends. All
quantification results were means of randomly selected 3-4 view fields, 5 sections per animal, and
6-10 mice per experimental group, unless otherwise specified in the figures and legends.
2.6.12. Quantitative RT-PCR
To detect mRNA levels of a-SMA, FAP, LOX, LOXL2, and LOXL4, a standardized realtime PCR was performed using SYBR green Master Mix (Takara) according the manufacturer’s
instructions. The primers are listed in Table 2.2.
2.6.13. Western blotting
Cells were washed, lysed in RIPA buffer (Cell signaling) supplemented with phosphatase
(Sigma-Aldrich) and protease (Roche) inhibitors, scraped and collected in pre-chilled tubes.
Lysates were then cleared by centrifugation at 15,000 g for 10 min at 4°C, and protein
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concentration was determined using Bradford assay (Bio-Rad). Standard immunoblotting
procedures were followed. Membranes were blocked in 5% BSA diluted in TBS with 0.05%
Tween 20 (TBST). Blots were probed with the antibodies listed in Table 2.1.
2.6.14. Immunoprecipitation
Antibody against integrin β3 (1:100) or caspase 8 (1:100) was added to the lysates for
incubation overnight at 4°C, with rabbit IgG (1:100) as a control antibody. Then Dynabeads
Protein A was added for incubation for another 1 h at 4°C. After washing 5 times with the lysis
buffer, the immunocomplexes were resuspended in protein loading buffer and were analyzed by
immunoblotting.
2.6.15. Apoptosis assay
Primary cells were cultured overnight. Fresh culture medium was added to the cells next
day. ProAgio (5 µM and 10 µM) was added to the medium and incubated for 24 h. After 24 h,
apoptosis was determined using an apoptosis kit.
2.6.16. LOX activity assay
For the in vivo analysis, blood was taken at the end of the experiment described above from
vehicle-treated and ProAgio-treated 4T1 and MMTV-PyMT mice. Serum and tumor lysates of
vehicle and ProAgio treated mice was detected using LOX activity kit.
2.6.17. Tumor hypoxia
For detection of tumor hypoxia, hypoxyprobe-1 (60mg/kg, solid pimonidazole
hydrochloride) was intravenously injected in the mice 1 h before extraction. Tumors were fixed in
10% formalin overnight, embedded in paraffin and cut into 5 µm sections. Tumor sections were
IHC stained as per manufacturer’s instructions.
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2.6.18. Drug diffusion to assess the functional vasculature
Alexa Fluor 488 conjugated paclitaxel was diluted in sterile PBS and administered via tail
vein. Consequently, mice were euthanized after 45 min. Tissues were fixed in OCT medium and
subsequently sectioned. The drug diffusion was observed under fluorescence microscope with
DAPI nuclear stain.
2.6.19. Determination of paclitaxel concentration by HPLC
Paclitaxel stock solution was prepared at 500 µg/mL and 10, 25, 50, 75, 100 μg/mL were
prepared by further dilution of the standard stock solution in methanol. The apparatus used was
Agilent (insert model number here) with a DAD detector (insert model number here) at 227 nm.
Chromatographic separation was achieved using an Agilent C18 (insert model number here)
column at ambient temperature. The mobile phase used was ACN/sodium acetate buffer (0.01M,
pH 5.0) at 60/40, with a flow rate of 1 mL/min. The Rt for paclitaxel under these conditions was 12
minutes. 1g of tumor was weighed and ground under liquid nitrogen. They were then subject to
liquid-liquid extraction with diethyl-ether. Samples were centrifuged at 14,000 rpm for 10 minutes
and the organic layer was separated. 50 µL of the sample was then injected into the system.
2.6.20. In vivo vascular leakage and perfusion assay
At the end of 4T1 experiment, tumor vessel leakage was analyzed after i.v. injection of 100
μl of FITC-conjugated dextran (25 mg/ml) 30 min before sacrifice. For vascular perfusion studies,
100 μl of 594-conjugated tomato lectin (1 mg/ml) was i.v. injected 30 min before sacrifice.
2.6.21. Flow cytometry
Cells were blocked with anti-FcR (clone 2.4G2; Bio-Xcell) and then incubated with a
mixture of fluor-conjugated antibodies against CD45 and CD11b at 4°C in the dark for 30
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minutes. After staining, cells were washed, resuspended in PBS, and analyzed using LSRFortessa
(BD Bioscience). Data were analyzed using FlowJo software (Tree Star Inc.).
2.6.22. MTT assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to
determine viability of the indicated cells. Briefly, 3000 cells were seeded onto 96-well plates and
incubated overnight at 37°C. The cells were then treated with indicated chemotherapeutic agents
for 48 hours. Thereafter, MTT solution was added to each individual well, and the plates were
incubated for 4 h at 37°C. Then the media was removed and DMSO was added to dissolve the
formazan crystals. The absorbance was measured at 570 nm. Four replicate wells were included in
each analysis and at least three independent experiments were conducted.
2.6.23. Statistical analysis
All statistical analysis was performed using GraphPad Prism 6.0 software. The number of
animals and replicate in vitro experiments are described in each figure legend. Kaplan-Meier
survival curves were calculated using survival time for each mouse from all treatment groups.
Statistical analyses in the survival experiments were performed by log-rank (Mantel-Cox) test.
Data were statistically analyzed by comparing two appropriate groups. The P values were
calculated using unpaired two-tailed Student’s t-test. Analysis of experiments with more than two
groups was performed using one-way ANOVA with Tukey’s correction for multiple comparisons,
unless indicated otherwise. In some experiments involving multiple groups, in addition to multiple
comparisons, we directly compared two experimental groups of interest and applied Student’s t test
with 95% confidence interval; in these cases, the statistical significance is indicated for the overall
experiment (by one-way ANOVA with correction for multiple comparisons) as well as the two
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groups of interest (by Student’s t test). In all figures and tables, NS means P>0.05 and statistically
insignificant, *P<0.05, **P<0.01, ***P<0.001, and ****P<0.001.
Table 2.1. Key resources
Reagent or Resource

Source

Identifier

Ultravision Peroxidase block

Thermo Scientific

TA060H2O2Q

Ultravision Protein block

Thermo Scientific

TA060PBQ

Antibody diluent OP Quanto

Thermo Scientific

TA-125-ADQ

Betazoid DAB Chromogen kit

Biocare Medical

BDB2004L

Citrate buffer

Sigma-Aldrich

C9999-1000ML

Large Volume Mayer's Haematoxylin

Thermo Scientific

TA-125-MH

Direct PCR Lysis Reagent (Mouse ear)

Viagen Biotech

102-T

PCR Master Mix

Thermo Scientific

F548S

100bp DNA Ladderxs

Thermo Scientific

SM1143

Molecular Biology Agarose

Bio-Rad

1613101

α-SMA (Mouse)

Sigma-Aldrich

A5228

α-SMA (Rabbit)

abcam

AB5694

Cleaved caspase 3

abcam

AB49822

LOX

EMD Millipore

ABT112

Hif-1α

EMD Millipore

MAB5382

Pancytokeratin

abcam

AB27988

Ki67

abcam

AB15580

Integrin αVβ3 (23C6)

Santa Cruz Biotechnology

SC-7312

Integrin αV

Cell Signaling

4711S

Integrin β3

EMD Millipore

AB2984

PECAM-1/CD31

abcam

AB9498

Phospho Akt

Santa Cruz Biotechnology

SC-33437

Phospho Erk

Santa Cruz Biotechnology

SC-7383

Antibodies
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Vinculin

Thermo Scientific

700062

Rhodamine Phalloidin

Thermo Scientific

R415

Caspase-8

Thermo Scientific

MA1- 41280

EGF

abcam

AB9695

PDGF-BB

abcam

AB23914

IGF1

abcam

AB9695

Phospho PDGFRb

abcam

AB16868

Phospho EGFR

abcam

AB40815

Phospho IGF1R

Thermo Scientific

44-804G

CD11b (Clone M1/70)

Biolegend

101207

CD45 (Clone 30-F11)

Biolegend

103125

b-actin

Yurogen Biosystems

R15006MC4

Alexa Fluor 488 (anti-mouse)

Thermo Scientific

A-21424

Alexa Fluor 488 (anti-rabbit)

Thermo Scientific

A-21429

Alexa Fluor 555 (anti-mouse)

Thermo Scientific

A-11029

Alexa Fluor 488 (anti-rabbit)

Thermo Scientific

A-11034

Rabbit IgG

Cell Signaling

2729S

Chemicals, Peptides, and Recombinant Proteins
Paclitaxel

Sigma Aldrich

33069-62-4

Paclitaxel

TargetMol

T0968

Doxorubicin

EMD Millipore

324380

PDGF-BB (human)

Peprotech

100-14B

PDGF-BB (murine)

Peprotech

315-18

EGF (human)

Thermo Scientific

PHG0311

EGF (murine)

Thermo Scientific

PMG8041

IGF1 (human)

R & D Systems

291-G1

IGF1 (murine)

R & D Systems

791-MG

HGF (human)

R & D Systems

294-HG

HGF (murine)

R & D Systems

2207-HG
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Paclitaxel Oregon GreenTM 488 conjugate

Thermo Scientific

P22310

Dynabeads Protein A

Thermo Scientific

10002D

DAPI

Thermo scientific

36930

Hoechst

Thermo scientific

62249

Proteinase K

Thermo Scientific

EO0491

Biological Samples
Paraffin TNBC sections

Harbin Medical University cancer hospital, China

US Biomax

BR1202a, BR125A

Critical Commercial Assays
Annexin V Apoptosis detection kit

BD Biosciences

556547

Picro Sirus red staining kit

IHC world

IW-3012

LOX activity assay kit

Sigma Aldrich

AB112139

MTT assay kit

Sigma Aldrich

M5655

Hypoxyprobe kit

Hypoxyprobe, Inc

HP1-XXX

Lectin

Sigma Aldrich

73873

Dextran

Sigma Aldrich

FD10S

Mouse PDGF-BB Quantikine ELISA Kit

R & D Systems

MBB00

Mouse IGF-I/IGF-1 Quantikine ELISA Kit

R & D Systems

MG100

Mouse EGF Quantikine ELISA Kit

R & D Systems

MEG00

Experimental Models: Organisms/Strains
MMTV-PyMT (FVB/N background)

The Jackson Laboratory

Balb/C mice

The Jackson Laboratory

Nude mice

The Jackson Laboratory

Software and Algorithms
Graph pad PRISM 6
Adobe Photoshop CS6
Image J
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Table 2.2. List of primers
MMTV-PyMT
Primer type

Sequence

Catalog #

Transgene Forward

GGAAGCAAGTACTTCACAAGGG

oIMR0384

Transgene Reverse

GGAAAGTCACTAGGAGCAGGG

oIMR0385

Internal Positive Control Forward

CAAATGTTGCTTGTCTGGTG

oIMR8744

Internal Positive Control Reverse

GTCAGTCGAGTGCACAGTTT

oIMR8745

Gene

Species Forward sequence 5’

Reverse sequence 5’

LOX

Human GTTCCAAGCTGGCTACTC

GGGTTGTCGTCAGAGTAC

Mouse

CCTTCAGCCACTCTCCTCTG

GCACAGCTGTCACCAACATT

LOXL2 Mouse

GGAAAGCGTACAAGCCAGAG

GCACTGGATCTCGTTGAGGT

LOXL4 Mouse

ACCGAAGACAAAGCCACAAC

CACACGACACTGGCAGAGAT

FAP

AGACAGACTTGCTTCTTTTCAACA CAGGTTTGTAAACTCTTGAGGGACG

Mouse

β-Actin Human AACTGGGACGACATGGAGAA

TGGATGCCACAGGACTCCAT

Mouse

AGTGTGACGTTGACATCCGT

GCAGCTCAGTAACAGTCCGC

α-SMA Mouse

AGCTACGAACTGCCTGACGG

TTTCGTGGATGCCCGCTGAC

122

Table 2.3. PCR conditions for MMTV-PyMT mice genotyping
Temperature (OC) Time
94

2 min

94

20sec

65

15sec

-0.5 C per cycle decrease

68

10sec

5 repeat steps 2-4 for 10 cycles

94

15sec

60

15sec

72

10sec

72

2 min

10

Hold

Repeat steps 6-8 for 28 cycles
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3. MODULATION OF CANCER-ASSOCIATED FIBROTIC STROMA BY AN
INTEGRIN aVb3 TARGETING PROTEIN FOR PANCREATIC CANCER TREATMENT
3.1. Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with a five-year survival
rate of 8% after diagnosis. Dense fibrotic stroma orchestrated by cancer associated pancreatic
stellate cells (CAPaSCs) and collapsed tumor vessels are two major factors that contribute to
treatment failure. Targeting CAPaSCs represents a promising strategy for PDAC treatment. We
previously reported a rationally designed protein (ProAgio) that targets integrin avb3 at a novel
site and induces apoptosis in integrin avb3 expressing cells. We demonstrate here that integrin
avb3 is upregulated in CAPaSCs. ProAgio specifically induces apoptosis in CAPaSCs and
resorbs collagen in PDAC tumor, enabling drug delivery into the tumor. ProAgio alone and in
combination with gemcitabine (Gem) provides survival benefit when tested in GEM-KPC and
orthotopic KPC models of PDAC. Furthermore, ProAgio decreases intratumoral IGF1 levels due
to depletion of CAPaSCs and consequently decreases cytidine deaminase, a gemcitabine
metabolism enzyme in cancer cells, thereby reduces resistance to Gem-induced apoptosis.
3.2. Introduction
PDAC is one of the most lethal diseases with median survival below 6 months after
diagnosis. Despite intensive efforts in developing effective treatments, patient survival has only
improved marginally. Dense fibrotic stroma and ECM laid down by CAPaSCs is considered to
be one of the major contributors to resistance to anti-tumor therapies in this disease (Olive et al.,
2009; Provenzano et al., 2012; Provenzano and Hingorani, 2013). CAPaSCs also engage in
symbiotic growth factor and cytokine “cross-talk” with cancer cells that support tumor growth,
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survival, resistance to apoptosis, and metastasis (Eguchi et al., 2013; Hanahan and Weinberg,
2011; Vonlaufen et al., 2008a; Vonlaufen et al., 2008b). In return, cancer cells provide factors
that support pancreatic stellate cells (PaSCs) proliferation and survival. In addition, CAPaSCs
and its secreted ECM form a special immunosuppressive environment, which aids PDAC cells to
escape from immunologic recognition (Ene-Obong et al., 2013). Prior studies have shown that
depleting CAFs and fibrosis can improve efficacy of existing PDAC treatments in pre-clinical
models (Olive et al., 2009; Provenzano et al., 2012). However, recent studies of Sonic hedgehog
(Shh) and a-SMA gene deletion in GEM models of PDAC suggest that some fibrotic stroma in
PDAC may constitute a barrier that prevents metastatic spread of the tumor (Leake, 2014;
Ozdemir et al., 2014; Rhim et al., 2014). Depletion of fibrotic stroma results in increased
metastasis and shorter survival in pre-clinical models and some early phase clinical studies
(Catenacci et al., 2015; Ozdemir et al., 2014; Rhim et al., 2014). These studies aroused a very
important controversy, “ whether to target or not-target fibrotic stroma in cancer therapies,
particularly in treatment of PDAC?” (Carr and Fernandez-Zapico, 2016).
Integrin avb3 is not expressed or expressed in very low levels in most normal
tissues/cells. However, high levels of integrin avb3 are often detected in tissues at inflammatory
site, wound healing, and invasive cancers. The integrin is highly expressed in angiogenic
endothelial cells and collagen secreting myofibroblasts. Due to lack of expression in most normal
tissues/cells, it is believed that this integrin pair is an ideal and safe target for drug development
for multiple pathological conditions (Eliceiri and Cheresh, 1999; Millard et al., 2011; Wilder,
2002). We previously reported the development of a rationally designed protein (ProAgio) that
targets integrin avb3 at a novel site. ProAgio effectively induces apoptosis in avb3 expressing
cells (Turaga et al., 2016). It has previously been shown that activated hepatic stellate cells
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(HSCs) express high levels of integrin avb3 (Li et al., 2011; Patsenker et al., 2009; Zhou et al.,
2004). PaSCs share similar properties with HSCs (Erkan et al., 2010), which prompted us to
question whether activation of PaSCs leads to high expression of integrin avb3, thus constituting
an ideal target for ProAgio. We demonstrate here that activated PaSCs and CAPaSCs in PDAC
tumor express high levels of integrin avb3. By targeting integrin avb3, ProAgio effectively
induces apoptosis in the activated PaSCs and CAPaSCs. By simultaneously targeting CAPaSCs
and angiogenic endothelial cells, ProAgio is effective in PDAC treatment. ProAgio depletes
CAPaSCs, resorbs tumor collagen, and abrogates angiogenic vessels in PDAC tumor. ProAgio
treatment leads to the opening of collapsed tumor vessels, which increases tumor permeability,
and facilitates drug delivery. ProAgio treatment also decreases tumor hypoxia. Importantly,
depletion of cancer-associated fibroblasts by ProAgio also reduces various growth factors and
cytokines that are released from CAPaSCs, therefore breaks down the crosstalk between cancerassociated fibroblasts and cancer cells. As an example, we show that ProAgio decreases IGF1 in
the tumor. Decrease in IGF1 consequently decreases cytidine deaminase (Cda) in PDAC tumor,
thereby resulting in much enhanced gemcitabine efficacy in addition to increase in the drug
delivery. We conclude from our study that specifically targeting CAPaSCs by ProAgio, an
integrin avb3 targeting protein, leaving intact the normal or quiescent PaSCs, may provide
important treatment advantages.
3.3. Results
3.3.1. CAPaSCs express high levels of integrin avb3; ProAgio induces CAPaSCs apoptosis.
Integrin avb3 is highly expressed in activated HSCs (Li et al., 2011; Patsenker et al.,
2009; Zhou et al., 2004). To examine whether the integrin is also expressed in PaSCs and
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CAPaSCs, we first probed integrin avb3 levels in activated/inactivated human primary PaSCs.
Integrin avb3 is highly expressed in activated PaSCs. However, inactivated PaSCs expressed little
to no integrin avb3 (Fig. 3.1A). To evaluate the expression of integrin avb3 in PaSCs in PDAC,
we analyzed PDAC patient tumor tissues for the expression of integrin b3. We found that integrin
b3 was highly upregulated in the PDAC tumor tissues. The integrin expression was particularly
high in stromal component of the tumor as compared to the areas of the tumor with histologically
evident adenocarcinoma. Immunostaining also demonstrated that CAPaSCs exhibited higher
integrin b3 expression, while there was almost no integrin b3 staining in non-cancerous tissues
(Fig. 3.1B). Consistently, analyses of survivals of patients with high and low integrin av,
integrin b3, and a-SMA expressions in tumors from the KM-plotter data base (Nagy et al., 2018)
of PDAC patient data set reveal that integrin avb3 and a-SMA levels in tumor closely correlate
with poor patient survival (Fig. 3.2 A & B), indicating important role of integrin avb3 expressing
cells and a-SMA positive cancer-associated fibroblasts in cancer progression and patient
response to treatment. ProAgio induces apoptosis in avb3 expressing cells (Turaga et al., 2016).
We reasoned whether ProAgio could exert its effect on activated PaSCs. Clearly, ProAgio
effectively induced apoptosis in activated human primary PaSCs, while it had minimal effect on
inactivated PaSCs (Fig. 3.1C). Similar to our previous observation (Turaga et al., 2016), ProAgio
induced apoptosis in activated PaSCs by recruiting and activating caspase 8 at the intracellular
domain of the integrin β3 (Fig. 3.1D). Our findings suggest that targeting integrin avb3 by
ProAgio may be a unique approach that is capable of specifically depleting CAPaSCs in PDAC
to facilitate treatment.
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3.3.2. Targeting integrin avb3 by ProAgio inhibits tumor growth and provides survival
benefit.
To test the conjecture, we first examined the effects of ProAgio in mice bearing s.c.
xenograft tumors established by co-implanting activated human PaSCs with human Panc1 cells.
Co-implantation with human PaSCs significantly promoted tumor growth (Fig. 3.3A). ProAgio
inhibited Panc-1 tumor growth without PaSCs co-implant, while the inhibitory effects were
greater when Panc1 was co-implanted with human PaSCs (Fig. 3.1E). Consistently, tumors in
mice of ProAgio treatment group weighed less at the end of the experiment compared to the
vehicle group (Fig. 3.3B). Upon activation, PaSCs attain a myofibroblast-like phenotype,
upregulating a-SMA and integrin avb3 and secrete collagen. As ProAgio effectively induced
apoptosis in activated PaSCs, we reasoned whether ProAgio would exert its effects in vivo on coimplanted PaSCs, and thus on the collagen secreted by the PaSCs. Immunostaining showed that
a-SMA positive cells were reduced with much higher reduction in the PaSCs co-implanted
tumors (Fig. 3.1 F & H), Masson’s trichrome stain demonstrated a decrease in intratumoral
collagen content following ProAgio treatment (Fig. 3.1 G & I). The co-implanted PaSCs
facilitated Panc1 proliferation in tumor as demonstrated by increased Ki67 staining. ProAgio
abrogated the effects of tumor proliferation promoted by PaSCs (Fig. 3.3 C & D). Similar to our
previous observation, ProAgio treatment decreased the tumor vasculature (Fig. 3.3 E & F).
It is noteworthy that the Panc1 s.c. xenograft model does not recapitulate some important
properties of patient PDAC tumors, especially the dense fibrotic stroma and the collapsed
intratumoral vessels. To accurately evaluate the effects of depletion of CAPaSCs by ProAgio on
PDAC, we employed a genetically engineered mouse (GEM) LSL-KrasG12D/+; LSL-Trp53R172H/+;
Pdx-1-Cre (KPC) model (Ref to as GEM-KPC) (Hingorani et al., 2005; Olive et al., 2009) (Fig.
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3.5 A & B). ProAgio single-agent modestly prolonged GEM-KPC mice survival (Fig. 3.4A).
Orthotopic model of PDAC is another model system that well mimics patient PDAC tumor
microenvironment. In addition, due to rapid growth of tumor (Tseng et al., 2010), orthotopic
model is excellent to test the treatment effects of drug on PDAC. Thus, the effectiveness of
ProAgio on PDAC was also tested in mice bearing orthotopic tumors derived from cells isolated
from the tumor of KPC mouse (KPC 961 cell line (Torres et al., 2013), Referred to as OrKPC
thereafter). ProAgio provided significant survival benefit compared to vehicle (Fig. 3.4B).
Analyses of tumor sections from GEM-KPC mice at the end of survival experiment or
immediately after 20 doses of ProAgio treatment revealed a significant reduction in the levels of
fibrosis, as shown by reduced intratumoral collagen contents (Fig. 3.4 C & D), and levels of αSMA positive fibroblasts (Fig. 3.4 E & F). In consistence, mRNA levels of α-SMA and FAP
measured by qRT-PCR were significantly reduced in the tumor lysates of GEM-KPC mice upon
treatment with ProAgio (Fig. 3.4 G), suggesting reduction in CAPaSCs by ProAgio in the tumor.
We previously demonstrated that ProAgio exhibits anti-angiogenic activity due to induction in
apoptosis of angiogenic endothelial cells (Turaga et al., 2016). We, therefore, analyzed the
effects of ProAgio on tumor vessels in the treated GEM-KPC and OrKPC tumors. Unlike
previous observations that depletion of cancer associated fibroblasts by genetically depleting
Sonic hedgehog gene (Shh) promotes tumor angiogenesis (Olive et al., 2009), depletion of
CAPaSCs by ProAgio did not result in increase of vessel density in both GEM-KPC and OrKPC
tumors (Fig. 3.6 A & B, 3.5 C & D). However, ProAgio treatment did exhibit a profound effect
on the tumor vasculature as the majority of intratumoral vessels were noted to be prominently
open and, when measured, the mean vessel luminal area was significantly increased (Fig. 3.6 A
& C; 3.5 C & E). A similar phenomenon was also observed and reported by Olive, K.P. and
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colleagues (Olive et al., 2009). This is presumably due to relief of high intratumoral pressure
because of depleted rigid and dense collagen fibrils.
3.3.3. Depletion of CAPaSCs by ProAgio increases intratumoral drug delivery.
One of the major reasons for chemo-resistance in PDAC is the impediment of drug
delivery due to the presence of dense collagen fibrils that physically block drug distribution
inside the tumor and the completely collapsed intratumoral blood vessels that lead to poor blood
perfusion (Chauhan et al., 2014; DelGiorno et al., 2014). ProAgio reduced tumor collagen
content and opened the intratumoral vessels without an increase in angiogenesis. We, therefore,
believed that ProAgio could eliminate both drug delivery barriers and thereby facilitate the
delivery of chemotherapeutic agents to tumor. To evaluate the effects of ProAgio on drug
delivery, GEM-KPC mice were treated with 8 daily doses of ProAgio, followed by one
intravenous dose of Gemcitabine (Gem). Tumor lysates were subsequently analyzed. ProAgio
treatment resulted in an over 2.5-fold increase in intratumoral Gem delivery (Fig. 3.6D). Similar
increase was also observed in ProAgio treated OrKPC mice upon intravenous administration of
fluorescent probe conjugated molecules (Paclitaxel ~1 kDa and IgG ~160 kDa) after 8 daily
doses of ProAgio (Fig. 3.6 E & F).
Strong increase in drug molecule intratumoral delivery predicts treatments efficacy of
ProAgio in combination with cytotoxic or other anti-cancer drugs. We carried out treatment of
ProAgio in combination with a low dose of Gem (50 mg/kg i.p. twice weekly) in both GEMKPC and OrKPC models. The treatment started at a late stage of cancer development (at the end
of 13 weeks of GEM-KPC, 30 days after orthotopic tumor implantation) (Fig. 3.7 A & B). In the
GEM-KPC model, Gem alone provided a marginal survival benefit, ProAgio alone provided a
modest survival benefit, while ProAgio + Gem dramatically prolonged GEM-KPC mice survival
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(Fig. 3.7C). Similar results were observed in OrKPC model (Fig. 3.7D). An increase in apoptosis
in the stromal area was observed in the ProAgio treated group, while this increase was not
observed in the Gem treated group (Fig. 3.7E). ProAgio alone did not lead to a substantial
increase in apoptosis in areas of histologically evident adenocarcinoma in the tumor. Over threefold increase in apoptosis in adenocarcinoma area was observed in the ProAgio + Gem
combination group compared to the ProAgio alone group (Fig. 3.7F), suggesting that ProAgio
induced apoptosis in stromal fibroblasts, while it had less effects on PDAC cells. In case of the
combination, ProAgio increased the delivery of Gem, which led to cancer cell apoptosis. The
observation was consistent with in vitro tests with PDAC cells and PaSCs (Fig. 3.8A). Also, the
combination of ProAgio and Gem did not have an additive effect on cultured pancreatic cancer
cells (Fig. 3.8B). We measured the collagen contents and levels of a-SMA positive cells in the
tumors of treated mice. Both ProAgio and ProAgio + Gem reduced intratumoral collagen content
and a-SMA positive cells in GEM-KPC (Fig. 3.7 G-J) and OrKPC tumors (Fig. 3.8 D-G). Due to
reduction in intratumoral collagen, ProAgio and ProAgio + Gem treatments resulted in reduced
tumor weight (Fig. 3.8C). We again analyzed delivery of the fluorescence probe conjugated
paclitaxel and IgG to the tumors under ProAgio and ProAgio + Gem treatment. Interestingly, the
ProAgio + Gem combination further dramatically increased the drug molecule delivery (Fig. 3.9
A-C) compared to ProAgio alone. Although we do not yet understand the molecular mechanism
by which ProAgio + Gem further increases tumor permeability, such drastic increase in intratumoral delivery of drug molecule would confer a good treatment benefit.
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3.3.4. Depletion of CAPaSCs by ProAgio enhances Gem efficacy by altering Gem
metabolism.
ProAgio+Gem combined therapy offers a strong survival benefit over Gem or ProAgio
alone. We sought to elucidate molecular mechanism(s) that may contribute to such strongly
enhanced antitumor activity of the combination therapy. We examined the intratumoral levels of
the Gem prodrug 2′,2′-difluorodeoxcytidine (dFdC) and the inactivated and activated metabolites
(2′,2′-difluorodeoxyuridine (dFdU) and gemcitabine triphosphate (dFdCTP)) (Jia and Xie, 2015;
Plunkett et al., 1995; Toschi et al., 2005). We found that the combination treatment led to a
higher dFdC:dFdU ratio and an increased amount of dFdCTP (active drug form) in tumors (Fig.
3.10 A & B). Thus, in addition to increased Gem delivery, ProAgio also increased the active
drug form of Gem (dFdC) and decreased the inactive derivative (dFdU). We therefore asked how
ProAgio prevented the conversion of Gem to its inactive metabolite. It is documented that one
mechanism by which PDAC becomes resistant to Gem is the conversion of Gem to its inactive
derivative dFdU by upregulation of cytidine deaminase (Cda) (Mini et al., 2006). We, therefore,
histologically examined the enzyme Cda in tumors of ProAgio treated mice. Cda is primarily
expressed in the tumor cells. ProAgio and the combination treatment decreased Cda expression
in GEM-KPC (Fig. 3.10 D & E) and OrKPC tumors (Fig. 3.11 A & B). Immunoblot of tumor
extracts confirmed the decrease in Cda levels in GEM-KPC tumors upon ProAgio treatment (Fig.
3.10C). Gem dFdC is a prodrug form of dFdCTP. It needs to be converted to dFdCMP by
an enzyme named deoxycytidine kinase (Dck). Another pyrimidine kinase Tdk is also capable of
increasing dFdCTP from Gem (Mini et al., 2006). Thus, we examined whether increase in
dFdCTP under ProAgio treatment was due to increase in Dck and/or Tdk. Clearly, ProAgio did
not alter Dck or Tdk levels in the tumor (Fig. 3.11 C-G). ProAgio also did not result in change of
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Multidrug resistance-associated protein 1 (ABCC1) (Fig. 3.11G), another important player
involved in cancer cell Gem resistance (Bergman et al., 2003). It is well documented that IGF1
signaling plays an important regulatory role in Cda expression (Ireland et al., 2016; Nakano et
al., 2007). Examination of IGF1R phosphorylation and Cda levels in PDAC patient tissue
samples revealed a close correlation (Fig. 3.12 A & B), suggesting a possible role of IGF1R in
regulating Cda in pancreatic cancer. Addition of IGF1 to the culture of KPC 961 cells
upregulated Cda expression in the cells (Fig. 3.12E), verifying the role of IGF1 in upregulation
of Cda in this PDAC cell line. IGF1 is a common growth hormone mainly produced by liver in a
healthy individual (Laron, 2001). In cancerous tissue, cancer associated fibroblasts are the main
cells that secrete IGF1 (Gascard and Tlsty, 2016; Hirakawa et al., 2016; Werner and Bruchim,
2010). Furthermore, high insulin levels in pancreas may upregulate IGF1 expression and activate
IGF1R signaling in PDAC tumor (Korc, 2007). Since ProAgio depleted CAPaSCs, we
questioned whether ProAgio reduced IGF1 in PDAC, and thus consequentially suppressed Cda
expression. We first examined the secretion of IGF1 by quiescent PaSCs vs activated PaSCs, and
pancreatic cancer cells vs activated PaSCs. Clearly, activated PaSCs secrete higher levels of
IGF1 than quiescent PaSCs (Fig. 3.13A). We also found that activated PaSCs secrete higher
levels of IGF1 than quiescent PaSCs (Fig. 3.13B). Furthermore, xenograft tumors of Panc1 coimplanted with PaSCs secrete higher levels of IGF1 than the tumors without co-implantation
(Fig. 3.13C). We then examined the IGF1 levels in tumors of ProAgio and the combination
treated GEM-KPC mice. Evidently, ProAgio and the combination treatment led to a reduced
IGF1 in GEM-KPC tumors (Fig. 3.10 F & G). In addition, the effect of ProAgio on IGF1
secretion was significantly higher in co-implanted tumors than without co-implantation in Panc1
xenograft mouse model (Fig. 3.13C). ProAgio also led to a reduction in IGF1R levels and IGF1R
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phosphorylation in the tumors (Fig. 3.12 C & D). Consistently, in the presence of IGF1, KPC
961 cells were less susceptible to apoptosis induction by Gem (Fig. 3.12F), and knockdown of
Cda made the KPC 961 cells more sensitive to apoptosis induction by Gem (Fig. 3.12 G & H).
3.3.5. Depletion of CAPaSCs by ProAgio decreases hypoxia in PDAC tumor.
ProAgio and ProAgio + Gem offered a very important advantage in PDAC treatment, as
a substantial decrease in metastasis was observed in GEM-KPC mice (Fig. 3.14 A-C). Reduction
in metastasis potentially has a critical impact on PDAC patient survival. Since ProAgio did not
affect the pancreatic cancer cells, we wondered how ProAgio treatment inhibited PDAC
metastasis. ProAgio reduced dense collagen bundles in the tumor, which disrupted the
superhighway for PDAC cancer cell migration, and thus metastasis. In addition, ProAgio opened
the collapsed blood vessels in PDAC tumor (see Fig. 3.6 A-C, 3.5 C-E), which would decrease
hypoxia in tumor. Indeed, ProAgio decreased Hif1a levels in the treated tumors (Fig. 3.14 D &
E). Hypoxia is known to upregulate and activate IGF1 receptor (IGF1R) (Joung et al., 2007).
ProAgio decreased IGF1 due to depletion of CAPaSCs in the tumor. ProAgio also decreased
hypoxia. We, therefore, believed that the effect of ProAgio on IGF1R signaling in the tumor, in
addition to reducing cancer cell apoptosis resistance (Villanueva et al., 2010), might also play a
role in PDAC metastasis. Cell migration assay demonstrated that IGF1 stimulated cell migration
under hypoxia condition, while IGF1 had limited effects on cell migration under normoxic
conditions. The effect of IGF1 on cell migration was dose-dependent, as IGF1 had no significant
effect on migration at a concentration as low as 1 ng/ml (Fig. 3.15 A-D).
3.3.6. Effects of specific targeting of CAPaSCs by ProAgio.
Despite the known pro-tumorigenic properties of cancer associated fibrotic stroma, recent
studies suggest that depletion of fibrotic stroma has the potential to accelerate the disease and
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lead to cancer progression (Leake, 2014; Ozdemir et al., 2014; Rhim et al., 2014). To assess how
cancer associated fibroblast depletion by ProAgio affects the differentiation and aggressiveness
of PDAC tumors, we analyzed pancreatic tumor tissue from GEM-KPC mice at the end of
survival experiment. In concert with longer survival, tumor tissues from ProAgio treated GEMKPC mice were more differentiated and had a decreased pathologic disease progression when
compared with that of vehicle-treated mice (Fig. 3.14 F & G). We analyzed the tumor
proliferation marker, Ki67 in vehicle and ProAgio treated mice and found that ProAgio treated
mice had decreased cell proliferation (Fig. 3.15 E & F). ProAgio treatment also significantly
decreased tumor metastases to the liver (Fig. 3.14 A-C). We asked why targeting fibrotic stroma
by ProAgio did not result in more poorly differentiated and aggressive tumor as observed by
other strategies that target fibrotic stroma (Leake, 2014; Ozdemir et al., 2014; Rhim et al., 2014).
The important difference is that ProAgio induces apoptosis via targeting integrin avb3. In PDAC,
only CAPaSCs (activated PaSCs) are integrin avb3 positive, while inactivated PaSCs are avb3
negative. Thus, we believe that ProAgio only depletes the CAPaSCs, leaving intact the normal or
quiescent PaSCs. To verify this unique targeting property, we examined the status and levels of
PaSCs by retinol staining (retinol stains inactivated PaSCs) in the treated GEM-KPC tumors.
Clearly, there was almost no inactivated PaSCs (retinol positive) in vehicle treated tumors.
However, the inactivated PaSCs levels were higher in tumors of ProAgio + Gem treated animals
(Fig. 3.16 A & B). Furthermore, we stained the sections of treated tumors with adipophilin, a
marker for quiescent PaSCs (Nielsen et al., 2017), and cleaved PARP, an apoptosis marker.
Consistent with retinol staining, there was lesser adipophilin stain in the tumor sections of
vehicle treated animals. ProAgio led to around 2-fold, and ProAgio + Gem led to over 6-fold,
increase in adipophilin stain compared to those of vehicle-treated group (Fig. 3.16 C & D). There
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was almost no adipophilin and cleaved PARP co-stain in any case. Thus, both in vitro and in vivo
studies suggest that ProAgio only induces CAPaSCs apoptosis. We do not fully understand the
mechanism by which ProAgio and ProAgio + Gem lead to increase in inactivated/quiescent
PaSCs in tumor. It is possible that the treatments, especially the combination, eliminate some
cancer cells. Thus, the driving force (cancer cells) for PaSCs activation or cancer association is
reduced. The explanation is consistent with the fact that the increase in inactivated PaSCs in the
ProAgio + Gem group is higher than ProAgio alone group.
3.4. Discussion
We demonstrate here that targeting integrin avb3 by ProAgio specifically induces
apoptosis in CAPaSCs, which enables reduction of stromal collagen in the tumor. Reduction of
collagen consequently opened the collapsed blood vessels in the tumor. Removal of physical
block by depletion of dense collagen and opening of collapsed vessels resulted in increased
delivery of drug molecules into the tumor. Induction of apoptosis of CAPaSCs by ProAgio also
remarkably reduced IGF1, and possible other growth factors and cytokines, that is mainly
produced by cancer associated fibroblasts in cancerous tissue, which consequently resulted in
decrease and inactivation of IGF1R in cancer cells. Decrease and inactivation of IGF1R
suppressed Cda expression, which stabilized Gem in cancer cells that is equivalent to increase in
active Gem concentration in cancer cells. Moreover, opening of the collapsed blood vessels
reduced hypoxia. Reduction in hypoxia in conjunction with decreased IGF1 and inactivation of
IGF1R decreased cancer cell migration, thereby decreasing cancer metastasis. Thus, it is clear
that ProAgio enacts multiple effects on PDAC by specifically acting on CAPaSCs and
angiogenic endothelial cells (Fig. 3.16E and 3.17).
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It is generally believed that dense fibrotic stroma is a major obstacle for successful treatment of
PDAC. CAFs support cancer cell growth, survival, resistance to apoptosis, and metastasis. Thus,
it is speculated that depletion of fibrotic stroma would be therapeutically advantageous in PDAC.
Indeed, recent success in clinical studies of the stromal modifying agent PEGPH20 (Hingorani et
al., 2016), a recombinant enzyme, which degrades stromal hyaluronic acid (HA), a critical matrix
component of cancer stroma, has demonstrated that addition of this agent to standard
chemotherapy for PDAC patients with dense tumor stroma can improve patient outcome in early
clinical trials, although the improvement is far from satisfactory. However, recent studies of
Sonic hedgehog (Shh) and a-SMA gene deletion in PDAC GEM models suggest that some
fibrotic stroma in PDAC may constitute a barrier that prevents metastatic spread of the tumor
(Leake, 2014; Ozdemir et al., 2014; Rhim et al., 2014). Depletion of fibrotic stroma results in
increased metastasis and shorter survival in pre-clinical models and some early phase clinical
studies (Catenacci et al., 2015; Ozdemir et al., 2014; Rhim et al., 2014). These studies aroused a
very important controversy, “whether to target or not-target fibrotic stroma in cancer therapies,
particularly in treatment of PDAC?” (Carr and Fernandez-Zapico, 2016). It should be noted that
Shh or a-SMA gene deletion leads to global deletion of fibroblasts resulting in downstream
effects in excess of what would be expected from a tumor- targeted therapeutic. Pharmacological
inhibition of Shh signaling may also impose effects far beyond fibroblasts. Importantly, unlike
globally targeting fibroblasts, specifically acting on cancer-associated fibroblasts by ProAgio
may confer an advantage in cancer therapy. Indeed, ProAgio treatment did not lead to more
aggressive cancer with increased metastasis and did not increase angiogenesis in the tumor as
observed with Shh or a-SMA gene deletion or Shh inhibition. A recent large-scale patient tumor
study demonstrates that percentage of stromal cell determine the phenotypic nature of PDAC,
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increase in stromal cells leads to increase in both high proliferative and high migratory
phenotype. Effectiveness of ProAgio in PDAC treatment provides a good explanation for the
observation, as ProAgio specifically depletes CAPaSCs leading to decrease in PDAC cancer cell
proliferation and migration (Ligorio et al., 2019).
One main advantage of targeting integrin avb3 by ProAgio is decrease in PDAC
metastasis upon ProAgio treatment. Our experiments demonstrate that ProAgio affects metastasis
of tumor cells by following mechanisms: (1) ProAgio depletes CAPaSCs that encourage tumor
cell metastasis. (2) ProAgio decreases collagen that provides superhighway for tumor cell
migration – metastasis. (3) ProAgio opens collapsed PDAC blood vessels, which decreases
tumor hypoxia. Decrease in tumor hypoxia reduces tumor cell metastasis. (4) IGF1 promotes the
migration of KPC cells, particularly under hypoxia condition. ProAgio reduces IGF1 levels in
the tumor by depleting CAPaSCs and therefore reduces metastasis.
Enzymatic inactivation of gemcitabine is the main reason leading to cancer resistance to
this anti-cancer drug. Intriguingly, ProAgio decreases IGF1 by depleting CAPaSCs, which
consequently suppresses Cda expression in cancer cells. It is recently shown that CAPaSCs also
traps Gem in the cancer stroma (Hessmann et al., 2018). Depletion of CAPaSCs by ProAgio
would release the trapped Gem and increase available Gem to cancer cells. As Gem has been
approved for the treatment of multiple different cancer types (Toschi et al., 2005), it will be
interesting to test whether the same mechanism will be true to the Gem treatment resistance in
other cancers. Since ProAgio depletes CAPaSCs, the major source cells that secrete IGF1 in the
tumor, it is anticipated that it will be more effective than the IGF1R blockade antibody (Qu et al.,
2017) for PDAC and other cancer treatment in this regard.
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Figure 3.1. CAPaSCs express integrin avb3 and ProAgio induces CAPaSCs apoptosis.
(A) Levels of αV (IB: Integrin αV) and β3 (IB: Integrin β3) integrin in activated and inactivated
human primary PaSCs were analyzed by immunoblot. PaSCs were activated by culturing for 48
h in the presence of 5 ng/mL TGF-β. Inactivated PaSCs are the cells that are in day one culture
without TGF-b. (B) Representative images (left), and quantification of integrin β3 positive cells
in stromal and adenocarcinoma (cancer cells) area of the IHC staining of integrin β3 of PDAC
patient tumor tissue samples compared with normal adjacent pancreas (n=69). (C) Apoptosis of
activated (act. PaSCs, red bar) or inactivated (PaSCs, grey bar) PaSCs after treatment with
indicated concentrations of ProAgio was measured by an apoptosis kit. Cell apoptosis is
presented as percent apoptosis by defining the apoptosis of untreated cells as 0%. (D) Coimmunoprecipitation of caspase 8 with integrin b3 (IP:integrin b3) in extracts of activated human
primary PaSCs that were treated with 5 µm ProAgio for 6 h was analyzed by immunoblot
(IB:caspase 8). Immunoblot of integrin b3 (IB:integrin b3) indicates amount of b3 precipitated
down in the co-IP. Immunoblot of ProAgio (IB:ProAgio) indicates co-precipitation of ProAgio
with integrin b3. (E) Mean tumor volume of s.c. xenograft of Panc1 with (solid lines) or without
(dot lines) co-implantation of PaSCs upon treatment with vehicle (black lines) or 10 mg/kg
ProAgio (12 daily doses, red lines) (n=6). (F, H) Representative images of IF staining of α-SMA
(red) (F) and Masson’s trichrome (blue) staining for collagen (H). (G, I) Quantitative analyses of
IF staining of α-SMA (G) and Masson’s trichrome staining in tumor sections of Panc1 xenograft
(with or without PaSC co-implantation) mice treated with vehicle or 10 mg/kg ProAgio. Error
bars in C and E represent mean ± S.E.M.
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Figure 3.2. Expression of integrin aV, b3, and a-SMA correlates with PDAC patient
survival.
(A, B) Overall survival (A) and Relapse free survival (B) of PDAC patients in the groups of high
and low expression of integrin av (ITGAV, left), integrin b3 (ITGB3, middle), and a-SMA
(ACTA2, right) were plotted from KM-plotter data base. ITGAV, ITGB3, and ACTA2
expression high (red line) denotes that the mRNA levels of the gene in the tumor of the patient
are higher than the median value of mRNA of the gene in the entire patient group, and
expression low (black line) denotes that the mRNA levels of the gene in the tumor of the patient
are lower than the median value of mRNA of the gene in the entire patient group. Number at
bottom of each panel indicates patient number. The hazard ratio (HR) and log-rank P-value are
indicated in each panel.
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Figure 3.3. ProAgio inhibits tumor growth and angiogenesis of Panc1 s.c. xenograft.
(A) Mean tumor volume of s.c. xenograft of Panc1 with (gray line, Panc1 + CAPaSCs) or
without (black line, Panc1) co-implantation of PaSCs. (B) Mean tumor weight of Panc1 s.c.
xenograft with or without co-implantation of PaSCs upon treatment with vehicle or ProAgio (12
daily doses) (n=6). (C, E) Representative images of immunofluorescence staining of Ki67 (C,
red) and CD31 (E, red), and (D, F) quantitative analyses of IF staining of Ki67 (D) and
quantification of mean vessel density, branch points, and vessel length based on CD31 staining
(F) in tumor sections of Panc1 xenograft (with or without PaSCs co-implantation) mice treated
with vehicle or ProAgio. Quantification of Ki67 staining is presented as % of Ki67+ nuclei per
view field (with PaSCs co-implantation, upper three panels, or without PaSCs co-implantation,
bottom three panels). Nuclei were stained with DAPI (blue) in (C) and (E). Error bars in A and B
represent mean ± S.E.M.
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Figure 3.4. ProAgio depletes CAPaSCs by targeting integrin αVβ3 and resorbs tumor
collagen.
(A, B) Kaplan-Meier survival analysis of GEM-KPC (Median survival (days): Vehicle=20;
ProAgio=51) (A), and OrKPC (B) mice treated with vehicle or 10 mg/kg ProAgio (Median
survival (days): Vehicle=31; ProAgio=39) (10 daily doses + 10 alternate day doses). Treatment
was started after 13 weeks of age of GEM-KPC mice in A, or 30 days after tumor inoculation in
B. The numbers in the parentheses are the group size. (C) Representative images of Masson’s
trichrome (Trichrome, blue) and Sirius red (Sirius red, red) staining of tumor sections from
GEM-KPC mice treated with vehicle or 10 mg/kg ProAgio at different time points (Rx 20, at end
of 20 doses, End stage, end of survival experiments). (D) Quantitative analyses of Sirius red
staining (presented as Sirius red+ area %) for vehicle or 10 mg/kg ProAgio treatment groups. A
higher staining of Sirius red is observed in vehicle treated tumors on day 80 (Rx 20 doses) than
ProAgio treated tumors on day 110 (end stage) in GEM-KPC mice (p<0.001; n=7-9). (E, F)
Representative images of IHC staining of α-SMA (E) and quantification of αSMA+ area % (F) in
tumor sections of vehicle or ProAgio treated GEM-KPC mice. (G) mRNA levels of aSMA (left
panel) and FAP (right panel) in the tumor tissue lysates of GEM-KPC mice treated with vehicle
or ProAgio (n=4) were analyzed by qRT-PCR. The mRNA levels in the tumor extracts were
normalized to mRNA level of b-actin. Error bars in G represent mean ± S.E.M.
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Figure 3.5. ProAgio opens tumor vessels without increase in angiogenesis in OrKPC
model.
(A) Endogenous alleles of KrasG12D and Trp53R172H are conditionally activated in the
pancreata of LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (triple mutant) mice. (B)
Specific PCR analysis of genomic DNA of generated GEM-KPC mice. (C) Representative
images of IHC staining of CD31 in tumor sections of vehicle or ProAgio treated OrKPC mice.
Arrows indicate the tumor vessels. (D, E) Quantitative analyses of CD31 vessel stain density (D)
and vessel lumen area (E) in tumor sections of vehicle or ProAgio treated OrKPC mice.
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Figure 3.6. ProAgio opens compressed tumor vessels and increases drug delivery.
(A) Representative images of IHC staining of CD31 of tumor sections from GEM-KPC mice
treated with vehicle or 10 mg/kg ProAgio. Arrows indicate example blood vessels. (B, C)
Quantifications of CD31 positive vessels density (B) and mean vessel lumen area (C) of in tumor
sections of vehicle or ProAgio treated GEM-KPC mice. (D) Intratumoral Gem levels measured
in extracts of tumors of vehicle and 10 mg/kg ProAgio (after 8 daily doses) treated GEM-KPC
mice 2 hours after i.v. dose of Gem (n=6). Gem levels were presented as ng of Gem per mg
tumor tissue. (E, F) Representative fluorescence images of Alexa-fluor 555 conjugated IgG,
~160 kDa (red) and Alexa-fluor 488 conjugated paclitaxel, ~1 kDa (green; left panel, 10X; right
panel, 30X) (F) and quantification of fluorescence signals from paclitaxel and IgG (E) in tumor
sections of vehicle or ProAgio treated OrKPC mice using Image J. Quantification is presented as
fold change of “Fluorescence integrated density (fold)” by comparing to the mean value of the
vehicle treatment group as 1. Image analysis was performed by thresholding for positive staining
and normalizing to total tissue area. Fluorescence probe conjugated IgG and paclitaxel were i.v.
injected after 8 daily doses of 10 mg/kg ProAgio treatment. Tumors were harvested and
processed 40 minutes after the i.v. injection (analyses: n=5 mice per treatment group, n=7-8
images per mouse). Nuclei were stained with DAPI (blue), and yellow indicates colocalization.
Error bars in D, and E represent mean ± S.E.M.
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Figure 3.7. Depletion of CAPaSCs by ProAgio enhances effectiveness of gemcitabine.
(A, B) 10 mg/kg ProAgio and 50 mg/kg Gem treatment regimen of GEM-KPC (A) and OrKPC
(B) mice. (C, D) Kaplan-Meier survival analyses of GEM-KPC (Median survival (days):
Vehicle=12; Gem=34.5; ProAgio=49; ProAgio+Gem=155)) (C), and OrKPC (Median survival
(days): Vehicle=31; Gem=28; ProAgio=39; ProAgio+Gem=58)) (D) mice upon indicated
treatments. The numbers in the parentheses are the group size. (E, F) Quantification of IHC
staining of cleaved caspase 3 in stromal area (Stromal CC3+ cells/HPF, cleaved caspase 3
positive cells per view field) (E) and adenocarcinoma area (Epithelial CC3+ cells/HPF) (F) in
tumor sections from GEM-KPC mice upon indicated treatment. (G, I) Representative images of
Sirius red staining (G) and IHC staining of a-SMA (I) in tumor sections of GEM-KPC mice
treated with indicated agents. (H, J) Quantitative analyses of Sirius red stain area (Sirius red+
area %) (H), and IHC a-SMA stain area (a-SMA+ area %) (J) in sections of tumors from GEMKPC mice treated by indicated agents.
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Figure 3.8. ProAgio depletes CAPaSCs and resorbs collagen in tumors of OrKPC model.
(A) Cell viability of indicated cells upon treatment with ProAgio (5 µM) and Gem (1mM) was
analyzed by MTT assay. (B) Cell viability of KPC 961 cells treated with ProAgio, Gem, and
ProAgio+Gem combination was analyzed by MTT assay. In (A) and (B), the viability of vehicle
treated cells (Control) is define as 100%. (C) Mean tumor weight of OrKPC mice (n=7) treated
with indicated agents at the end of the treatment (mice were sacrificed at end of the treatment
and tumors were resected and weighed). (D, E) Representative images of Sirius red staining of
collagen (D) and quantitative analysis of collagen positive area (E) in tumor sections of OrKPC
mice treated with indicated agents. (F, G) Representative images of IHC staining of α-SMA (F)
and quantitative analysis of positive α-SMA stain area (G, α-SMA (fold), fold change by
comparing to the mean value of the vehicle treated group as 1) in tumor sections of OrKPC mice
treated with indicated agents. Error bars in A, B, C, G represent mean ± S.E.M.
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Figure 3.9. ProAgio increases drug delivery. ProAgio + Gem further increases tumor
permeability.
(A, B, C) Representative fluorescence images of Alexa-fluor 555 conjugated IgG, ~160 kDa
(red) and Alexa-fluor 488 conjugated paclitaxel, ~1 kDa (green) (A) and quantification of
fluorescence signals (B, C) in tumor sections of OrKPC mice treated with indicated agents.
Quantifications are presented as fold change of “Fluorescence integrated density (fold)” by
comparing to the mean value of the vehicle treatment group as 1. Fluorescence probe conjugated
IgG and paclitaxel were i.v. injected after 8 daily doses of ProAgio (ProAgio), 3 doses of Gem
(Gem), or 8 doses of ProAgio + 3 doses of Gem (ProAgio + Gem) treatments. Tumors were
harvested and processed 40 minutes after the i.v. injection of IgG and paclitaxel (analyses: n=5
mice per treatment group, n=7-8 images per mouse). Nuclei were stained with DAPI (blue), and
yellow indicates colocalization. Error bars in represent mean ± S.E.M.
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Figure 3.10. Depletion of CAPaSCs by ProAgio alters Gem metabolism and reduces cancer
cells resistance to Gem.
(A, B) Intratumoral levels of dFdCTP (A) and dFdC:dFdU ratio (B) in tumor tissues of GEMKPC mice treated with the indicated agents measured by HPLC/MS. The concentrations of
dFdCTP, dFdC, and dFdU in tumor tissues were analyzed 2 h after the last dose of Gem (n=6).
(C) The levels of Cda (IB:Cda) in tumor extracts of vehicle or ProAgio treated GEM-KPC mice
were analyzed by immunoblot. Immunoblot of GAPDH (IB:GAPDH) is a loading control. (D, F)
Representative images of IHC staining of Cda (D) and IGF1 (F) in tumor sections of GEM-KPC
mice treated with indicated agents. (E, G) Quantitative analyses of IHC stains of Cda (Cda+ area
(fold), fold changes by comparing to the mean value of the ProAgio treatment group as 1) (E)
and IGF1 (IGF1+ area (fold), fold changes by comparing to the mean value of the ProAgio
treatment group as 1) (G) in tumor sections of GEM-KPC mice treated with indicated agents.
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Figure 3.11. ProAgio reduces cancer cell Gem resistance by reducing Cda in cancer cells.
(A, B) Representative images of IHC staining of Cda (A) and quantitative analyses of Cda
positive stain area (B) in tumor sections of OrKPC mice treated with indicated agents.
Quantitation of Cda staining is presented as Cda+ area (fold), fold change by comparing to the
mean value of the ProAgio treatment group as 1. (C, E) Representative images of IHC staining
of Dck (C) and Tdk (E), and (D, F) quantitative analyses of Dck positive stain area (D) and Tdk
positive stain area (F) in tumor sections of ProAgio treated GEM-KPC mice. (G) The mRNA
levels of Cda, Dck, Tdk, and ABCC1 genes in the tumors extracts of indicated treatment cohorts
(n = 6) were analyzed by qRT-PCR. The mRNA levels in the tumor extracts were normalized to
mRNA level of b-actin.
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Figure 3.12. ProAgio decreases Cda in cancer cells by decreasing IGF1 signaling.
(A) Representative images of IHC staining of pIGF1R (left panel; 4X, and 10X enlarged images)
and Cda (right panel, 4X, and 10X enlarged images) in tumor sections of PDAC patients (n=40).
(B) Correlation of pIGF1R protein expression with Cda protein expression. Regression analysis
for expression of pIGF1R (IHC) versus Cda (IHC) in tumor sections of PDAC patients (n=12)
(C, D) Representative images of IHC staining of pIGF1R (C) and quantitative analyses of
pIGF1R positive staining (D, pIGFR+ cells/HPF, pIGFR positive cells per view field) in tumor
sections of vehicle or ProAgio treated OrKPC mice. (E) The levels of Cda (IB:Cda) in KPC 961
cells that were treated with IGF-1 (0 ng/ml and 10 ng/ml) were analyzed by immunoblot.
Immunoblot of b-actin (IB: b-actin) is a loading control. (F) Apoptosis of KPC 961 cells after
treatment with Gem (1 µM, grey bar, or 1 mM, black bar) in the presence (+IGF1) or absence (IGF1) of 10 ng/ml IGF1 was measured by an apoptosis kit. Cell apoptosis is presented as percent
apoptosis by defining the apoptosis of untreated cells as 0%. (G) Cell viability of KPC 961 cells
with (Cda siRNA) or without (ctrl siRNA) knockdown of Cda treated with indicated
concentrations of Gem was measured by MTT assay. (H) The levels of Cda (IB:Cda) in KPC
961 cells after Cda knockdown (Cda siRNA) compared with control (ctrl siRNA) were analyzed
by immunoblot. Immunoblot of b-actin (IB: b-actin) is a loading control. Error bars in F and G
represent mean ± S.E.M.
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Figure 3.13. ProAgio decreases IGF1 secreted by activated PaSCs.
(A) Levels of IGF1 secreted by inactivated PaSCs (without TGF-b, grey bar) or activated PaSCs
(with 5ng/ml TGF-b, black bar). (B) Levels of IGF1 secreted by indicated cells. (C) Levels of
IGF1 in the serum of s.c. xenograft mouse model of Panc1 or Panc1 co-implanted with activated
human PaSCs treated with vehicle or ProAgio (n=5). IGF1 levels were analyzed by ELISA.
Error bars represent mean ± S.E.M.
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Figure 3.14. Depletion of CAPaSCs by ProAgio decreases metastasis and poorly
differentiated tumors.
(A) Representative images of H&E staining of liver tissue sections of GEM-KPC mice treated
with indicated agents. Liver metastasis lesions were confirmed under microscope and marked by
a black dotted circle in the images. (B, C) Percentage of GEM-KPC mice treated with vehicle or
10 mg/kg ProAgio that exhibit different number of liver metastatic nodules (>5: more than 5
nodules, 1-5: between 1 to 5 nodules, 0: no metastatic nodule) (B). Number of metastatic nodules
in the liver of GEM-KPC mice treated with vehicle or ProAgio (C). Metastatic nodules were
assessed by gross inspection of liver of each treated mouse by naked eye or under microscope.
(D, E) Representative images of IHC staining of Hif-1α (D), and quantitative analyses of Hif-1α
stains (E, Hif-1a+ area (fold), fold change by comparing to the mean value of the ProAgio
treatment group as 1) in tumor sections of GEM-KPC mice treated with vehicle or ProAgio. (F,
G) Representative images of H&E staining (F) and pathological assessment (G) of the tumors of
GEM-KPC mice treated with vehicle or ProAgio. Error bars in C and G represent mean ± S.E.M.
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Figure 3.15. IGF1 signaling increases cell migration under hypoxia condition.
(A, B) In vitro scratch wound healing assay of KPC961 cells cultured under hypoxia and
untreated (left) or treated with IGF1 (right) compared with those cultured under normoxia as a
control (A) and quantitative analyses of the migrating cells in the scratched areas (B). (C, D) The
scratch wound healing assay of KPC 961 cells cultured under hypoxia and treated with indicated
concentrations of IGF1 for the indicated amounts of time compared with those cultured under
normoxia as a control (C), and Quantitative analyses of the migrating cells in the scratched areas
after IGF1 treatment (D). (E, F) Representative images of IHC staining of Ki67 (E), and
quantitative analyses of Ki67 positive stain area (F) in tumor sections of vehicle or ProAgio
treated GEM-KPC mice. Error bars in B and D represent mean ± S.E.M.
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Figure 3.16. Targeting integrin avb3 specifically depletes CAPaSCs in tumor.
(A, B) Representative images of oil red staining (A) and quantitative analysis of oil red staining
(B, Oil red+ area (fold), fold change by comparing to the mean value of the vehicle treated group
as 1) in tumor sections of GEM-KPC mice treated with indicated agents (n=4). (C, D)
Representative IF images of co-staining of adipophilin (green) and cleaved PARP (red) (C) and
quantification of adipophilin staining (D, adipophilin+ area (fold), fold change by comparing to
the mean value of the vehicle treatment group as 1) in tumor sections of GEM-KPC treated with
indicated agents using Image J (n=5). Image analysis was performed by thresholding for positive
staining and normalizing to total tissue area. Nuclei were stained with DAPI (blue). (E)
Schematic illustration of the mechanism depicting the action of ProAgio in PDAC tumor. Error
bars in B and D represent mean ± S.E.M.
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Figure 3.17. Graphical abstract depicting the action of ProAgio in PDAC.
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3.5. Materials and methods
3.5.1. Cell lines
The mouse pancreatic cancer cell line KPC961 was a kind gift from Dr. Surinder K.
Batra (University of Nebraska Medical Center). These cells were isolated from the tumors
arising in KPC mice. Panc-89 cells were kindly provided by Dr. Ritu Aneja (GSU). Human
pancreatic cancer cell lines, including Panc-1, Miapaca-2, Capan-1 were acquired from ATCC,
PaSCs were purchased from ScienCell Research Laboratories and the cells were cultured
according to the manufacturer’s instructions. PaSCs were activated by adding TGF-β (5ng/mL)
for 48 h.
3.5.2. Tumor implantation and monitoring
Xenograft mouse model: 1x106 Panc-1 cells, 1x106 PaSC and 1:1 ratio of Panc-1 cells +
PaSCs were suspended in Hanks Balanced Salt Solution (HBSS) and injected subcutaneously in
nude mice. Orthotopic mouse model: C57BL/6J mice were first anesthetized with a single
intraperitoneal (i.p.) injection of ketamine (100 mg/kg) and then the pancreas was exposed
through an abdominal incision. A single cell suspension of 0.5x105 KPC cells suspended in 50
µL of HBSS was injected directly into the pancreas using a 30 G needle (BD). Leakage occurred
in less than 5% of mice, and only mice without leakage during injection were included in the
experiments. After inoculation of KPC cells, the pancreas was carefully returned to the
peritoneal cavity and the abdomen was closed with 4-0 Vicryl suture (ETHD7796) as described
by Torres et al., 2013. After tumor implantation, all mice were monitored daily for the disease
progression by abdominal palpation and for overall signs of morbidity such as immobility,
hunched posture, and ruffled fur. Moribund mice were euthanized by CO2 inhalation. For
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survival studies, mice were followed until death or euthanized by a blinded observer when signs
of morbidity were evident.
3.5.3. GEM KPC mice
GEM KPC mice harbor heterozygous conditional mutant alleles of Kras and Trp53 as
well as a pancreatic-specific Cre recombinase (Pdx1-Cre). We obtained KrasLSL-G12D/+,
Trp53LSL-R172H, and Pdx1-Cre mice with C57BL/6J background from The Jackson
Laboratory. The mice were generated by breeding as described by Hingorani et. al and the
offsprings were genotyped as per the protocol provided by the vendor. The primers and the
genotyping conditions have been described in Table 3.4 and Table 3.5 respectively.
3.5.4. Drug preparation
Gemcitabine hydrochloride (Gem) was purchased from EMD Millipore Corp. (Billerica,
MA) and suspended in sterile normal saline at 5mg/mL. GMP grade ProAgio-30 kDa PEG
provided by Amoytop Biotech was prepared in PBS at a stock concentration of 7 mg/ml. Drugs
were filter sterilized through a 0.22 μM Millex GV syringe filter before usage. The working
solution was stored at 4ºC for up to a maximum of one week.
3.5.5. Drug study treatment groups
Mice were treated with either PBS (vehicle) or 50 mg/kg of Gem dissolved in saline, or
ProAgio 10mg/kg, or ProAgio 10 mg/kg + Gem 50 mg/kg. Survival study structure enrollment
of GEM KPC mice was completely random. Endpoint criteria included the development of
severe cachexia, abdominal ascites, and significant weight loss exceeding 20% of initial weight,
or physical inactivity. Mice developing vaginal papillomas and visible external tumors on ears
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and eyes were excluded from the study. GEM KPC and orthotopic KPC (OrKPC) mice were
enrolled into treatment groups randomly by an investigator blinded to their current tumor burden.
3.5.6. Mean vascular density (MVD)
5 μM paraffin tissue sections from the xenograft experiment were probed with anti-CD31
antibody and counterstained with hematoxylin. Mean vascular density was determined as the
number of CD31 positive blood vessels per 40X field. 4-7 fields were quantified per tumor
(Turaga et al., 2016). For OrKPC and KPC GEM tumor samples, lumen area of CD31 positive
stained vessels was measured using Adobe Photoshop CS6.
3.5.7. Histology and Histopathology
5 μm sections of paraffin-embedded pancreatic tissues were analyzed for H&E (Thermo
Fisher Scientific), Picro-Sirius red (IHC world) and Masson’s trichrome (IHC world) according
to the manufacturer’s instructions. Liver metastasis was analyzed by manually quantifying H&E
stained liver sections at 20X HPF. For histopathological scoring, an experienced pathologist who
was blind to the tumor status of the GEM KPC mice scored H&E staining independently for each
histological hallmark on the scale of 0 to 3. The predominant histological phenotype gave the
pathological score of the whole tumor as follows: 1, well differentiated; 2, moderately
differentiated; and 3, poorly differentiated. Necrosis in the tumor was also analyzed.
3.5.8. Immunohistochemistry
5 μm sections of paraffin-embedded pancreatic tissues were sectioned. Antigen retrieval
was performed in 10mM citrate buffer (Sigma-Aldrich #C999), pH 6.0 by boiling at 90°C for 45
min. Endogenous peroxidases were quenched using peroxidase block. Remaining steps were
carried out with protein UV block and antibodies were diluted in antibody diluent. Primary
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antibodies were counter stained with either Rabbit HRP-polymer or Mouse HRP-Polymer and
DAB Chromogen system was used to visualize the protein followed by counterstaining with
hematoxylin. Note: Antigen retrieval for CD31 was performed in Tris Buffer, pH 9.0. Detailed
list of antibodies is mentioned in Table 3.2.
Along with cells undergoing apoptosis, tumors with apparent necrosis also typically stain
for cleaved caspase 3 (CC3). Staining associated with necrosis was not considered for CC3
quantification and cells immediately adjacent to necrosis were also not considered. Similarly,
cells undergoing anoikis that are positive for CC3, typically observed in the lumens of ductal
structures formed by well-differentiated neoplastic pancreatic cancer cells were also excluded
from analysis.
3.5.9. Immunofluorescence
Freshly sectioned frozen tissues were fixed in pre-chilled acetone. The samples were
permeabilized with 0.05% Triton X-100 PBS, blocked in 10% goat serum and incubated with
primary antibody for 1 h at room temperature. Alexa Fluor conjugated secondary antibody was
incubated for 1 h at room temperature. DAPI was then used for counterstaining the nuclei and
images were obtained by Keyence microscope. Detailed list of primary and secondary antibodies
is mentioned in Table 3.2.
3.5.10. Vascular labeling and drug diffusion to assess the functional vasculature
Alexa Fluor 595 conjugated goat IgG (Thermo Fisher Scientific # A-11032) and Alexa
Fluor 488 conjugated paclitaxel (Thermo Fisher Scientific #P22310) were resuspended,
premixed and diluted in 200 μL sterile PBS. Prior to use, the mixture was centrifuged at 14,000 g
on a microfuge for 10 minutes to remove any particulate matter. Mice were anaesthetized by
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inhalation of isofluorane gas and 100 μl (0.4 mg total) of the conjugated mixture was
administered via tail vein. Consequently, mice were euthanized after 45 min. The perfusion
analysis was observed under fluorescence microscope with DAPI nuclear stain.
3.5.11. Determination of dFdCTP concentration by HPLC-MS
Mice were injected i.p. with 100 mg/kg gemcitabine and sacrificed after 4 h. Tissues
were rapidly dissected and snap frozen in liquid nitrogen. Specimens were ground under liquid
nitrogen with a mortar and pestle. The powdered contents were suspended in 0.4N perchloric
acid and sonicated in an ice bath. Solids were removed by centrifugation, the pellet was washed
with perchloric acid, and the supernatants were combined. Following neutralization with KOH
and removal of KClO4 by centrifugation, a portion of the supernatant was analyzed by highpressure liquid chromatography. Briefly, chromatographic analysis was performed on an Agilent
series 1290 UHPLC system equipped with a binary pump, a degasser, a thermostatic column
compartment (Agilent Technologies, Palo Alto, CA, US). Chromatographic separation was
carried out at 40 on a Zobax column (3.0 mm × 150.0 mm, 5 μm). The mobile phase was a
mixture of acetonitrile (A) and 0.1% formic acid in water (B) with a gradient elution as follows:
0 min, 20% A; 3 min, 95% A; 5.5 min, 95% A; 6 min, 20 % A with a flow rate was 0.6 mL/min
and injection volume of 5 µL. Sample cooler was maintained at 5°C during analysis. Mass
spectrometric analysis was performed on a 6545QTOF mass spectrometer (Agilent
Technologies, Santa Clara, CA, USA) equipped with electrospray ionization source in positive
mode. The mass range was recorded from m/z 65 to 1000 Da. Data acquisition was performed
with MassHunter workstation (Agilent Technologies, USA). The analysis was performed in
positive mode with full mass scan range of 65-1000 Da. The mass spectrometric conditions were
as follows: nebulizer pressure, 45 psig; capillary voltage, 3500 V; fragmentor voltage, 175 V;
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drying gas flow, 12 L/min; drying gas temperature, 275°C; sheath gas flow, 11 L/min; sheath gas
temperature, 350°C. During all the runs, the QTOF was calibrated by two reference masses
(121.0508 and 922.0097 Da) flowing at continuous flow rate of 100 µL/min. Before analysis, the
TOF/MS was calibrated using a reference solution consisting of masses (121.0508, 149.0233,
322.0481, 922.0097, 1221.9906 and 1521.94 Da) with resolution of greater than 10,000. For
gemcitabine and dFdU, linearity was established in aqueous solution and saline. The method
developed was sensitive and specific with no interference from matrix at the retention of analytes
or internal standard with an LLOQ of 7.81 nM for both analytes. Phenacetin (500 ng/mL) was
used as internal standard. All samples were analyzed with calibration curve standards spanning a
range of 7.81 nM to 1000 nM. The amount of gemcitabine triphosphate was normalized to the
ATP level determined in the same sample analysis. Samples with inadequate concentrations of
ATP were excluded from analysis.
3.5.12. Immunoblotting and Co-immunoprecipitation
Lysates were prepared from cell pellets in RIPA lysis buffer. Proteins from lysates were
separated on NuPAGE Novex Bis-Tris 10% gels (Invitrogen). Gels were transferred to
nitrocellulose membranes (Millipore) and probed with antibodies specific to integrin αV, integrin
β3 (Sigma-Aldrich, SAB4300361), α-SMA, GAPDH, caspase 8, Cda, and β-actin. For coimmunoprecipitation, antibody against integrin β3 (1:100) or caspase 8 (1:100) was added to the
lysates for incubation overnight at 4°C, with rabbit IgG (1:100) as control antibody. The lysates
were incubated with Dynabeads Protein A (Thermo Fisher Scientific, Cat No. 10002D)
according to the manufacturer’s instructions.
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3.5.13. Transfection of KPC961 cells
For siRNA transfection, KPC961 cells were plated at 5 × 105 cells per ml in 6-well plates
and transfected with mouse Cda siRNA (#sc-60342) with Lipofectamine® RNAiMAX
Transfection Reagent (Thermo Fischer Scientific, Cat No. 13778030) according to the
manufacturer’s instructions.
3.5.14. Apoptosis assay
For analyzing apoptosis in adherent KPC961 cells, FITC-Annexin V Apoptosis Detection
Kit was used according to the manufacturer´s protocol. The cells were grown directly on a
coverslip. 5 µL of annexin V-FITC was added and incubated in dark for 5 min. The coverslip
was inverted on a glass slide to visualize cells. The cells were observed under Keyence
microscope. The ratio of number of cells stained green to number of nuclei was taken.
3.5.15. Proliferation assay
ProAgio was added to the KPC961 cells in a dose-dependent manner. Consequently,
BrdU cell proliferation assay was carried out according to the manufacturer’s instructions.
Spectrophotometer microplate reader was used to detect BrdU at 450 nm.
3.5.16. Oil Red O staining
10 μM fresh frozen tissues were air dried, fixed in ice cold formalin, rinsed with prestained solution to avoid carrying water into Oil Red O. The sections were incubated with prewarmed Oil Red O solution for 8-10 min in 60ºC and further counterstained with Mayer's
hematoxylin for 30 sec. Red droplet area was quantified and represented as fold-change.
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3.5.17. qRT-PCR assay
qRT–PCR was performed using a Luna Universal qPCR master mix, NEB Inc. (Catalog#
M3003L) according to the manufacturer’s instructions. The primer sequences are listed in Table
3.3 and Table 3.4. Data were collected and analyzed using a 7500 Fast Real-Time PCR System
(Applied Biosystems).
3.5.18. Migration assay
The 2D migration assay was performed using KPC961 cells seeded in 6-well plates. Cells
were incubated until the plates were 90% confluent for optimum cell attachment and
proliferation. Normal serum RPMI media was used during seeding and proliferation. Cells were
washed and no serum media was replaced for 30 min in two conditions: normoxia and hypoxia.
Hypoxia was maintained using a hypoxia incubation chamber with gas cylinder composing 1%
O2, 5% CO2, 94% N2. Sterile pipette tip was used to make three parallel scratches across the
plate approximately 5 mm apart. Each scratch was labeled at the base of the plate to maintain the
location while taking images. Images were taken at 0 h. Cells were incubated in respective
conditions for 24 h. Cells were observed, and images were taken after 24 h. The distance of the
scratch was measured and represented as percentage wound heal.
3.5.19. Statistical analyses
Statistical analyses were carried out using the GraphPad Prism 6.0 software. The number
of animals is specified in each figure legend. Kaplan-Meier survival curves were calculated using
survival time for each mouse from all treatment groups. Statistical analyses in the survival
experiments were performed by log-rank (Mantel-Cox) test. All in vitro experiments were
carried out in triplicates minimum. For tumor burden analyses and image quantifications,
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statistical significance was assayed by either Student’s t-test and/or one-way ANOVA for
multiple comparisons followed by post-hoc Tukey’s test. Box plots show range, median and
quartiles. *P < 0.05; **P < 0.01, ***P < 0.001, **** P < 0.0001; n.s. denotes not significant. All
data are presented as mean ± S.E.M. or as box plots.
3.5.20. Patient samples
Dr. Alyssa Krasinkas from Winship Cancer Institute, Emory hospital, provided
pancreatic cancer tissue samples. The information about the patients is described in Table 3.1.
Table 3.1. PDAC patient information
Mean
Patient ID

age

Accessory Findings
Classification Tumor grade

(Treatment Effects)

pT2, pN2

No known presurgical findings

(years)
S18-17468 B5

75

G3: Poorly
differentiated

S18-17177 D10

72

pT3, pN2

G3: Poorly

No known presurgical findings

differentiated
S18-29207 D25

66

pT2, pN2

G2: Moderately No known presurgical findings
differentiated

S18-28291 D36

67

N/A

G3: Poorly

No known presurgical findings

differentiated
S18-17863 E9

70

ypT2, ypN2

G3: Poorly

Absent: Extensive residual cancer

differentiated

with no evident tumor regression
(poor or no response, score 3)

S18-26683 E18

69

ypT2, ypN2

G2: Moderately Absent
differentiated

S18-21141 E26

56

ypT2, ypN2

G3: Poorly

Absent: Extensive residual cancer

differentiated

with no evident tumor regression
(poor or no response, score 3)
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S18-25345 F15

55

N/A

G2: Moderately No known presurgical therapy
differentiated

S18-22400 F18

81

PT1c

G3: Poorly

No known presurgical therapy

differentiated
S18-29747 I22

80

N/A

G3: Poorly

Absent

differentiated
Primary Tumor (pT)
pT1c: Tumor 1-2 cm in greatest dimension
pT2: Tumor > 2 cm and <= 4 cm in greatest dimension
pT3a: Tumor directly invades pancreas (up to 0.5 cm)
Regional Lymph Nodes (pN)
pN1: Metastasis in one to three regional lymph nodes
pN2: Metastasis in four or more regional lymph nodes
Table 3.2. Reagents or resources
Reagent or Resource

Source

Catalog No.

Gemcitabine, HCl

EMD Millipore

504594

Gemicitabine-5’-triphosphate (dFdCTP)

Sierra Bioresearch

2,2-Difluoro-2-deoxyuridine

Santa Cruz Biotechnology

sc-220827

Ultravision Peroxidase block

Thermo Fisher Scientific

TA060H2O2Q

Ultravision Protein block

Thermo Fisher Scientific

TA060PBQ

Antibody diluent OP Quanto

Thermo Fisher Scientific

TA-125-ADQ

Betazoid DAB Chromogen kit

Biocare Medical

BDB2004L

DEPEX mounting media

Electron Microscopy Sciences

13514

Coverslips

Thermo Fisher Scientific

102420

Tris Base

Thermo Fisher Scientific

BP154-1

Tween-20

Sigma-Aldrich

P5927

Citrate buffer

Sigma-Aldrich

C9999-1000ML

Xylenes

Thermo Fisher Scientific

X5-4
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Ethanol

Decon Lab

22032601

Large Volume Mayer's Hematoxylin

Thermo Fisher Scientific

TA-125-MH

Direct PCR Lysis Reagent (Mouse Tail)

Viagen Biotech

102-T

PCR Master Mix

Thermo Fisher Scientific

F548S

100bp DNA Ladder

Thermo Fisher Scientific

SM1143

Molecular Biology Agarose

Bio-Rad

1613101

StainTray™ Slide Staining System

Simport Scientific

1159J70

Hypoxia Incubator Chamber

Stemcell Technologies

27310

Gas cylinder: 1% Oxygen, 5% Carbon Nexair

3921617153

dioxide, 94% Nitrogen
Antibodies
α-SMA (1:400)

abcam

AB5694

Cleaved caspase-3 (1:300)

abcam

AB49822

Cytidine deaminase (1:250)

Thermo Fisher Scientific

PA5-27478

Dck (1:500)

Thermo Fisher Scientific

PA5-21846

GAPDH (1:2000)

Santa Cruz Biotechnology

sc-32233

Hif1α (1:500)

MilliporeSigma

MAB5382

IGF1 (1:300)

Thermo Fisher Scientific

MA5-18035

pIGF-IRβ (1:200)

Santa Cruz Biotechnology

sc-390130

Integrin αV (1:300)

Santa Cruz Biotechnology

sc-6617 P

Integrin β3 (1:100)

Sigma-Aldrich

SAB4300361

PECAM-1/CD31 (1:50)

Abcam

AB9498

Tdk (1:500)

Thermo Fisher Scientific

PA5-13813

Ki67 (1:500)

Abcam

AB15580

Proteinase K

Thermo Fisher Scientific

EO0491

Chemicals, Peptides, and Recombinant Proteins
Recombinant murine IGF1 (50ng/ml)

R & D Systems

791-MG

Recombinant human IGF1

R & D Systems

291-G1
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Critical Commercial Assays
Picro Sirus red staining kit

IHC world

IW-3012

Masson’s trichrome kit

IHC world

IW-3006

Human IGF1 ELISA kit

R&D systems

DG100

Novaultra Oil red O stain kit

IHC world

IW-3008

Annexin V-FITC Apoptosis Kit

abcam

ab14085

BrdU Cell Proliferation Assay

EMD Millipore

2752

Experimental Models: Cell Lines
KPC 961

Gift from Dr. Batra (UNMC)

Capan-1

ATCC

CRL-1687

Panc-1

ATCC

CRL-1469

Panc-89

Gift from Dr. Aneja

MIA PaCa-2

ATCC

CRL-1420

Human PaSCs

ScienCell Research Lab

3830

Experimental Models: Organisms/Strains
Mouse: Kras+/LSL-G12D; (C57BL/6J)

The Jackson Laboratory

008179

Mouse: Trp53+/LSL-R172H

The Jackson Laboratory

008652

The Jackson Laboratory

014647

(C57BL/6J)
Mouse: Pdx1-Cre (C57BL/6J)
Software and Algorithms
GraphPad PRISM 6
Adobe photoshop CS6
Table 3.3. Primers for qRT-PCR: aV and b3
ITGAV forward

5’ TAGGAGCTTTTGGTGTAGAT 3’

ITGAV reverse

5’ GAAACTTTGAGAGCTGTTCC 3’

ITGB3 forward

5’ CTGCTGTAGACATTTGCTATGA 3’

ITGB3 reverse

5’ GCCAAGAGGTAGAAGGTAAATA 3’
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Table 3.4. Primers for Kras, p53, and Cre
Kras

The Jackson Laboratory

Kras-seq WT F: 5’-TGTCTTTCCCCAGCACAGT-3’

SIGMA ALDRICH

Kras-seq R: 5’-CTGCATAGTACGCTATACCCTGT-3’
Kras-seq Mutant F 5'-GCAGGTCGAGGGACCTAATA-3'
p53

The Jackson Laboratory

p53-seq F: 5’-AGCCTGCCTAGCTTCCTCAGG-3’

SIGMA ALDRICH

p53-seq R: 5’-CTTGGAGACATAGCCACACTG-3’
Internal Positive Control

The Jackson Laboratory

Forward 5’ -CTAGGCCACAGAATTGAAAGATCT- 3’

SIGMA ALDRICH

Reverse 5’ -GTAGGTGGAAATTCTAGCATCATCC- 3’
Cre transgene

The Jackson Laboratory

Cre F: 5’-GCGGTCTGGCAGTAAAAACTATC-3’

SIGMA ALDRICH

Cre R: 5’-GTGAAACAGCATTGCTGTCACTT-3’
Table 3.5. Genotyping PCR protocol
PCR conditions for KPC GEM genotyping
Allele: Trp53tm2.1Tyj cycling
Product length: HET = 297 bp and 350 bp MUT = 350 bp WT = 297 bp
Step

Temp (°C)

Time

1

94

3 min

2

94

30 sec

3

64

1 min

4

72

1 min

Note

Repeat steps 2-4 for 35 cycles

Allele: Generic Cre cycling
Product length: Transgene = ~100 bp Internal positive control = 324 bp
Step

Temp (°C)

Time

1

94

3 min

Note
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2

94

30 sec

3

51.7

1 min

4

72

1 min

5

72

2 min

Repeat steps 2-4 for 35 cycles

Allele: Krastm4Tyj cycling
Product length: Mutant = 100 bp Heterozygote = 100 bp and 250 bp Wild type = 250 bp
Step

Temp

Time

Note

(°C)
1

94

3 min

2

94

20 sec

3

65

15 sec

-0.5 C per cycle decrease

4

68

10 sec

Repeat steps 2-4 for 10 cycles

5

94

15 sec

6

72

10 sec

7

72

2 min

Repeat steps 6-8 for 28 cycles
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4. CONCLUSIONS AND DISCUSSION

Tumor microenvironment (TME) initiates and facilitates the progression of a multitude of
malignancies. The stromal component comprises of cells from mesenchymal, endothelial, and
hematopoietic origins arranged in the ECM, which interact with tumor cells and contribute to
tumorigenesis. TME-cancer cell cross talk regulates cancer progression via secretion of various
growth factors including, PDGF, EGF, IGF1, chemokines including, IL6, IL10, CCL2, cytokines
including, TGFb, IFN, IL-1b, and small metabolites. TME also has different components such as
hypoxia, angiogenesis, interstitial pressure, extracellular matrix (ECM), and ECM remodeling.
CAFs are one of the main components and the key players in the tumor stroma, implicated in the
tumor progression and drug resistance. CAFs secrete abundant ECM, including collagen
isoforms, laminin, and fibronectin predominantly that provides survival and migration cues to
cancer cells, and forms a barrier to drug delivery. In addition, CAFs are metabolically active and
also form an immunosuppressive milieu in the TME by recruiting immune suppressive cells,
through various pathways, such as TGFb, TNF, CXCL12, and inhibiting the activity of immuneeffector cells to assist in immune evasion (Liu et al., 2019). Although there are recent reports
highlighting the anti-tumor effects of CAFs, the tumor-promoting effects are widely described.
Recently, CAFs heterogeneity has been recognized, especially in breast and pancreatic cancer. In
breast cancer, four CAF subsets were identified based on six CAF markers, including integrin
b1/CD29, S100-A4/FSP1, FAP, aSMA, PDGFRb, and CAV1. These CAF subsets are: 1) CAFS1: CD29Medium FAPHigh FSP1Low-High aSMAHigh PDGFRbMedium-High CAV1Low; 2) CAF-S2:
CD29Low FAPNegative FSP1Negative-Low aSMANegative PDGFRbNegative CAV1Negative; 3) CAF-S3:
CD29Medium FAPNegative FSP1Medium-High aSMANegative-Low PDGFRbMedium CAV1Negative-Low; 4)
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CAF-S4: CD29High FAPNegative FSP1Low-Medium aSMAHigh PDGFRbLow-Medium CAV1Negative-Low.
CAF-S3 subset was mainly found in juxta-tumors, CAF-S2 in Luminal A tumors, CAF-S4 in
HER2 tumors, and CAF-S1 and CAF-S4 in TNBC tumors. Notably, CAF-S1 subset was
identified as a key player in immunosuppression. CAF-S1 enriched TNBC tumors exhibit high
levels of FOXP3+T cells and low levels of CD8+T cells compared with CAF-S4 enriched tumors
(Costa et al., 2018). Similarly, three CAF subpopulations were identified in PDAC, including
myofibroblastic, pro-inflammatory, and antigen-presenting. Myofibroblastic CAFs (myCAFs)
express high levels of aSMA; inflammatory CAFs (iCAFs) express low levels of aSMA, but
high levels of chemokines and cytokines; antigen-presenting CAFs (apCAFs) express major
histocompatibility complex (MHC) class II proteins. myCAFs are located adjacent to the cancer
cells, whereas iCAFs are located far within the dense stroma. myCAFs and iCAFs are
interconvertible cell states. In addition, apCAFs can convert to myofibroblasts, suggesting that
CAF subsets in PDAC represent dynamic and interconvertible states.
Extensive desmoplastic stroma that originates from CAFs is a crucial hallmark of PDAC,
which constitutes up to 90% tumor volume, and the major source of CAFs are pancreatic stellate
cells. Hypoxia is another important constituent of PDAC microenvironment and is closely
associated with desmoplasia-induced hypovascularization. Desmoplasia is a barrier to dug
delivery and T-cell infiltration and is accompanied by strong accumulation of myeloid cells.
MDSCs are elevated in PDAC patients, which further suppress T-cell function and inhibit antitumor response. The dominating cytokines in PDAC microenvironment are TGF-b, (IL)-6, 8, 10,
35, CCL-2, (CXCL)-1, 13, and GM-CSF. Altogether, PDAC microenvironment comprises of
desmoplastic and immunosuppressive milieu (Orth et al., 2019). Similarly, tumor-stroma ratio is
an important prognostic factor for TNBC patients. Stroma rich tumors are associated with low
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overall survival and relapse free survival. CAFs in breast cancer may originate from resident
fibroblasts, endothelial cells, epithelial cells, pericytes, bone marrow derived mesenchymal stem
cells. In TNBC, stromal stiffening is attributed to increase in LOX activity and associated with
tumor associated macrophage infiltration. In addition, stromal cell derived MMPs activity is
often increased in breast cancer. CAFs predominantly synthesize MMPs that regulate ECM
degradation and remodeling, resulting in tumor progression and metastasis. MMPs can also
contribute to tumor cell growth, inflammation, and angiogenesis. Notably, it has been reported
that the expression of MMP-9 is highest in TNBC, which results in aggressive metastatic
behavior. Therefore, selectively targeting CAF population represents a potential strategy for
treating solid tumors (Biffi et al., 2019).
CAFs have also been implicated in secondary tumor growth at metastatic sites. Excessive
collagen deposition in the breast tumor along with exertion of high contractile forces by CAFs
stiffen ECM and form ECM tracks to guide cancer cell invasion. CAFs have also been shown to
mediate collagen cross-linking and modulate tumor stiffness. Also, in breast cancer, LOX is one
of the primary enzymes secreted mainly by CAFs that cross-links collagen and facilitates
colonization of cancer cells at metastatic sites (Johnston and Lopez, 2018). Furthermore, HIF-1a
is hyperactivated in stroma rich TNBCs, and hypoxic condition generated by tight compression
environment due to dense collagen fibrils and impaired blood perfusion induces the secretion of
LOX (Gilkes and Semenza, 2013; Wang et al., 2016), resulting in enhanced metastasis.
The “seed and soil” hypothesis suggests that metastatic tumor cells spread to certain
organs because of their specific microenvironment, which results in organ-preference patterns in
tumor metastasis, and the metastatic patterns of breast cancer subtypes may differ significantly.
For instance, it has been reported that Luminal A subtypes have a propensity for bone
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metastases, whereas basal-like breast cancers are more prone to metastasize to the brain and
lungs than other subtypes. Further, metastatic sites have been shown to contain significantly
fewer tumor infiltrating leukocytes than the primary tumor. Intriguingly, the composition of the
metastatic infiltrating leukocyte population and their subsets in the primary site remained almost
unaltered in their paired metastatic tumor, irrespective of the metastatic location, suggesting that
the primary tumor plays a vital role in influencing immune composition (Yu and Di, 2017).
Furthermore, it has been shown that metastatic sites can bring their own soil, i.e. stromal
components, including activated fibroblasts from the primary site to the lungs. Interestingly,
fibroblasts are not just involved in the metastatic progression, but they play a vital role at
metastatic site where they promote cancer cell proliferation. A study has demonstrated that
fibroblasts produce periostin at the site of a micrometastasis that is critical for metastatic
colonization and initiation of a new tumor. Elucidating the mechanisms by which normal stromal
compartments of the secondary organ prevent or promote metastatic growth is extremely
important (Marsh et al., 2013).
Therapeutic strategies targeting tumor fibrotic stroma have been extensively explored,
particularly in PDAC treatment due to unique desmoplasia property of PDAC, however the
success is limited. Although evidences have demonstrated that dense fibrotic stroma closely
correlates with poor prognosis in TNBC patients, targeting CAFs, as a potential TNBC treatment
is not extensively explored. Even in PDAC, it is speculated that depletion of fibrotic stroma
would be therapeutically advantageous. It is because dense fibrotic stroma is a major hindrance
for the drug delivery. Also, dense fibrotic stroma orchestrated by CAFs support cancer cell
growth, survival, metastasis, and resistance to apoptosis. The stromal modifying agent PEGPH20
(Hingorani et al., 2016), a recombinant enzyme which degrades stromal hyaluronic acid (HA), a
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critical matrix component of cancer stroma, demonstrated in early Phase I and Phase II trials that
addition of this agent to standard chemotherapy for PDAC patients with dense tumor stroma can
be beneficial, however the combination therapy failed to improve median overall survival in
patients with metastatic pancreatic cancer. This study was terminated in Phase III due to poor
efficacy of the combination. In addition, recent studies of Sonic hedgehog (Shh) and a-SMA
gene deletion in PDAC GEM models suggest that some fibrotic stroma in PDAC may constitute
a barrier that prevents metastatic spread of the tumor (Leake, 2014; Ozdemir et al., 2014; Rhim
et al., 2014). Depletion of fibrotic stroma results in increased metastasis and shorter survival in
pre-clinical models and some early phase clinical studies (Catenacci et al., 2015; Ozdemir et al.,
2014; Rhim et al., 2014). Overall, these studies aroused an important controversy, “whether to
target or not-target fibrotic stroma in cancer therapies, particularly in treatment of PDAC?” (Carr
and Fernandez-Zapico, 2016). It should be noted that Shh or a-SMA gene deletion leads to
global deletion of fibroblasts resulting in downstream effects in excess of what would be
expected from a tumor-targeted therapeutic. Pharmacological inhibition of Shh signaling may
also impose effects far beyond fibroblasts.
Angiogenic vessels are another important component of tumor TME. Leaky angiogenic
vessels increase the interstitial pressure in the tumor and therefore increase the resistance to
blood flow, which results in reduced efficacy to tumor blood supply. The hyper-permeable
vasculature leads to the accumulation of metabolic products, such as lactic acid and carbonic
acid and decrease in extracellular pH. In addition, leaky angiogenic vessels quell oxygen supply,
resulting in hypoxia in TME. Hypoxia in turn supports tumor angiogenesis through HIFs, and
increase in pro-angiogenic molecules, such as VEGF, TNF, and PDGF. Leaky tortuous blood
vessels in the tumor benefit the tumor growth, however, the anti-tumor drug delivery is impaired
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(Jain, 2005). Notably, active angiogenesis in tumor closely relates to poor patient prognosis in
TNBC patients.
We previously reported a rationally designed protein, ProAgio that targets integrin αvβ3 at
a novel site and specifically induces apoptosis in the αvβ3-expressing cells. We demonstrate that
fibril producing CAFs in TNBC and CAPaSCs in PDAC express high levels of integrin αVβ3. In
addition, angiogenic endothelial cells have been shown to express high levels of integrin αVβ3.
The unique targeting specificity of ProAgio provides an effective approach to simultaneously
deplete CAFs (or CAPaSCs) and angiogenic tumor vessels.
In TNBC, depletion of CAFs by ProAgio leads to decrease in intratumoral collagen. In
addition, depletion of CAFs reduces intratumoral GFs that are likely released by CAFs, which
breaks-down the crosstalk between cancer cells and CAFs. LOX plays an important role in
cancer metastasis (Cox et al., 2013; Erler et al., 2006), and both cancer cells and CAFs secrete
high levels of LOX. In the tumor with dense fibrotic stroma, CAFs may be the main source cells
that secrete LOX (Pickup et al., 2013). Our data demonstrate that depletion of CAFs by ProAgio
decreases LOX in the primary tumor, blood circulation, and the metastatic site. Clearly, decrease
in LOX both at the primary tumor and metastatic site reduces TNBC metastasis as shown in both
4T1 and MMTV-PyMT models. ProAgio also induces apoptosis in aECs in TNBC tumors and
therefore diminishes the leaky tumor vasculature. Removal of dysregulated tumor angiogenic
vessels increases blood perfusion into tumor, which consequentially overcomes a drug delivery
barrier. Interestingly, increase in blood perfusion into the tumor due to abrogation of angiogenic
tumor vessels by ProAgio not only facilitates drug molecule delivery but also reduces tumor
hypoxia. Hypoxia is a critical regulatory factor in controlling expression and secretion of LOX.
Hypoxia is also one main driving force for cancer metastasis (Rankin and Giaccia, 2016).
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Simultaneous depletion of CAFs and angiogenic vessels in TNBC tumor by ProAgio leads to
decrease in secretion of LOX by CAFs and reduction in hypoxia, which also decreases hypoxiadriven LOX expression and secretion. Thus, it is clear that the dual action of ProAgio in LOX
expression/secretion and reduction in tumor hypoxia due to anti-angiogenesis activity of ProAgio
orchestrate special tumor microenvironment both at primary and metastatic tumor to reduce
metastasis. It is noteworthy that ProAgio decreases LOX by two-side of actions. First, by
depleting CAFs, ProAgio modulates breast TME and thus decreases secretion of LOX. Second,
ProAgio reduces stroma density and leaky tumor vessels, thus increases blood perfusion in the
tumor, which reduces hypoxia and hypoxia-induced LOX. A unique characteristic is that
ProAgio decreases LOX in the serum and the lung metastatic site. It is documented that
accumulation of LOX at metastatic site drives pre-metastatic niche formation, which further
enhances metastatic tumor growth. Thus, it is likely that reduction of metastatic tumor
colonization and growth upon ProAgio treatment is at least partially due to decreased formation
of pre-metastatic niche because of the reduction in LOX levels. Due to the important role of
LOX in TNBC metastasis, targeting LOX family has become an attractive strategy for breast
cancer treatment. It has been well documented that the challenge with LOX inhibition is that it
produces lathyrism (Rodriguez et al., 2008). Small-molecule LOX inhibitor, for example βaminopropionitrile (BAPN) proved to be ineffective in clinic, resulting in culminated clinical
trials. Therefore, an alternate approach to reduce LOX secretion by targeting CAFs is a
promising avenue to inhibit metastasis. We believe that ProAgio treatment is one such approach
where LOX secretion is reduced by targeting CAFs. Altogether, multiple effects of ProAgio due
to depletion of CAFs and anti-angiogenesis enable the protein to be a promising treatment drug
for TNBC, especially for patients with tumor rich in dense fibrotic stroma.
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Further, dense intratumoral collagen fibrils and leaky tumor vessels constitute barriers for
drug delivery (Jain, 2005; Miao et al., 2015). Therefore, removal of dense collagen fibrils and
reduction in leaky tumor angiogenic vasculature would enhance the delivery of
chemotherapeutic agents. On the other hand, depletion of CAFs by ProAgio also decreases
intratumoral levels of GFs that are mostly secreted by CAFs, which cuts-off the crosstalk
between cancer cells and CAFs. One important consequence is the reduction in cancer cell
apoptosis resistance that is stimulated by intratumoral GFs. The dual action of ProAgio results in
high efficacy of the combination therapies, e.g. ProAgio + chemotherapy agents in the TNBC
murine models. Importantly, the dual action of ProAgio allows achievement of high efficacy
using very low dose of chemotherapeutic agents (2-6-fold less dosage of PTX and DOX).
Significant lower dosage of cytotoxic anti-cancer drugs would greatly reduce toxic side effects of
the chemotherapeutic agents and improve the treatment efficacy. Our study apparently introduces
a strategy for TNBC treatment by simultaneously targeting stroma fibroblasts and angiogenic
vessels by ProAgio, particularly in combination with other anti-cancer chemotherapeutics.
Similarly, in PDAC mouse models, we demonstrate that targeting integrin avb3 by
ProAgio specifically induces apoptosis in CAPaSCs, which enables reduction of stromal
collagen in the tumor. Reduction in collagen consequently opens the collapsed blood vessels in
the tumor. Removal of physical block by depletion of dense collagen and opening of collapsed
vessels resulted in increased delivery of drug molecules into the tumor. Apoptotic induction in
CAPaSCs by ProAgio also remarkably reduces IGF1, and possible other growth factors and
cytokines, that are mainly produced by CAFs in cancerous tissue, which consequently results in
decrease and inactivation of IGF1R in cancer cells. Decrease and inactivation of IGF1R
suppresses Cda expression, which stabilizes Gem in cancer cells that is equivalent to increase in
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active Gem concentration in cancer cells. Moreover, opening of the collapsed blood vessels
reduces hypoxia. Reduction in hypoxia in conjunction with decreased IGF1 and inactivation of
IGF1R decreases cancer cell migration, thereby decreasing cancer metastasis. Thus, it is clear
that ProAgio enacts multiple effects in PDAC by specifically acting on CAPaSCs and angiogenic
endothelial cells. Indeed, ProAgio treatment did not result in more aggressive cancer with
increased metastasis and did not increase angiogenesis in the tumor as observed with Shh or aSMA gene deletion or Shh inhibition. A recent large-scale patient tumor study demonstrates that
percentage of stromal cell determine the phenotypic nature of PDAC. Increase in stromal cells
leads to increase in both highly proliferative and migratory phenotype. Effectiveness of ProAgio
in PDAC treatment provides a good explanation for the observation, as ProAgio specifically
depletes CAPaSCs leading to decrease in PDAC cancer cell proliferation and migration (Ligorio
et al., 2019).
Enzymatic inactivation of gemcitabine is the main reason leading to cancer resistance to
this anti-cancer drug. Intriguingly, ProAgio decreases IGF1 by depleting CAPaSCs, which
consequently suppresses Cda expression in cancer cells. It is recently shown that CAPaSCs also
traps Gem in the cancer stroma (Hessmann et al., 2018). Depletion of CAPaSCs by ProAgio
would release the trapped Gem and increase available Gem to cancer cells. As Gem has been
approved for the treatment of multiple different cancer types (Toschi et al., 2005), it will be
interesting to test whether the same mechanism will be true to the Gem treatment resistance in
other cancers. Since ProAgio depletes CAPaSCs, the major source cells that secrete IGF1 in the
tumor, it is anticipated that it will be more effective than the IGF1R blockade antibody (Qu et al.,
2017) for PDAC and other cancer treatment in this regard. Unlike globally targeting fibroblasts,
specifically acting on CAFs by ProAgio may confer an advantage in cancer therapy in PDAC
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and TNBC. Another unique property of ProAgio is that it does not affect established tumor
vessels. Importantly, no toxic effect of ProAgio has been observed in the pre-clinical models.
Although there are multiple advantages whilst targeting CAFs that have been extensively
demonstrated in preclinical murine models, several potential challenges still remain and require
careful considerations at the various developmental stages of the therapies. Majority of CAFtargeted therapeutics are function blocking antibodies, which have very limited penetration into
desmoplastic tumors, especially PDAC. ProAgio is a 11 KDa molecular weight peptide that can
easily penetrate into the tumor. Therefore, pre-treating desmoplastic tumors with ProAgio can
reduce the number of CAFs and/or the desmoplastic reaction they produce, which can be a
beneficial strategy to treat solid tumors with dense stroma. An important consideration while
designing the related clinical trial would be to implement the CAF-targeted therapies in early
phases of cancer treatment before or concurrently with neoadjuvant chemotherapy or
immunotherapy. Indeed, the blockade of CAF-derived factors may prevent the formation of
metastatic niches in primary or distant sites to reduce tumor recurrence and/or metastasis
following surgery.
The significance of ProAgio is not just limited to TNBC and PDAC treatment, but it can
be advantageous in other solid tumors, for example hepatocellular carcinoma (HCC) that is
characterized by the presence of abundant stroma. ProAgio effectively induces apoptosis in
hepatic stellate cells (HSCs), as they express high levels of integrin avb3. We are currently
investigating the mechanism of ProAgio in HCC and will report its extensive analysis in the
future. Further, ProAgio may hold clinical potential in other diseases, such as ocular diseases,
endometriosis, rheumatoid arthritis, liver fibrosis, and lung fibrosis. Although ProAgio has
shown to be beneficial in treatment of solid tumors in vivo, it can also cause wound-healing
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complications. In addition, it can also cause complications in the female reproductive cycle. The
likelihood of development of chronic wounds due to inadequate vascularization is high in
patients with diabetes and venous disorders. Successful management of dosage and duration of
ProAgio treatment may alleviate the wound-healing complications.
Further studies to uncover the hidden secrets of CAFs and effective therapeutics that
target CAFs and modulate TME are worth pursuing. Extensive evidence from recent studies
suggests that the immune response is crucial against tumors and is therefore attracting substantial
attention. Nonetheless, certain patients are more sensitive to immunotherapies than others. One
possibility is that while immunotherapies cannot be overcome by strengthening the immune
system alone, and this effect may be due to the immunosuppressive capability of the TME,
which is partially caused by CAFs. Therapies targeting the tumor stroma combined with
immunotherapies could abate this influence and thereby exert an antitumor immune response (Bu
et al., 2019). An interesting study would be to evaluate the effect of ProAgio in combination with
immunotherapy, either with anti-PDL1 or anti-CTLA4 or both. CAFs impair tumor-specific
cytotoxic T-cell activity by both direct and indirect mechanisms. CAFs can induce cytotoxic T
cell death via PDL2 and FASL pathways. By remodeling the ECM, CAFs can influence T-cell
migration and trap T cells in the dense stroma by forming a physical barrier. In addition, CAFs
can indirectly form an immunosuppressive milieu by triggering the infiltration and expansion of
other immune cells, such as myeloid derived suppressor cells (MDSCs), T-reg cells, and M2
macrophages. The exact mechanism by which CAFs regulate these cells is not known, however,
recent literature has shed light on various growth factors, chemokines, and cytokines that form a
favorable environment for tumor progression. CAFs promote MDSCs recruitment into the TME
by secreting CCL2. MDSCs are heterogeneous population of immature myeloid cells, which
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utilize several mechanisms to support immune suppression and metastases. Several amino acid
catabolic enzymes in MDSCs are implicated in forming an immunosuppressive environment. For
instance, arginase I expression in MDSCs facilitates catabolism of L-arginine into L-ornithine.
Further, indolamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) degrade
tryptophan to kyurenine. Depletion of both L-arginine and tryptophan result in CD8+ T-cells
paralysis in the TME. Also, tryptophan starvation results in the conversion of CD4+ T cells to T
reg cells. It has also been reported that CAFs induce reactive oxygen species (ROS)-generating
MDSCs in lung squamous carcinoma. Furthermore, MDSCs secrete MMPs that degrade ECM
both at the primary tumor and the secondary site, and thereby facilitate tumor cells invasion.
Therefore, abrogation of MDSCs from the TME can be a promising strategy, which can be
achieved with the depletion of CAFs. Additionally, it has been shown that CAFs secrete IL6 that
promotes neutrophil expansion and M-CSF that promotes macrophage M2 polarization, driving
tumorigenesis. Interestingly, CXCL12 produced by CAFs has been suggested in mediating Tcells exclusion from the tumor. Inhibition of CXCL12 ligand, CXCR4, facilitated the effector Tcells to reach the tumor. ProAgio treatment may convert the cold tumors to hot ones, by enabling
the tumor-killing immune cells to penetrate into the tumor. In addition, unveiling the role of
CAF-mediated pathways in regulating metabolic reprogramming and inflammation using
ProAgio as a tool to therapeutically target them may be beneficial. Targeting CAFs by ProAgio
may uncover the molecular mechanisms that regulate the cooperation of immune cells in cancer
promotion. Also, it may lead to a better understanding of the key signaling processes mediated
by CAFs. Deciphering the CAF-immune cell interaction would help to understand how tumors
shape their environment for their benefit and would pave way for comprehending the biology of
the solid tumors and identifying better therapy combinations.
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CAFs are considered as the weeds of the human body owing to their ability to survive
severe stress, including chemotherapy and radiotherapy that usually kills other cell types.
Radiotherapy is an effective and widely used treatment, with a majority of cancer patients
undergoing it at one point during treatment. Radiotherapy is primarily directed at killing cancer
cells; however, it also affects TME. Particularly, CAFs are radioresistant and go into senescence
upon radiotherapy. The secretome of CAFs, including CXCL12, TGF-b1, NO, IGF-1 changes,
resulting in activation of peri-tumoral fibroblasts to CAFs, their enhanced proliferation, and
CAF-mediated effects on the tumor. Radiotherapy also changes the metabolic profile of CAFs,
leading to increase in the invasiveness of the associated tumor cells. In short, radiotherapy
activates CAFs and thus modulates TME by activating a number of pathways that may
subsequently be associated with tumor radioresistance. Radiotherapy not only activates the
inflammatory pathways and induces fibrosis by secretion of different cytokines, chemokines, and
growth factors; it also induces expression of integrins within the stroma resulting in
chemoradiation resistance of tumors. Additionally, CAFs in vivo can induce autophagy and
subsequent irradiated tumor cell recovery. Autophagy promotes radioresistance by modulating
DNA damage repair or by enabling cells to survive hypoxia. It has been recently shown that
irradiated CAFs secrete high levels of IGF1 that initiates a detrimental paracrine IGF1R
activation loop resulting in reduced radiosensitivity and prime cancer cells for metastasis.
Radiotherapy activated CAFs contribute to tumor progression and targeting CAFs by ProAgio
may be a valid approach for improving radiosensitivity in desmoplastic cancer. Hypoxia is
another major factor that plays a crucial role in radioresistance owing to reduced oxygenmediated fixation of DNA damage and HIF-1a mediated cell survival. Increase in oxygen
delivery, normalization of tumor vessels, and inhibition of HIF-1a are being tested to reduce
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hypoxia, improve radiotherapy response, and prevent tumor recurrence after therapy (Barker et
al., 2015). The anti-angiogenic effect of ProAgio may further improve the radiotherapy response,
as hypoxia gets significantly reduced due to elimination of leaky tumor vessels in ProAgio
treated tumors.
In summary, the CAF-targeted therapies offer a novel opportunity of enhancing the
treatment response of cytotoxic therapies, such as chemotherapy and irradiation. CAF-targeted
therapies may synergize with other therapeutic modalities, ultimately improving the therapeutic
outcome of patients with desmoplastic cancers. Indeed, inclusion of immunomodulatory,
vascular normalization, and anti-fibrotic treatments should be considered to maximize
therapeutic benefits and prevent post-irradiation tumor recurrence and metastasis. Future studies
that decipher the complex tripartite interaction between CAFs, immune cells, and cancer cells
will provide a solid foundation for the design of effective combined therapies against cancer with
minimum unwanted off-target effects (Ansems and Span, 2020). Since TME has a pivotal role in
determining tumor outcomes, we believe that the synergistic potential of therapies will be the
future of cancer therapy.
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APPENDIX
P68 RNA Helicase Facilitates Breast Cancer Progression by Promoting Proliferation and
Migration via PDGFR-b/AR Axis.
Appendix A. Abstract
Aberrant expression of p68 RNA helicase (p68), a prototypical member of the DEAD
box family of RNA helicases, contributes to tumor development and progression. p68 tyrosine
phosphorylation induced by PDGF signaling facilitates cancer metastasis by promoting EMT. In
this report, we show that p68 promotes breast cancer cell EMT and cell migration by
upregulation of PDGF receptor b (PDGFR-b). Knockdown of p68 in MDA-MB-231 and BT549
cells significantly decreases PDGFR-b both in mRNA and protein levels. P68 promotes EMT
and cell migration in response to PDGF-BB stimulation via upregulation of PDGFR-b,
suggesting that p68 enhances PDGF signaling by a positive feedback loop in cancer cells.
Furthermore, our study reveals that p68 mediates the effects of PDGFR-b in regulation of
androgen receptor (AR) in breast cancer cells. We demonstrate that p68 and PDGFR-b coregulate AR expression and promote androgen-mediated proliferation in breast cancer cells. Our
studies uncover an important pathway of p68-PDGFR-b axis in promoting breast cancer
progression.
Appendix B. Introduction
p68 RNA helicase (DDX5), a prototypic member of the DEAD box family of RNA
helicases (Lane and Hoeffler 1980), is crucial for the cell development, division, and organ
maturation (Stevenson, Hamilton et al. 1998). As a RNA helicase, ATPase and RNA unwinding
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activity of p68 have been well documented (Hirling, Scheffner et al. 1989, Iggo and Lane 1989).
The previous reports also demonstrate the important role of p68 in diverse cellular processes,
such as pre-mRNA, rRNA, miRNA processing, cell proliferation, and cell migration via
epithelial mesenchymal transition (EMT) (Yang, Lin et al. 2006, Yang, Lin et al. 2007, FullerPace 2013). Expression and post-translational modifications of p68 have been implicated in
cancer development and progression.
Platelet derived growth factor receptor b (PDGFR-b) is a receptor tyrosine kinase that is
implicated in cell proliferation upon PDGF-BB stimulation (Betsholtz 2004, Jechlinger, Sommer
et al. 2006). Evidences indicate an increase in PDGFR-b signaling in different stages of breast
cancer and that it is highly upregulated in the human late stage mammary tumors. PDGFR-b
expression has also been correlated with an invasive phenotype in human breast cancer
(Jechlinger, Sommer et al. 2006). It has been established that an autocrine (platelet derived
growth factor (PDGF-BB) and its cell surface receptor (PDGFR-b) loop is established in breast
cancer cells through upregulation of both ligands and receptors, which results in cancer cell
proliferation, migration, survival, and drug resistance (Guha 1991, Lokker, Sullivan et al. 2002,
Yu, Ustach et al. 2003, Bonner 2004).
Nuclear localization of PDGFR-b upon PDGF-BB stimulation has recently been
reported. Nuclear interaction of PDGFR-b controls cell proliferation by chromatin remodeling
and regulation of p21 levels (Papadopoulos, Lennartsson et al. 2018). Also, nuclear PDGFR-b
has been shown to control androgen receptor (AR) expression (Cuenca-Lopez, Montero et al.
2014, Papadopoulos, Lennartsson et al. 2018). Notably, AR overexpression is associated with
breast cancer aggressiveness (Moinfar, Okcu et al. 2003). It has also been reported that p68 RNA
210

helicase is a coactivator of various steroid hormone receptors, including AR (Clark, Fuller-Pace
et al. 2008). Clark et al. have previously demonstrated that p68 recruits AR and b-catenin to the
promoter regions of androgen responsive genes, including prostate specific antigen resulting in
increased AR transcriptional activity in prostate cancer (Clark, Hadjimichael et al. 2013).
Aberrant expression of p68 and PDGFR-b has been documented in three major human
cancers, including breast cancer (Seymour and Bezwoda 1994, Haines, Cajulis et al. 1996,
Paulsson, Sjoblom et al. 2009, Hashemi, Masjedi et al. 2019), colon cancer (Singh, Haines et al.
1995, Fujino, Miyoshi et al. 2018), and prostate cancer (Clark, Coulson et al. 2008, Nordby,
Richardsen et al. 2017), suggesting the crucial role of both in tumorigenesis and cancer
progression. Both p68 and PDGFR-b play an important role in cell proliferation and migration
that are critical to cancer development. We have previously shown that p68 mediates PDGFinduced EMT by displacing axin from b-catenin (Yang, Lin et al. 2006). Here, we demonstrate
that p68 also regulates PDGFR-b expression by a positive feedback loop in breast cancer cells.
Upregulation of PDGFR-b by p68 resulted in enhanced EMT and migration of MDA-MB-231
and BT549 cells. Although, recent report has shed light on the translocation of PDGFR-b inside
the nucleus, the role of the receptor nuclear localization in tumor progression is not well
understood. Our study unveils a novel mechanism of AR regulation through p68-PDGFR-b axis.
We show that p68 and nuclear PDGFR-b co-regulate AR and thereby mediate androgen
dependent cell proliferation. Taken together, our findings reveal an important new mechanism of
regulation through p68-PDGFRb-AR axis resulting in enhanced cancer cell proliferation and
migration, and therefore progression of breast cancer.
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Appendix C. Results
Appendix C.1. Elevation in p68 expression is associated with low overall survival in breast
cancer patients.
We examined p68 levels by immunostaining the breast carcinoma patient tissue array, as
well as the normal breast tissue. The expression of p68 displayed marked elevation in the breast
carcinoma tissue when compared to the normal healthy breast tissue (Figure iA). Further, we
analyzed the impact of p68 expression on the overall survival (OS) in breast cancer patients
using publicly available data set (Nagy, Lanczky et al. 2018). High expression of p68 closely
correlates with low OS in patients with breast cancer (Figure iB). We then analyzed p68 levels in
multiple breast cancer cell lines and found that p68 is highly expressed in the tested breast cancer
cell lines (Figure iC). Altogether, our results suggest that p68 is elevated in breast cancers, and
expression of p68 may play a critical role in breast cancer progression.

Figure i. Overexpression of p68 in tumor is associated with low overall survival in breast
cancer patients. (A) Representative images of immunohistochemistry staining of p68 in healthy
breast and breast tumor tissue of patients. (B) Kaplan-Meier survival analysis of low and high
DDX5 gene expression (DDX5 low (n=347); DDX5 high (n=742) in the tumor of breast cancer
patients. (C) Levels of p68 (IB: p68) in the indicated breast cancer cell lines were analyzed by
immunoblot. b-actin (IB: b-actin) is the loading control.
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Appendix C.2. P68 RNA helicase mediates PDGF signaling in promoting EMT and cell
migration of breast cancer cells.
We previously reported that tyrosine phosphorylation of p68 mediates the effects of
PDGF-induced EMT via promoting b-catenin nuclear translocation. p68 and Ca2+-calmodulin
interaction promotes cells migration (Wang, Gao et al. 2013). To elucidate the role of p68 in
breast cancer cells migration stimulated by PDGF, we performed scratch-wound and Boyden
chamber assay with two highly invasive breast cancer cell lines, MDA-MB-231 and BT549. We
first knocked-down endogenous p68 in the cells by RNAi. Both Boyden chamber and scratch
wound assay showed that p68 knockdown significantly reduced cell migration upon PDGF-BB
stimulation when compared with scrambled siRNA (Figure iii A-D). Interestingly, we noted
clear morphological differences with or without p68 knockdown upon PDGF-BB stimulation.
These morphological differences clearly indicated the role of p68 in epithelial-mesenchymal
transition (EMT) upon PDGF stimulation (Figure ii). To validate the observation, we examined
the expression of EMT markers upon PDGF stimulation in p68 knockdown cells. The
mesenchymal markers, including vimentin, N-cadherin, and snail, were significantly reduced
both in mRNA (Figure iii E) and protein (Figure iii F) levels upon PDGF treatment in p68
knockdown cells, while the epithelial markers E-cadherin were significantly increased both in
mRNA (Figure iii E) and protein (Figure iii F) levels upon PDGF treatment. The results indicate
that p68 mediates the effects of PDGF-BB in promoting breast cancer cells EMT and migration.
Figure ii. Representative images of
phase contrast microscopy of PDGFBB stimulated MDA-MB-231 cells
upon p68 knockdown compared with
the control.
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Figure iii. P68 RNA helicase knockdown decreases migration of breast cancer cells in
response to PDGF-BB stimulation. (A - D) In vitro scratch wound healing assay (A) and
Boyden chamber assay (C) of MDAMB231 (left panel) and BT549 (right panel) cells upon p68
knockdown in response to PDGF-BB stimulation compared with control siRNA and quantitative
analyses of the migrating cells (B, D). (E & F) Relative mRNA expression (E), and immunoblot
analysis (F) of EMT markers such as vimentin (IB: vimentin), N-cadherin (IB: N-cadherin),
Snail (IB: Snail), and E-cadherin (IB: E-cadherin) in PDGF-BB (20ng/ml, 24 h) stimulated
MDAMB231 and BT549 cells upon p68 knockdown compared with control siRNA. Knockdown
efficiency of p68 (IB: p68) was analyzed by immunoblot. b-actin (IB: b-actin) is the loading
control. Error bars represent mean ± S.E.M. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by
unpaired Student’s t-test.
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Appendix C.3. P68 RNA helicase regulates PDGFR-b expression in breast cancer cells.
PDGF-BB induces migration and invasion of cancer cells, including breast cancer cells.
Previous reports have shown that PDGFR-b overexpression correlates with invasiveness of
breast cancer (Jechlinger, Sommer et al. 2006). Since we observed a decrease in EMT and
migration in p68 knockdown cells upon PDGF-BB treatment, we sought to investigate the effects
of p68 knockdown on PDGF-BB signaling, probing the levels of phospho-PDGFR-b in the p68
knockdown breast cancer cells upon PDGF-BB stimulation. In addition to decrease in phosphoPDGFR-b, we also observed a decrease in PDGFR-b levels in both MDA-MB-231 and BT549
cells (Figure iv A & B). In consistent, we found p68 knockdown also led to reductions in mRNA
of PDGFR-b a two-fold decrease in MDA-MB-231 cells and a ten-fold decrease in in BT549
cells compared with the scrambled siRNA controls (Figure iv C). To determine whether the
effect of p68 on intracellular PDGFR-b and phospho-PDGFR-b is specific, we measured the
levels of c-FOS, a PDGFR-b responsive gene upon p68 knockdown. The mRNA levels of c-FOS
were decreased both in p68 knockdown MDA-MB-231 and BT549 cells upon PDGF-BB
treatment (Figure v). However, p68 knockdown did not alter the phosphorylation and expression
of other growth factor receptors, including EGFR and FGFR in the breast cancer cells (Figure iv
A–C). Thus, our data indicates that p68 plays a role in regulating PDGFR-b expression in
response to PDGF stimulation in breast cancer cells. We reasoned whether the effect of p68
knockdown on the cell migration is due to the reduction in PDGFR-b expression. To test this
conjecture, we performed scratch wound assay with MDA-MB-231 and BT549 cells in which
p68 was knocked down and PDGFR-b was exogenously expressed in the p68 knockdown cells.
Evidently, p68 knockdown reduced cell migration under PDGF-BB treatment. Exogenous
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expression of PDGFR-b recovered the migration reduction of the cells in which p68 was
knocked down (Figure iv D-F). Furthermore, we tested migration of MDA-MB-231 cells in
which PDGFR-b was knocked down or the receptor was exogenously expressed with or without
p68 knockdown. Knockdown of p68 or PDGFR-b decreased migration of MDA-MB-231 cells.
Exogenous overexpression of PDGFR-b relieved the effects of p68 knockdown on MDA-MB231 cells migration (Figure vi A). We further examined the expression of EMT markers,
including vimentin, snail, and E-cadherin, to validate the observation. Consistent with our
previous observation, a decrease in vimentin/snail and an increase in E-cadherin were observed
upon p68 knockdown. Exogenous expression of PDGFR-b in p68 knocked-down MDA-MB-231
and BT549 cells increased levels of vimentin, snail and decreased E-cadherin (Figure vi B). It
was also noted that exogenous overexpression of PDGFR-b restored the fibroblast-like
morphology of p68 knockdown MDA-MB-231 and BT549 cells (Figure vi C). Our findings
suggest that p68 mediates PDGF-BB signaling in promoting EMT and cell migration by
regulation of PDGFR-b expression.
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Figure iv. P68 RNA helicase transcriptionally regulates PDGFR-b expression in breast
cancer cells. (A) Levels of p-PDGFRb (IB:p-PDGFRb) and pERK ½ (IB:ERK1/2), an
established effector of PDGFR-b signaling in MDAMB231 and BT549. (B, C) Immunoblot
analysis (C) of PDGFR-b (IB: PDGFR-b), EGFR (IB:EGFR), and FGFR (IB:FGFR) and their
relative mRNA expression (D) in PDGF-BB stimulated MDAMB231 and BT549 cells upon
p68 knockdown. Knockdown efficiency of p68 (IB:p68) was analyzed by immunoblot. b-actin
(IB:b-actin) is the loading control for total cellular proteins. (D) In vitro scratch wound healing
assay of MDAMB231 cells transfected with p68 siRNA or co-transfected with p68 siRNA and
PDGFRb compared with control siRNA at 0 h and 24 h upon PDGF-BB stimulation. (E & F)
Quantitative analyses of the migrating PDGF-BB stimulated MDAMB231 (F), and BT549
Error bars represent mean ± S.E.M. **P<0.01, ****P<0.0001, ns denotes non-significant by
unpaired Student’s t-test.
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Figure v. (A) Relative mRNA expression of c-FOS, a PDGFR-b responsive gene in
MDAMB231 and BT549 cells stimulated with PDGF-BB upon p68 knockdown. Error bars
represent mean ± S.E.M. **P<0.01, ***P<0.001 by unpaired Student’s t-test.

Figure vi (A) Quantitative analyses of migrating MDAMB231 cells in the scratched areas
upon indicated conditions. The results represent findings of three independent experiments. (B)
Immunoblot analyses of EMT markers such as E-Cadherin, Snail, and Vimentin in PDGF-BB
stimulated MDAMB231 and BT549 cells upon indicated conditions. Knockdown efficiency of
p68, PDGFR-b, and PDGFR-b overexpression was analyzed by immunoblot. b-actin (IB:bactin) is the loading control. (C) Representative images of phase contrast microscopy of
PDGF-BB stimulated MDAMB231 cells upon indicated conditions. Error bars represent mean
± S.E.M. **P<0.01, ****P<0.0001, ns denotes non-significant by unpaired Student’s t-test.
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Appendix C.4. p68 and PDGFR-b co-regulate AR expression and mediate DHT-induced
proliferation in breast cancer cells.
P68 RNA helicase has been demonstrated as an AR transcriptional coactivator (Clark,
Coulson et al. 2008). On the other hand, PDGFR-b controls AR expression (Cuenca-Lopez,
Montero et al. 2014). Importantly, AR is commonly expressed in breast cancers and is associated
with poor prognosis of patients (Moinfar, Okcu et al. 2003). Therefore, we sought to investigate
whether p68 and PDGFR-b co-regulate AR expression in breast cancer cells. We first validated
that p68 knockdown in both MDA-MB-231 and BT549 cells resulted in reduction in AR in the
cells both in protein and mRNA levels (Figure vii A & B). It has been demonstrated that tyrosine
phosphorylation plays an important role in PDGF-BB induced cell proliferation via upregulation
of cyclin D1 and c-Myc (Yang, Lin et al. 2007). It is well established that androgen
[dihydrotestosterone (DHT)] treatment promotes cell proliferation in prostate cancer and breast
cancer (Hackenberg, Hofmann et al. 1988, Lin, Sun et al. 2009). We investigated the effects of
p68 on cell proliferation under treatment of PDGF-BB and DHT. We observed that there was an
increase in cell growth rate of MDA-MB-231 and BT549 cells upon DHT treatment in addition
to PDGF-BB stimulation. However, the growth rate increase by DHT treatment was diminished
by p68 knockdown (Figure vii C). Clearly, p68 regulates AR expression and consequently the
function of AR in promoting breast cancer cell proliferation in response to androgen stimulation.
PDGFR-b has also been shown to control AR expression. Therefore, we further investigated AR
expression in PDGFR-b knockdown breast cancer cells. We found a significant reduction in both
protein (Figure viii A) and mRNA (Figure viii B) levels of AR upon PDGFR-b knockdown both
in MDA-MB-231 and BT549 cells. Cell proliferation was significantly inhibited in the PDGFR219

b knockdown cells upon DHT treatment (Figure viii C). Our results suggest that both p68 and
PDGFR-b regulate AR expression and control AR dependent proliferation in breast cancer cells.

Figure vii. P68 RNA helicase regulates AR expression and mediates the effect of DHT in
proliferation of breast cancer cells. (A & B) Immunoblot analysis (A), and relative mRNA
expression (B) of AR in PDGF-BB stimulated MDAMB231 and BT549 cells upon p68
knockdown. Knockdown efficiency of p68 (IB: p68) was analyzed by immunoblot. b-actin (IB:
b-actin) is the loading control. (C) Cell proliferation of MDAMB231 and BT549 cells untreated
(open bar) or treated (filled bar) with DHT (1 nM for 24 h) upon p68 knock down compared with
the control. The experiments were performed in triplicate. Error bars represent mean ± S.E.M.
*P<0.05, **P<0.01, ***P<0.001, ns denotes non-significant by unpaired Student’s t-test.

Figure viii. PDGFR-b regulates AR expression and mediates the effect of DHT in
proliferation of breast cancer cells.
(A & B) Immunoblot analysis (A), and relative mRNA expression (B) of AR in PDGF-BB
stimulated MDAMB231 and BT549 cells upon PDGFR-b knockdown. Knockdown efficiency
of PDGFR-b (IB: PDGFR-b) was analyzed by immunoblot. b-actin (IB: b-actin) is the loading
control. (C) Cell proliferation of MDAMB231 and BT549 cells untreated (open bar) or treated
(filled bar) with DHT (1 nM for 24 h) upon PDGFR-b knock down compared with the control.
The experiments were performed in triplicate. Error bars represent mean ± S.E.M. **P<0.01,
***P<0.001, ns denotes non-significant by unpaired Student’s t-test.
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Since p68 regulates PDGFR-b expression, we sought to test whether exogenous
expression of PDGFR-b in p68 knockdown cells would alter the cellular AR levels.
Interestingly, expression of PDGFR-b in p68 knockdown breast cancer cells restored AR
expression both in protein (Figure ix A) and mRNA (Figure ix B) levels, suggesting that p68
may regulate AR expression via PDGFR-b. Cell proliferation assay further corroborated our
finding that exogenous expression of PDGFR-b in p68 knockdown MDA-MB-231 and BT549
cells resulted in an increase in cell proliferation upon DHT treatment (Figure ix C & D). Taken
together, our data suggest that p68 and PDGFR-b co-regulate AR expression and mediate
androgen dependent proliferation in breast cancer cells.
Appendix C.5. Nuclear PDGFR-b regulates AR expression in breast cancer cells.
To understand the mechanism by which PDGFR-b regulates AR expression in breast
cancer cells, we examined the levels of PDGFR-b in MDA-MB-231 cells upon PDGF-BB
stimulation. High nuclear PDGFR-b was observed in the treated cells (Figure x A), which is
consistent with the observation by Papadopoulos et al. that PDGFR-b translocate to the cell
nucleus in response to PDGF-BB stimulation. The nuclear PDGFR-b plays an important role in
controlling cell proliferation. In addition, PDGFR-b kinase activity is not essential for nuclear
accumulation of the receptor (Papadopoulos, Lennartsson et al. 2018). To validate whether the
receptor kinase activity is required for PDGFR-b nuclear localization, we examined the nuclear
PDGFR-b upon addition of phospho-PDGFR-b inhibitor, AG1296. In response to PDGF-BB
stimulation, the nuclear PDGFR-b levels did not experience any significant change upon
AG1296 treatment (Figure x A & B). We analyzed the AR levels in the PDGF-BB stimulated
cells in the presence of AG1296. Clearly, AG1296 treatment did not change the AR levels in the
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cells, however expression of PDGFR-b responsive genes, including vimentin, snail, and Ncadherin, was significantly reduced (Figure x C). Thus, our results indicate that nuclear PDGFRb regulates AR expression in breast cancer cells.
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Figure ix. P68 RNA helicase and PDGFR-b co-regulate AR expression and mediate the
effects of DHT in induction of proliferation of breast cancer cells.
(A & B) Immunoblot analyses (A), and relative mRNA expression (B) of AR in MDAMB231
and BT549 cells stimulated with PDGF-BB upon indicated conditions. Knockdown efficiency of
p68 (IB:p68) and PDGFR-b (IB:PDGFR-b), overexpression of PDGFR-b was analyzed by
immunoblot and mRNA expression was normalized to b-actin. Immunoblot of b-actin (IB:bactin) is the loading control. (C & D) Cell proliferation of MDAMB231 (C) and BT549 (D)
treated with DHT (1 nM, 24 h) upon indicated conditions compared with the control. The
experiments were performed in triplicate. Error bars represent mean ± S.E.M. *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001, ns denotes non-significant by unpaired Student’s t-test
and ANOVA.
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Figure x. Nuclear PDGFR-b regulates AR expression in breast cancer cells.
(A) Representative images of immunofluorescence staining of PDGFR-b (red) MDAMB231
cells treated with PDGFR-b inhibitor, AG1296 with or without PDGF-BB stimulation for 24 h
compared with the control. Nuclei were stained with Hoescht (blue). (B) Levels of AR (IB:AR)
in MDMB231 cells upon indicated conditions were analyzed by immunoblot. Levels of
pPDGFR-b (IB:pPDGFR-b), PDGFR-b (IB:PDGFR-b) and p68 (IB:p68) are the controls,
indicating the efficiency of AG1296, PDGFR-b knockdown efficiency, and total p68
respectively. b-actin (IB:b-actin) is the loading control.
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Appendix D. Discussion
P68 RNA helicase aberrant expression is associated with poor prognosis of patients and
breast cancer progression (Paulsson, Sjoblom et al. 2009). We have previously reported that p68
promotes cell migration and proliferation via Wnt/b-catenin signaling pathway (Yang, Lin et al.
2006). In this study, we report that p68 regulates expression of the growth factor receptor,
PDGFR-b in response to PDGF-BB stimulation, and thereby promote EMT and enhances
migration of breast cancer cells. The role of p68 in regulation of PDGFR-b expression under
stimulation of the growth factor forms an important positive feedback loop in facilitating breast
cancer progression via promoting EMT and cell migration. In addition, p68 cooperates with
PDGFR-b to co-regulates AR expression therefore facilitating androgen dependent proliferation
in breast cancer cells. Both PDGFR-b and AR are very important prognostic marker for breast
cancer patients. Apparently, p68 plays a critical role in coordinates both PDGF and androgen
signaling in breast cancer progression.
P68 has been demonstrated as a co-activator of AR (Clark, Fuller-Pace et al. 2008),
Androgen receptor is highly expressed in invasive breast cancer and prostate cancer cells. A
recent report highlights the androgen-mediated invasiveness of triple negative breast cancer
(TNBC) through AR/Src/PI3-K complex (Giovannelli, Di Donato et al. 2019). Androgeninduced proliferation via androgen receptor has also been well documented. Additionally,
PDGFR-b has been shown to control AR expression (Cuenca-Lopez, Montero et al. 2014).
Because p68 decreases the levels of AR, and p68 regulates PDGFR-b upon PDGF stimulation,
we therefore believe that there is regulatory axis of p68-PDGFR-b-AR in PDGF-BB and
androgen signaling, p68 and PDGFR-b co-regulate AR expression in breast cancer cells. This
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regulatory axis mediates and coordinates the effects of both androgen and PDGF-BB signaling in
promoting breast cancer progression. How p68 controls these two gene expressions remains an
open question. P68 regulates the transcription of numerous genes, including Snail 1 (Carter, Lin
et al. 2010), androgen receptor (AR) (Clark, Fuller-Pace et al. 2008). It has also been reported
that p68 interacts with histone deacetylase 1, RNA polymerase II holoenzyme, and p300/CBP,
suggesting its function in transcription (Nakajima, Uchida et al. 1997, Wilson, Bates et al. 2004).
A reasonable speculation is that, under PDGF-BB stimulation, p68 maybe phosphorylated. The
phosphorylated p68 translocate to the cell nucleus and acts on PDGFR-b transcription. Nuclear
p68 may also act as a co-activator for PDGFR-b in AR transcription. PDGFR-b and AR
inhibition have been considered as approaches for cancer therapy. However, neither inhibition of
PDGFR-b nor AR has been successful in the clinic so far. The cooperation between p68 and
PDGFR-b in regulation of AR may potentially be a reason for the failures.
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Appendix E. Materials and Methods
Appendix E.1. Cell lines and treatments
Breast cancer cell lines MDAMB231, BT549, T47D, MCF7, HCC1806 were purchased
from ATCC and were cultured as per manufacturer’s instructions. In all the experiments, cells
were stimulated with 1nM PDGF-BB unless otherwise stated in figures and legends. Treatment
with PDGFR-b inhibitor, AG1296 (Cayman, 146535-11-7) at a concentration of 5 µM was used
to inhibit PDGFR-b signaling.
Appendix E.2. Transfection
To knock down p68, PDGFR-b in MDAMB231 and BT549 cells, siRNA p68 (SCBT, sc37141) or siRNA PDGFR-b (SCBT- sc29442) respectively was transfected with 20-50 nM of
siRNA for 48 h using Lipofectamine™ RNAiMAX Transfection Reagent kit (Thermo Fisher
Scientific). To overexpress PDGFR-b in MDAMB231 and BT549 cells, 2.5 µg of PDGFR-b
plasmid (Origene- RC206377) was transfected for 48 h using Lipofectamine™ 3000
Transfection Reagent kit (Thermo Fisher scientific).
Appendix E.3. Immunoblotting
The proteins were analyzed by immunoblotting probed with p68 (SCBT, sc-126730),
PDGFRb Abclonal, A2180), phospho-PDGFRb SCBT, Sc365465) phospho-EGFR (Abclonal,
Ab 40815), EGFR (Cell signaling, 26465), FGFR (SCBT, sc-390423), N-Cadherin (Invitrogen,
33-3900), E-Cadherin (Biosciences, 610404), Vimentin (Protein tech, 60330), Snail (Abcam,
17732), AR (Agilent, M356201), b-Actin (2bscientific, R15006MC4) antibodies according to the
manufacturer’s instructions.
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Appendix E.4. Scratch Assay
MDAMB231 and BT549 cells were cultured and transfected with control siRNA, p68 si
RNA, PDGFR b plasmid or co-transfected with p68 siRNA and PDGFR b plasmid for 48 h in
the presence of 10 nM PDGF-BB. Multiple scratches were introduced in the cultured plates. The
scratch treated cells were directly visualized under the microscope.
Appendix E.5. Boyden chamber assay
Falcon® Permeable Support, 24 well plate with 8.0 μm transparent PET membrane
chambers (Life sciences) was used to measure the migration of MDAMB231 and BT549 cells.
The test cells were first transfected with either control si RNA or si p68 RNA (SCBT, sc-37141)
for 48 h in regular cell culture plates. The treated cells were re-suspended into optimum medium
(without serum) and seeded onto the PET membrane chamber. The DMEM culture medium with
10% FBS was added to the outer chambers. After 12 h incubation, medium in the inner chamber
was removed and the cells attached to the outer bottom side were fixed with paraformaldehyde
and stained with 0.5% crystal violet. The stained cells were imaged under the inverted
microscope.
Appendix E.6. Immunohistochemistry
Breast cancer array (US Biomax, BC08118a) was deparaffinized and incubated in Lab
Vision Hydrogen peroxide block and blocked with Lab Vision Protein block reagent. Tissue
array was incubated with rabbit monoclonal antibody against p68 (1:500 dilution) for 1 h at room
temperature followed by detection with the Horseradish Peroxidase- 3,3′-Diaminobenzidine
(DAB). Nuclear counterstaining was done using hematoxylin.
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Appendix E.7. Immunofluorescence
Cells were fixed in paraformaldehyde and blocked with 5% goat serum at room
temperature for 1 h. The cells were incubated with PDGFR-b (1:200) antibody in a humidified
chamber overnight. Anti-rabbit secondary antibody conjugated with Alexa Fluor-555 was used to
label PDGFR-b. Nuclei were stained and mounted with DAPI (Life technologies, S36938).
Images were visualized in a confocal microscope.
Appendix E.8. Real time-PCR
RNA isolation was performed by generic Trizol-phenol chloroform protocol. The isolated
RNA was quantified using Nanovue plus™ spectrophotometer (Biochrom, 28956057). cDNA
was prepared using the Thermo scientific C-DNA kit. Real time PCR was performed using Luna
Universal qPCR master mix (M3003L, NEB Inc) according to the manufacturer’s instructions.
The primer sequences for the genes are: DDX5 (F- GCCGACGTCAACGGGAAAGT, RCGTTGTCACGTGGCTGTACC),

PDGFR-b

TGATGTTCTCACCCTGGCGG),

AR

AGGAATCCCTCTCTGCTCGC),
ATTCAAGTCTCAGCGGGCTC),
TGGCCCAGTTACACGTATCC),
ATCTCCGGAGGTGGGATG),

(F-

(F-

CCCCTTTCTGGCCTGATGCTC,

R-

GAAAGCGACTTCACCGCACC,

R-

Vimentin

(F-TCCGCACATTCGAGCAAAGA,

R-

N-cadherin

(F-GCCAGAAAACTCCAGGGGAC,

R-

Snail
E-cadherin

(F-GCTGCAGGACTCTAATCCAGA,

R-

(F-TCATGAGTGTCCCCCGGTAT,

R-

TCTTGAAGCGATTGCCCCAT),

EGFR

(F-GGCAGGAGTCATGGGAGAA,

R-

GCGATGGACGGGATCTTAG),

FGFR

(F-ATGGCAACCTTGTCCCTG,

R-

CAGCGCACCTCTAGCGAC),

c-FOS

(F-

GTGTCCACCGCTGCCTTC,

R-

GCCACCATTGCTGAAGGGATT). The primers were designed using NCBI Blast. Quantitative
PCR was done under the following thermocycler conditions: 95°C for 2 min, and 40 cycles of
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95°C for 30s, 62°C for 1 min, and 95°C for 30s. Data was collected from 7500 Fast Real-Time
PCR System (Applied Biosystems).
Appendix E.9. MTT assay
MDAMB231 and BT549 cells transfected with control siRNA or p68 siRNA were treated
with or without DHT (1 nM) for 24 h. To analyze the cell proliferation, these treated cells were
incubated with Thiazolyl Blue Tetrazolium Bromide (MTT) (Millipore sigma, M5655) for 4 h at
37°C. The absorbance was measured at 595 nm.
Appendix E.10. Kaplan-Meier survival
KM plotter (www.kmplot.com) was used to analyze the correlation of DDX5 mRNA
expression to the overall survival (OS) of breast cancer patients. Log rank p-value and hazard
ratio (HR) with 95% confidence intervals were calculated and displayed on the webpage.
Appendix E.11. Statistical analysis
To compare the two appropriate groups, the data sets were statistically analyzed.
The P values were calculated using unpaired two-tailed Student’s t-test or ANOVA test. NS
denotes non-significant: P>0.05, *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.
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